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Abstract 
Paracetamol has been used in combination with caffeine for many years, however the 
mechanism by which they ameliorates pain is inconclusive. This thesis examines 
some of the possible mechanisms of action. 
Competition binding studies were used to evaluate if paracetamol displaced binding 
for the NBTI-transporter and the NOP receptor. Paracetamol did not compete for 
either of these two systems. Audioradiographic studies with [3H]paracetamol 
revealed that paracetamol binds ubiquitously throughout the brain and spinal cord and 
that there was some indication that paracetamol might have-a spinal site of action. 
In vivo studies in the hotplate and tail immersion tests in wildtype and adenosine A2A 
knockout mice suggested that paracetamol may interact with the adenosine A2 
receptors indirectly to produce antinociception. Furthermore caffeine administered 
alone was not antinociceptive in these pain models, and in addition attenuated or 
abolished the antinociceptive effect of paracetamol. 
Spinal cord slices from ten-day-old mice were incubated with [3H]arginine to evaluate 
the effect of paracetamol and caffeine on the conversion to [3H]citrulline and the 
consequent release of nitric oxide (NO). Paracetamol and caffeine alone inhibited 
stimulated-release of NO, and when slices were treated with the drugs in combination 
they abolished the stimulated-release of NO. 
Murine microglia cultures were used to ascertain the inhibitory action of paracetamol 
and caffeine alone and in combination on the stimulated release of prostaglandin E2 
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(PGE2). Paracetamol and caffeine alone and in combination decreased the stimulated 
release of PGE2, although this inhibition failed to reach significance. Caffeine also 
did not antagonise the adenosine A2A receptor, as the presence of this subtype could 
not be detected in these murine microglial cultures. 
In conclusion paracetamol and caffeine both inhibit PGE2 and spinal NO release, and 
in combination these effects are potentiated. In addition, paracetamol may interact 
with the adenosine A2 receptors to produce analgesia. 
- viii - 
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Chapter 1 
Introduction 
-I- 
1.1 General introduction 
Paracetamol has been used therapeutically alone and in combination with other 
compounds for over half a century, however the mechanism by which paracetamol 
elicits its effect has yet to be determined. Caffeine, one of the most widely consumed 
behaviourally active substances in the world, is frequently combined with 
paracetamol and other mild analgesics to potentiate their effect. Most commonly used 
pharmacologically as an unselective adenosine antagonist, the mechanism by which 
caffeine exhibits adjuvant properties has yet to be established and the literature has 
failed to provide evidence that this effect is due to the antagonism of this receptor 
family. 
1.1.2 Pain Pathways 
Exposure of the skin or other organs to potential damaging stimuli elicits an 
unpleasant sensation of "pain". Pain is-produced by the noxious stimulus being 
transmitted as a message to the higher centres of the nervous system (see Millan, 
1999). Peripheral afferent fibres detect noxious stimuli and input the message to the 
dorsal horn where it is relayed directly or indirectly to the thalamus and 
somatosensory cortex (see Milian, 1999). These fibres can be classified into three 
types on the basis of diameter, conductance velocity and structure (see Table 1) 
AS-fibres transmits a first phase of pain that is rapid and sharp, and the C-fibres evoke 
a second phase of dull pain (Handwerker & Kobal, 1993; see Milian, 1999). There 
are several classes of both C and AS fibres. C-fibres exist as chemospecific 
nociceptors, thermoreceptors and low threshold mechanoreceptors (see Milian, 1999). 
There is another class of nociceptors so-called "silent" nociceptors, they are a subset 
-2- 
of unmyelinated C-fibres in the skin, joints and viscera that are normally irresponsive 
to noxious stimuli, however under conditions of inflammation these fibres are 
sensitised by a variety of chemical mediators (Dmitrieva & McMahon, 1996). AS 
fibres have been described as existing in two forms Type I and H. Type I are 
activated by high intensity mechanical stimuli in the noxious range 
(mechanoreceptors) and Type II display a lower threshold and respond less rapidly to 
heat stimuli (see Millan, 1999). 
Table 1. Comparative properties of primary afferent fibres 
Fibre Description Threshold Conduction DH Principle Receptors 
for laminae transmitters engaged 
activation innervated 
C Thin, High Slow I, II SP/NKA NKi12 
(0.4-1.2µm), intensity 0.5-2.0 m/sec IVN, X CGRP, CGRP 
unmyelinated EAA NMDA, AMPA 
Noxious mGLU 
AS Medium High Intermediate I-V SP/NKA NK1n 
(2-6 µm), intensity 12-30 m/sec CGRP, CGRP 
myelinated EAA NMDA, AMPA 
Noxious mGLU 
Aß Large Low Fast llI-X EAA AMPA 
(> 10 µm), intensity 30-100 m/sec 
myelinated 
Innocuous 
All primary afferent fibres can transmit non-nociceptive information but only the C 
fibre and AS-fibres transmit nociceptive information. SP- substance P, NKA- 
Neurokinin A, CGRP- Calcitonin-gene related peptide, EAA- excitatory amino acids, 
NK- neurokinin, NMDA- N-methyl-D-aspartate, AMPA- Alpha-amino-3-hydroxy-5- 
methyl-4-isoxazolepropionic acid , mGLU- metatrophic glutamate receptor. Adapted 
from Millan (1999). 
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Fig 1. Simplified version of the transfer of nociceptive information. Peripheral 
afferent fibres (PAF) activate the projection neurones (PN) in the dorsal horn of the 
spinal cord, from which the nociceptive information is conducted to the higher centres 
of the brain (thalamus and somatosensory cortex) directly or indirectly via 
interneurones (IN). Adapted from Millan (2002). 
Ascending nociceptive pathways 
Peripheral afferent fibres activate the projection neurones in the dorsal horn and this 
nociceptive information is conducted to the higher centres in the brain (Almeida & 
Lima, 1997). It has been suggested that glutamate and other excitatory amino acids, 
via the actions at both ionotropic and metabotropic receptor are involved in the 
transfer of nociceptive information from the spinothalamic tract to the thalamus and 
-4- 
from the spinomesenephalic tract to the periaqueductal grey (Fig 1) (see Salt & 
Eaton, 1996). 
Descending nociceptive pathways 
Peripheral afferent fibres can either directly stimulate the projection neurones or 
indirectly engage the projection neurones via excitatory interneurones. Peripheral 
afferent fibres can also target inhibitory interneurones, which can interact with 
projection neurones the excitatory interneurones or the terminals of the fibres 
themselves (see Millan, 2002). Therefore descending pathways may modulate 
nociception through the any of theses element in the dorsal horn. Pathways mediating 
descending inhibition attenuate the release of pronociceptive mediators from 
peripheral afferent fibres and directly or indirectly (via inhibitory intemeurones), 
suppress their excitation of the projection neurones (see Millan, 2002). In contrast 
descending facilitation pathways enhance mediator release directly or via the 
excitatory interneurones to enhance the excitation of the projection neurones. There 
are many neurotransmitters and other substances involved in the transmission of pain, 
however they are not exclusively involved in facilitation or inhibition but involved in 
both (Fig 2) (see Millan, 2002). 
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Fig 2. Overview of the transmitters and other substances involved in the 
modulation of nociceptive information in the dorsal horn. On the left hand side, 
modulators contributing to the facilitation of pain (pronociceptive processes) and on 
the right hand side, modulators contributing to the inhibition of pain (antinociceptive 
processes). Transmitters are contained in descending pathways themselves inhibitory 
interneurones (ININ) and excitatory interneurones (EXIN) and primary afferent 
terminals. Two anatomically undefined area are also shown one containing 
antinociceptive modulators adenosine (ADO) and cannibiods (CB) and the other 
containing pronociceptive modulators nitric oxide (NO) and prostaglandins (PG). 
Abbreviations: DRG, dorsal root . ganglion; PN, projection neurones; CCK, 
cholecystokinin; SP, substance P, GLU, glutamate; DYN, dynorphin; NMDA, N- 
methyl-D-aspartate; Ach, acetylcholine; GAL, galanin; GABA, g-hydroxy-butyric 
acid; ENK, enkephalin; NOC, nociceptin; EM, endomorphin; 5HT, 5- 
hydroxytryptamine; NA, noradrenaline; D, dopamine; Hist, histamine; VP, 
vasopressin and OT, oxytocin. Taken from Milian, (2002). 
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1.2 Paracetamol 
1.2.1. History 
Paracetamol and its pro-drugs were the products of the developing chemical industry 
in Germany at the end of the nineteenth century. These new compounds would 
replace the age-old and increasingly unpopular methods of bleeding, purging and 
sweating to reduce fever, which were deemed to be detrimental to the patient's health 
(see Prescott, 1996). Paracetamol and compounds such as antipyrine (phenazone), 
acetanilide, acetophenetidin and acetylsalicylic acid (aspirin) were all primarily 
introduced as antipyretics but there was increasing evidence to suggest that they had 
the ability to ameliorate mild to moderate pain (see Prescott, 2000). 
Acetanilide was synthesised in 1853 by reacting aniline with acetyl chloridelacetic 
anhydride, however it was not used therapeutically until 1886. Two physicians in 
Strasbourg, Cahn & Hepp (Cahn & Hepp, 1886) discovered the therapeutic properties 
of acetanilide, when they were mistakenly supplied acetanilide instead of naphthalene 
for the treatment of worms. They observed that although the infection still 
predominated, the patient's temperature was lowered. Their consequential report told 
of the antipyretic action and the ability to reduce pain in rheumatism (Cahn & Hepp, 
1886; 1887a; see Prescott, 1996). However, acetanilide was discovered to be 
excessively toxic giving rise to haemolysis and methaemoglobinaemia, and as a result 
the search for less toxic compounds began. Phenacetin was introduced into medical 
practice a year after acetanilide and rapidly gained wide popularity. However, this 
compound also exhibited toxic effects and was implicated in analgesic-abuse 
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nephropathy and has consequently been withdrawn in the majority of countries (see 
Prescott, 1996). 
Paracetamol was first synthesised in 1878 by Morse, who prepared it inadvertently by 
reacting p-nitrophenol with tin and glacial acetic acid to produce p-aminophenol, after 
which aminophenol was subsequently acetylated to acetaminophen (paracetamol) 
(Morse, 1878; see Prescott, 2000). However, the first clinical use of paracetamol was 
attributed to von Mering, who only briefly described its antipyretic and antineuralgic 
properties whilst noting that it exhibited similar side effects such as hepatotoxicity 
and nephrotoxixity to its parent compound, aminophenol (Mering, 1893; see Prescott, 
2000). 
The first detailed account of its clinical use appeared in 1894, when Hinsberg & 
Treupel (1894) demonstrated that paracetamol (500 mg) was as effective as 
phenacetin (700 mg) and acetanilide (1 g) in reducing a patients fever. The acute 
toxicity of paracetamol in guinea pigs, rabbits and dogs, was also described, which 
lead to a disinterest in this promising compound (Hinsberg & and Treupel, 1894; see 
Prescott, 2000). 
Paracetamol was re-discovered between 1948 and 1949 as the major metabolite of 
both acetanilide and phenacetin in man (Brodie & and Axelrod, 1948; Brodie & 
Axelrod, 1949) and rabbit (Smith & Williams, 1949; Smith & Williams, 1948). Flinn 
& Brodie (1948) demonstrated that paracetamol (325 mg) elevated the pain threshold 
in women subjected to cutaneous heat radiation, thereby confirming analgesic 
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efficacy for the first time. This renewed interest in paracetamol, and by 1950 it was 
marketed in the USA in combination with caffeine and aspirin (Triogesic), although it 
was withdrawn a year later following three cases of agranulocytosis. The cases were 
later reviewed and a causal relationship was deemed unlikely, so paracetamol was 
then reintroduced as a prescription drug. By 1955 the combination drug was available 
without prescription and was subsequently marketed in the UK and Australia the 
following year (see Prescott, 2000). Over the next decade paracetamol was 
subsequently introduced to many other countries (Prescott, 1996). During the 1960s 
and 70s the toxicity of non-prescription analgesics and their combinations was a cause 
for concern. Once investigated it was established that paracetamol was safe in man if 
kept within therapeutic doses (<10g/day) (Farrell, 1986), and appeared to exhibit 
fewer side effects such as gastrointestinal toxicity compared to aspirin (see Dubois et 
al., 1998; Goulston, 1964), or the methaemoglobinaemia and haemolysis seen with 
acetanilide and phenacetin (Greenberg & Lester, 1947). As a consequence the use of 
paracetamol has increased and to date paracetamol remains one of the more popular 
mild analgesics and over-the-counter remedies. 
1.2.2. Absorption, distribution, metabolism, excretion and toxicity 
Paracetamol is a lipid soluble weak organic acid (pKa 9.5) (see Clissold, 1986), which 
is absorbed rapidly (0.5 hrs) from the gastrointestinal tract by passive non-ionic 
diffusion into the systemic circulation (Bagnall et al., 1979). Paracetamol crosses cell 
membranes easily, including the blood brain barrier, leading to a relatively equal 
concentration (1500-2000 nmol/g) of paracetamol in all tissues including the brain 
after an oral dose of 500 mg/kg in the rat (Fischer et al., 1981). In humans, peak 
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plasma concentrations of 10-20 mg/l (70-132 µmol/l) are observed between 30-120 
min (Anderson et al., 1996; Prescott, 1996). This therapeutic plasma concentration is 
achieved by oral or intravenous administration of 10-20 mg/kg paracetamol. or rectal 
administration of 40 mg/kg paracetamol (Anderson et al., 1996; Peterson & Rumack, 
1978; Prescott, 1996). Paracetamol is uniformly distributed throughout the bodily 
fluids in a volume of about 0.9 I/kg, in humans and animals (see Prescott, 1996). 
Only a small fraction of orally administered paracetamol is lost to first pass 
metabolism giving a high bioavailability (see Prescott, 1996). Although there are 
species differences in the extent of first pass metabolism, man and common 
laboratory animals seem to share the same major and minor routes of metabolism (Fig 
3) (see Prescott, 1996). 
Fig 3: Paracetamol metabolism In different species, represented by the average 
percentage of urinary excretion of conjugates. It is only possible to make general 
comparisons due to the various experimental differences such as dose, mute and 
experimental conditions. Adapted from Prescott (1996). 
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Paracetamol is metabolised by a number of Phase II conjugation enzymes to form 
non-toxic water-soluble products that can be excreted in the urine. There are however 
important quantitative species differences in the individual conjugates excreted (Fig 
3) and different susceptibility to toxicity (see Prescott, 1996). 
Under normal circulmstances 95 % of paracetamol is metabolised by the phase II 
conjugation enzymes, UDP-glucuronyltransferase and sulfotransferase, both of which 
require energy rich donors, UDP-glucuronic acid (UDPGA) and 3'phosphadenosine 
5'phosphosulfate (PAPS) respectively. Sulphate conjugation predominates at low 
concentrations of paracetamol and glucuronide conjugation at higher concentrations 
of paracetamol, due to the kinetics of the enzymes and the limited cell supply of 
PAPS compared to UDPGA. When the cell supply of PAPS and UDPGA are 
exhausted paracetamol is consequently metabolised by a phase I reaction, in this case 
cytochrome P450 (CYP450) enzyme which oxidises paracetamol to a reactive 
intermediate, N-acetyl-p-benzoquinoneimine (NAPQI) (Mitchell et al., 1973a) (Fig 
4. ). 
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Fig 4. The metabolism of paracetamol. When paracetamol saturates the UDP- 
glucuronyltransferase (1) and sulfotransferase (2), CYP450 (2E1) (3) metabolises it to 
a reactive intermediate, the intermediate can be detoxified by glutathione-S- 
transferase (4), but once the cellular glutathione levels are depleted the intermediate 
binds to cellular constituents. Other minor routes of metabolism, can involve Phase I 
reactions such as hydroxylation (5) followed by a Phase 11 conjugation such as 
methylation (6) which requires SAM (S-adenosyl methionine) as a cofactor. Adapted 
from Prescott (1996). 
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A species susceptibility/sensitivity to toxicity is therefore dependent on the rate at 
which paracetamol saturates the conjugation enzymes and its consquent formation to 
the reactive intermediate (Seddon et al., 1987; Tee et al., 1987). This intermediate 
can be safely excreted by another Phase II conjugation enzyme, glutathione-S- 
transferase. Glutathione is conjugated to the reactive intermediate and can be safetly 
excreted directly into the urine, or excreted into the bile where further metabolism 
takes place with cysteine or mercapturic acid before excretion (Fig 2). However, if 
high concentrations of paracetamol are metabolised to NAPQI, the limited hepatic 
glutathione stores, are dose-dependently reduced (Price & Gale, 1987). Davis et al 
(1974) found that the severity at which hepatic damage occurred correlated with the 
depletion of glutathione. Once the glutathione stores are exhausted the active 
intermediate becomes covalently bound to vital cell constituents followed by the onset 
of hepatotoxicity within the 12-48 hr (Mitchell et al., 1973b). Early glutathione 
treatment prevents cell injury by improving the detoxification of the reactive 
metabolite (Knight et al., 2002). However cysteamine is a more effective treatment 
for paracetamol overdose if administered within the first ten hr. It is thought that 
cysteamine protects the liver from hepatic necrosis by combining with NAPQI in the 
same way as glutathione, and'also by inhibiting the formation of the active metabolite 
(Prescott et al., 1974). 
CYP450 activation of paracetamol to its reactive intermediate has been attributed 
more specifically to the CYP450 2E1 (CYP2EI) subtype (Thomsen et al., 1995). 
This enzyme is well conserved across the mammalian species and it has been shown 
that mice lacking the CYP2E1 gene are considerably less sensitive to paracetamol- 
induced hepatotoxicity than the wildtype mice (Lee et al., 1996b). Once the reactive 
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intermediate binds to cellular proteins including mitochondrial proteins, it can inhibit 
mitochondrial respiration with the subsequent depletion of ATP causing oxidant stress 
and the production of reactive oxygen species. An increase in NAPQI may not be the 
only mechanism by which paracetamol can produce toxicity, it has been suggested 
that soluble compounds such as nitric oxide (NO), reactive oxygen species, tumor 
necrosis factor a (TNFa) and interleukins produced by macrophages and hepatocytes 
can all contribute to toxicity (Blazka et al., 1995; Gardner et al., 1998; Jaeschke et al., 
2003). Gardner et al (1998) observed that rats treated with a high dose of paracetamol 
exhibited centrilobular damage which correlated with an upregulation of inducible 
nitric oxide synthase (iNOS) expression and a subsequent production of NO, which 
was evident within 6 hr of treatment. Furthermore in 2002 Gardner et al 
demonstrated that not only were iNOS knockout mice less sensitive to paracetamol- 
induced hepatotoxicity 12 hr after administration, but also that the hepatic expression 
of TNFa was significantly increased and interleukin 10 (IL-10) expression was 
reduced, suggesting that some of these effects may be mediated by altering the 
production of pro-and anti-inflammatory cytokines important in tissue repair (Gardner 
et al., 2002). Nitrotyrosine residues, a marker for peroxynitrite, a powerful oxidant 
that can modify cellular macromolecules, has also been found in hepatocytes of mice 
and rats after paracetamol insult, suggesting that reactive nitrogen species may also 
have a role to play in toxicity (Gardner et al., 1998; Gardner et al., 2002; Jaeschke et 
al., 2003; Michael et al., 2001). 
Therapeutic concentrations of paracetamol exhibit few side effects if any and in 
particular there is a lack of the gastrointestinal bleeding exhibited by other NSAIDs. 
There have been a few isolated incidents of anaphylactic reactions mediated by 
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immunoglobin E (de Paramo et al., 2000; Stricker et al., 1985; Van Diem & Grilliat, 
1990). However, in the majority of reports of the clinical efficacy of paracetamol, 
there is no mention of adverse effects while in others the interpretation is difficult 
because the control data are limited or the paracetamol was administered in 
combination (see Prescott, 1996). The side effects that were reported appeared to be 
similar to those observed in patients receiving the placebo (McQuay et al., 1990; 
Skjelbred et al., 1977; Smith et al., 1975; Wilson et al., 1991), the most common 
complaints being drowsiness and dizziness (Bloomfield et al., 1981; Forbes et al., 
1983; McQuay et al., 1986). 
1.23 Mechanisms of action 
The mechanism of action of paracetamol has not been elucidated, although there have 
been a variety of mechanisms postulated including the following: central inhibition of 
prostaglandin synthesis (Flower & Vane, 1972); modulation of the central L-arginine- 
NO pathway and the inhibition of the neurones excited by substance P (Bjorkman, 
1994; Hunskaar et al., 1985); the involvement of the endogenous opioid pathway 
(Raffa et al., 2000; Sandrini et al., 200la) and the activation of spinal 5- 
hydroxtryptamine (5HT3-receptor mediated) descending pathways (Pelissier et al., 
1995). 
1.2.3.1. Cyclooxygenase inhibition 
Paracetamol has very similar analgesic and antipyretic properties to the non-steroidal 
anti-inflammatory drugs (NSAIDs), which act via the inhibition of the 
cyclooxygenase (COX) enzymes, thereby inhibiting the release of prostaglandins, 
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which are mediators of pain and inflammation. COX or prostaglandin H2 synthase 
(PGHS) is the enzyme that catalyses a two-step bis-oxygenase reaction, COX 
arachidonic acid is converted to its unstable intermediate endoperoxide hydroperoxide 
PGG2, and subsequently reduces this intermediate by a two electron reduction to its 
corresponding endoperoxide alcohol PGH2 (see Smith et al., 2000). These two 
reactions occur at distinct but structurally and functionally interconnected sites, the 
COX and peroxidase (POX) active sites (Fig 5. ) (see Smith et al., 2000). 
The COX reaction is peroxide-dependent (Smith & Lands, 1972), and requires 
substrates from the peroxidase cycle to initiate the reaction (Kulmacz et al., 1985). 
The mechanism by which this is achieved was first proposed by Dietz et al (1988) 
who observed that a tyrosine (Tyr385) radical was needed to activate the COX 
reaction. Initially either an alkyl peroxide or peroxynitrite derived from condensation 
of NO and superoxide, oxidised the heure group in the peroxidase site. This oxidised 
herne group oxidises a neighbouring tyrosine located in the COX active site and the 
resulting tyrosine radical abstracts a hydrogen atom from arachidonate to initiate the 
COX reaction (Fig 6. ) (see Smith et al., 1996). 
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Fig 5. The arachidonic acid cascade. Arachidonic acid is hydrolysed from the 
membrane phospholipids, phosphatidylcholine and phosphatidylinositol, in response 
to a stimuli such as a cytokine, growth factor or circulating hormone. Arachidonic 
acid is then converted by COX to PGH2, which is subsequently isomerised to a 
biological active prostanoid product such as prostaglandin E2 (PGE2) or thromboxane. 
Adapted from Smith et al (1996) and Versteeg et al (1999). 
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Fig 6. Branched chain tyrosyl mechanism for COX: (1) The peroxidase cycle is 
initiated by the resting heure (Fe3+) undergoing a2 electron (e) reduction by a lipid 
peroxide to yield oxy-fenyl porphyrin x -cation radical (Fe 
i yrPP ) and an alcohol 
derived from the oxidized lipid peroxide. (2) Oxy-ferryl radical undergoes an 
intermolecular electron transfer from Tyr385 to the heure group to produce a tyrosyl 
radical. (3 & 4) Alternatively the oxy-ferryl cation can undergo two single electron 
reductions to return the heure to its resting state. (5) When the COX site is occupied 
by arachidonic acid (AA) the tyrosyl radical abstracts a hydrogen atom to yield an 
archidonate radical. (6) Sequential oxygen addition at C II and C15 yield the 
endoperoxide hydroperoxide PGG2' radical. (7) PGG2 diffuses to the peroxidase 
active site where it is converted to its corresponding alcohol PGH2 (1), leaving the 
tyrosyl radical to regenerate. (8) Tyrosyl radical compound is reduced and can cycle 
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through the peroxidase cycle independently of the COX turnover. Adapted from Tsai 
& Kulmacz (2000). 
Isofnrms and their structure 
There are two widely accepted isoforms of COX, COX I and COX 2. 
Cyclooxygenase I (COX 1) is constitutively expressed and involved in prostaglandin 
biosynthesis in response to hormone stimulation, resulting in prostanoids which 
mediate "housekeeping" functions including ovulation and initiation of labour, bone 
metabolism, nerve growth and development, and the regulation of renal water and 
sodium metabolism, stomach acid secretion, haemostasis and immune responses 
(Dubois et al., 1998; Malkowski et al., 2000). This isoform is expressed in a variety 
of tissues including the blood vessels, stomach, kidney, platelets and glial cells and 
the central nervous system (CNS). The cyclooxygenase 2 (COX 2) isoform is the 
inducible form of the enzyme and is expressed transiently in response to growth 
factors, tumour promoters and cytokines (Malkowski et al.. 2000). However, COX 2 
is expressed constitutively in a few organs such as the CNS (see Beiche et al., 1996; 
Versteeg et al., 1999). The two isoforms are both associated with the luminal 
surfaces of the endoplasmic reticulum, and the inner and outer nuclear envelope (Otto 
& Smith, 1994). COX 2 however appears to be more concentrated within the nuclear 
envelope (Morita et al., 1995). Both isoforms have a molecular weight of 71 K and 
both have approximately 600 amino acids, of which 60-65 % are identical in sequence 
within an individual species (see Vane et al., 1998). The individual isoforms share 
85-90 % identity within different species (see Smith et al., 2000). The human COX 2 
gene is a small gene of 8.3 kb and produces mRNA of 4.5 kb. whereas human COX I 
originates from a much larger 22 kb gene and produces a small 2.8 kb mRNA product 
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(Herschman, 1996; Otto & Smith, 1995). The mRNA are then spliced and then 
translated into their relevant enzymes. The COX enzymes are homodimers, and each 
monomer consists of three regions, an epidermal growth factor-like domain, the 
membrane binding domain and aC terminal globular catalytic domain (Kurumbail et 
al., 1996; Picot et al., 1994). The epidermal growth factor-like domain forms a 
portion of the dimer interface and is essential for folding of the enzyme (see Smith et 
al., 2000). The membrane binding domain is of unusual orientation, as although these 
enzymes are integral membrane proteins they do not contain a transmembrane 
sequence (see DeWitt, 1999). Instead, the membrane binding domain contains four 
short, consecutive, amphiphatic a helices (A-D), the last of which merges into the 
catalytic domain. Helices A-D of both monomers are situated with their hydrophobic 
surfaces facing outwards away from the hydrophilic surface of the catalytic domain 
thereby creating a large hydrophobic patch on the exterior of the protein (Picot et al., 
1994). This patch interacts with the hydrophobic interior of the bilayer, thereby 
anchoring the dimer to one leaf of the lipid bilayer (Fig 7. ) (Otto & Smith, 1996; Picot 
et al., 1994). The helices also surround an opening or "channel" through which fatty 
acid substrates and NSAIDs are believed to enter the COX active site, as due to the 
orientataion of the helices in the membrane the substrates must gain access to the 
active site via the interior of the lipid membrane (Fig 7. ) (Picot et al., 1994). 
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Fig 7. Ribbon diagrams of the ovine COX1 homodimer: (A) Helices (A-D) 
integrated into one face of the luminal surface of the membrane bilayer. (B) The 
enzyme complex is a dimer of identical subunits (grey and light green). The enzyme 
has two different active sites, COX and a peroxidase site (dark blue), which is needed 
to activate the heure group (bright green). The active sites are buried within the 
protein and are reachable by a hydrophobic channel that lies within the amphiphatic 
helices (pink). This channel acts like a funnel guiding the substrate out of the 
membrane and into the enzyme. Taken from Picot et al (1994). 
The amino acid conformation for substrate binding sites and the catalytic regions are 
almost identical in both isoforms (Kurumbail et al., 1996). However, there are a few 
differences that can change substrate and inhibitor specificity e. g. COX 2 can utilize a 
wider range of fatty acids as substrates than COX 1 (Otto & Smith, 1995). COX 2 
also appears to have an additional binding pocket for NSAIDs (Malkowski et al., 
2000). The substitution of a few amino acids can change the binding characteristics 
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of the isoforms. Isoleucine in the COX 1 active site is exchanged for a valine in the 
COX 2 active site and the same substitution is also made on the edge of the active 
site. The less bulky side chain in valine opens up the hydrophobic side pocket in the 
COX 2 active site, which is not accessible in COX 1 (DeWitt, 1999). Arginine is one 
of the few charged amino acids within the COX 1 active site (Arg 120), and forms ionic 
bonds with the carboxylic moiety of NSAIDs and arachidonic acid (DeWitt, 1999). 
However, in the COX 2 active site Arg120 only plays an accessory role. The larger 
binding pocket reduces the charge and steric crowding around Arg120, and hydrogen 
bonds are formed with arachidonic acid only (Rieke et al., 1999) whilst the majority 
of inhibitors form a non-ionic bond (see Simmons et al., 2000). 
Inhibition of the COX isofonns 
Unlike the NSAIDs, paracetamol only weakly inhibits COX 1 and 2 at a therapeutic 
dose. Paracetamol inhibits the activity of both ovine COX I (IC5o of 419 µM) and 
murine COX 2 (IC50 of 372 µM) equipotentently in IL-la-stimulated human 
umbilical vein endothelial cells, however paracetamol had no effect on platelets 
(Boutaud et al., 2002). In a whole blood assay paracetamol has a ICso of >100 pM 
and 49 µM at COX 1 and COX 2 respectively, whereas other NSAIDs such as 
indomethacin and diclofenac have an IC50 < 0.8µM for both isoforms (FitzGerald & 
Patrono, 2001; Warner et al., 1999). In intact cells cultured from bovine aortic 
endothelial cells the IC50 values of paracetamol were 17.9 µmoili for COX 1 and 133 
tmoU1 for COX 2 (see Dahl & Raeder, 2000). The high concentration required for 
COX inhibition may explain the weak anti-inflammatory action of paracetamol. 
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Initial studies (Ferrari et al., 1990; Ferreira et al., 1978; Flower & Vane, 1972) 
suggested that paracetamol may inhibit prostaglandin synthesis selectively in the 
CNS, leading to the hypothesis that the antipyretic and analgesic actions are a central 
effect, whereas any anti-inflammatory action is a peripheral effect. Flower & Vane 
(1972) were the first to establish that aspirin (IC50 = 6.6 µg/ml) was over 10 times 
more potent than paracetamol (IC50 = 100 µg/ml) as a peripheral COX inhibitor in dog 
spleen. However, as a central COX inhibitor, paracetamol (ICso = 14 µg/ml) appeared 
to be just as potent as aspirin (ICso =1I µg/ml, rabbit brain) and it was proposed that 
paracetamol inhibits specific COX isoforms in the CNS, which show different 
sensitivities to different compounds (Flower & Vane, 1972). 
Flower et al (1972) was unable to measure a reduction in inflammation in response to 
paracetamol in carageenin-induced oedema in the rat paw. In contrast, Robak (1980) 
observed paracetamol diminished carageenin-induced oedema of the rat paw three to 
four hr after carageenin injection. Further, paracetamol administered peripherally and 
centrally has also been shown to inhibit hyperalgesia associated with the carageenin- 
induced oedema of the rat paw, although the peripheral dose required to achieve 
inhibition was greater than the centrally administered dose (Ferreira et al., 1978). 
Paracetamol administered peripherally could still be acting through a central site of 
action due to the ease at which paracetamol crosses the blood brain barrier. When 
paracetamol was simultaneously administered intracerebroventricularly and 
intraplantarly a synergistic effect was observed, which was comparative to the 
analgesia produced by a four fold higher dose of paracetamol administered at one site 
(Ferreira et al., 1978). Bannwarth et al (1992) observed a significant concentration of 
paracetamol (0.78-2.40 µg/ml) in CSF 20 min after intravenous administration, 
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reaching a maximum concentration at 4 hr that exceeded plasma concentrations, 
compatible with a central site of action. 
According to the branched chain mechanism (Fig 4) COX activity can be inhibited 
when reducing agents are capable of quenching the tyrosyl radical back to the resting 
state (Ouellet & Percival, 2001). Paracetamol alone had no inhibitory effect on 
purified ovine COX 1 and human COX 2, although the potency of paracetamol was 
increased 30 fold by the presence of the peroxide scavenger, glutathione peroxidase. 
In the presence of a low peroxide concentration (i. e. in the presence of glutathione 
peroxidase) paracetamol was a good reducing agent of both isoforms (Ouellet & 
Percival, 2001). Ouellet & Percival (2001) demonstrated that paracetamol interacts 
with the peroxidase cycle by the observation that preincubation with paracetamol (10- 
1000 µM) protects human COX 2 and to lesser' extent ovine COX I against H202- 
dependent inactivation. Therefore it was concluded that paracetamol acts to reduce 
the active oxidised form of COX to the resting form of the enzyme, thereby 
quenching the tyrosyl radical. Therefore, inhibition would be more effective under 
conditions of low peroxide concentration because lowering the peroxide concentration 
decreases the rate at which the COX cycle is initiated (Ouellet & Percival, 2001). 
This was further demonstrated in human umbilical vein endothelial cells, when pre- 
treatment with t-butyl hydroperoxide dose-dependently reversed paracetamol-induced 
inhibition of COX activity by increasing the peroxide concentration (Boutaud et al., 
2002). 
Inhibition of the synthesis of prostaglandin 
Although paracetamol does not appear to inhibit either COX isoform at 
therapeutically relevant concentrations, it has been shown that paracetamol is a potent 
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inhibitor of prostaglandin biosynthesis (Feldberg & Gupta, 1972; Feldberg et al., 
1972; Malmberg & Yaksh, 1994; Muth-Selbach et al., 1999). Paracetamol has also 
been shown to block the IL-la-stimulated synthesis of prostacyclin and PGE2 in 
human umbilical vein endothelial cells, although paracetamol had no effect on the 
basal activity of either synthase (Boutaud et al., 2002). In peritoneal macrophages, 
paracetamol also inhibits LPS-stimulated PGE2 synthesis, although in these cells this 
inhibition appears to be related to a reduction in COX 2 expression (Tordjman et al., 
1995). In healthy volunteers it has been shown that paracetamol reduces the urinary 
excretion of PGE2 metabolites without altering the urinary excretion of unchanged 
PGE2, indicating that the total synthesis of PGE2 in the body was reduced in the 
presence of paracetamol (Bippi & Frolich, 1990). 
A potential mechanism or partial mechanism for the analgesic effect of paracetamol 
could involve the inhibition of the spinal release of PGE2. Beiche et al (1996) has 
shown that both the COX isoenzymes are constitutively expressed in the spinal cord 
with COX 2 being predominant. In addition to local actions at the site of injury, 
prostaglandins are also thought to act in the spinal cord to facilitate the transmission 
of pain responses (Yamamoto & Nozaki-Taguchi, 1996). Malmberg & Yaksh (1995) 
and Scheuren et al (1997) both reported PGE2 release from the spinal cord after 
peripheral noxious stimulation. Paracetamol dose-dependently reduced the spinal 
release of PGE2 associated with flinching behaviour in the formalin test, indicating an 
action partially mediated by the inhibition of spinal PGE2 release (Muth-Selbach et 
al., 1999). 
-25- 
PGE2 synthesised from COX 2 is essential for fever (Cao et al., 1995; Cao et al., 
1997; Li et a[., 1999; Simmons et al., "2000), and it has been postulated that fever 
causing prostaglandins originate from the perivascular microglia and meningeal 
macrophages throughout the brain after systemic challenge (Breder & Saper, 1996; 
Elmquist et al., 1997). PGE2 is synthesised by PGE synthase, which exists in both, 
membrane and cytosolic forms, the former being glutathione-dependent (Jakobsson et 
al., 1999). The COX enzymes show distinct specificity for the two types of PGE 
synthase depending on the cellular environment. Membrane PGE synthase (mPGES) 
has been found to be functionally coupled to COX 2 in preference to COX 1 in 
macrophages and osteoblasts following proinflammatory stimuli, particularly when 
the supply of arachidonic acid was limited. However, increasing the supply of 
arachidonic acid by increased activation of cytosolic PLA2 allows mPGES to be 
coupled with COX 1 (Murakami et al., 2000). 
Prostaglandins, PPAR and fever 
There are two classes of PG receptor; the G-protein coupled receptors and the orphan 
nuclear transcription factors, more commonly termed peroxisome proliferator 
activated receptors (PPARs) which act directly as transcription factors (Dubois et al., 
1998). The prostanoid receptors are encoded by different genes and are named after 
the prostaglandins that activate them (Table 2). 
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Table 2: Signal transduction and distribution of the Prostanoid receptors 
Class Receptor Subtype G-protein 2° messenger Expression 
PGD2 DP Gs cAMP T, Least abundant, platelets, 
Ca2+ T lung, stomach, bronchial 
epithelial, dendritic cells 
CRTH2 G, cAMP . 
ý, Th2 lymophocytes, 
Ca'+ T eosinophils and basophils 
PGE2 EP EP, Unidentified Ca +T Fibroblasts, kidney, lung 
and stomach 
EP2 Gs cAMP T Smooth muscle 
EP3 G;, Gs, Gq cAMP Widely distributed 
PI response 
EP4 Gs cAMP T 
PGF2a FP Gq PI response Corpus luteum, kidney, 
heart, lung stomach, ocular 
tissue 
PGI2 IP Gs, Gq, G; cAMP U, PI Platelets, blood vessels, 
response neurons of the DRG, 
kidney, liver, heart, co- 
localized with Sub P 
precursor 
TXA2 TP Gq, Gs PI response, Tissues rich in vasculature 
((x), G; (ß) cAMP . 
ýT such as heart, placenta 
platelets, vascular smooth 
muscle, brain, small 
intestine 
DRG, dorsal root ganglia; PI, phosphatidylinositol; Sub P, substance P; i, decrease; 
1', increase Adapted from Hata & Breyer (2004) 
TXA2 has been most extensively characterised in its modulation of haemodynamic 
and cardiovascular function. In humans the TXA2 prostanoid (TP) receptor exists as 
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two splice variants TPa4 which was first cloned from the placenta and platelets, and 
TPß which was originally cloned from endothelial cells, Both variants have been 
detected in tissues expressing the TP receptor (Raychowdhury et al., 1994). The role 
of the TP receptor in haemostasis is supported by studies indicating that defective TP 
receptor signalling has been linked to bleeding disorders (Hirata et al., 1994) and 
furthermore TP knockout mice have been shown to have coagulation deficiencies 
(Thomas et al., 1998). The TP receptor has also been implicated in the modulation of 
T-cell activation, TXA2 is produced by macrophages and dendtritic cells and has been 
proposed to play a role in regulating T-cell differentiation and proliferation 
(Kabashima et al., 2003). Inhibition of thromboxane synthesis or direct TP receptor 
antagonism decreases the alloproliferative response of the lymphocyte population in a 
model of cellular immune response (Ruiz et al., 1992), and, TP knockout mice exhibit 
a reduction in the T-cell proliferative response following mitogen and alloantigen 
stimulation (Thomas et al., 2003). In contrast, TP knockout mice have also been 
shown to exhibit an increase in contact hypersensitivity, suggesting a inhibitory role 
for the TP receptor in dentritic cell-T-cell interaction (Kabashima et al., 2003). 
In the early 1980's PGD2 was shown to be the predominant prostanoid produced by 
activated mast cells, which initiated IgE-mediated allergic responses (Roberts et al., 
1980). The PGD2 prostanoid (DP) receptor binds PGD2 and its metabolite PGJ2 with 
equal affininty (see Hata & Breyer, 2004). In addition to its role as a inflammatory 
mediator, PGD2 has been shown to have many other roles incuding, platelet 
aggregation (Whittle et al., 1985), vasodilation and vasoconstriction (Giles & Leff, 
1988) and sleep induction (Mizoguchi et al., 2001). PGD2 also binds to the more 
recently discovered prostanoid receptor, a chemoattractant receptor on Th2 cells 
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(CRTH2), with comparible affinity to the DP receptor (Hirai et al., 2001; Nagata et 
al., 1999). CRTH2 also binds PGJ2 with equal affinity to PGD2 itself (Sawyer et al., 
2002) raising the possibility that metabolites of PGD2 may differentially exert effect 
through the CRTH2 receptor. DP knockout mice exhibit a reduced airway 
hypersensitivity and Th2-mediated lung inflammation in the OVA-induced asthma 
model, suggesting that the DP receptor mediates the effects of PGD2 released by mast 
cells during the asthmatic response (Matsuoka et al., 2000). In contrast, to this pro- 
inflammatory response, PGD2 activates the DP receptors expressed in dendritic cells, 
which inhibits dentritc cell migration leading to a reduced proliferation and cytokine 
production by antigen-specific T-cells (Hammad et al., 2003). 
PGE2 is a major product of the cyclooxygenase reaction, and COX I derived PGE2 
performs a number of protective functions, such as maintaining the integrity of the 
gastric mucosal and the maintenance of normal renal function. In certain 
circumstances, PGE2 has been observed to perform multiple, and at times opposing 
functional effects, which can be explained in part by the existence of four PGE2 
prostanid (EP) receptors (Table 1), and the unique multiple splice variants of the EP3 
receptor. EP3 and EP4 have the highest affinity for PGE2 (Kd <1 nM) whereas EP1 
and EP2 bind at a lower affinity (Kd > 10 nM) (Abramovitz et al., 2000). EP I 
appears to be involved in inflammatory pain, as EP1 receptor antagonists reduce 
hyperalgesia in the carageenan-induced paw inflammation model in rats (Nakayama 
et al., 2002). Furthermore, EP1 knockout mice exhibit a reduced stretching response 
in the writhing test associated with a reduction in pain sensitivity, and similar results 
were observed by antagonising the production of PGE2 in wildtype mice (Stock et al., 
2001). 
-29- 
Minami et al (2001) demonstrated that EP1 and EP3 receptors were involved in 
different types of pain. EPI knockout mice failed to illicit a response to PGE2- 
induced mechanical allodynia, whereas EP3 knockout mice did not produce PGE2- 
induced thermal hyperalgesia at low PGE2 concentrations, and EP3 agonists were also 
shown to induce hyperalgesia (Minami et al., 2001). However formalin induced pain 
could not be ascribed to either subtype (Minami et al., 2001). In addition, the EP 
receptors have been shown to produce proinflammatory effects and anti-inflammatory 
effects. LPS-induced oxidative damage is suppressed in EP2 knockout mice, and this 
suppressed oxidative damage is also observed in wildtype mice treated with NSAIDs 
(Montine et al., 2002) indicating that EP2 receptor activation is involved in the 
generation of the innate immune response and is pro-inflammatory in this model. 
However, in vitro studies on macrophages have reported that the PGE2 modulates 
macrophage function by inhibiting cytokine release, and this is due to the activation of 
the EP4 receptor (Nataraj et al., 2001; Takayama et al., 2002). Furthermore, the EP2 
receptor has also been shown to primarily mediate the PGE2-induced anti proliferative 
effect on T-cells (Nataraj et al., 2001), which would indicate an anti-inflammatory 
role for the EP receptors. 
PGE2 not only has roles in the onset of pain and inflammation, but has also been 
shown to be partially responsible for the production of pyresis (see Aronoff & 
Neilson, 2001; Mancini et al., 2001; Scammell et al., 1996). EP3 receptor knockout 
mice were the only EP subtype knockout mice to fail to illicit a febrile response to the 
administration of PGE2, IL-lß or LPS, therefore indicating that EP3 activation is 
responsible for the onset of fever (Ushikubi et al., 1998). 
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PGI2 or prostacyclin binds to the PGI2 prostanoid (IP) receptor and is the primary 
prostaglandin produced by endothelial cells and plays an important role in vascular 
homeostasis, functionally opposing the effects of TXA2. In addition, prostacyclin has 
been reported to have cardioprotective effects during ischaemia/reperfusion injury 
(Xiao et al., 2001) and is an important mediator of acute inflammation and 
inflammatory pain transmission (Doi et al., 2002; Murata et al., 1997). IP knockout 
mice have reduced inflammatory and pain responses in the carageenan-induced paw 
model and the acetic acid writhing test (Murata et al., 1997). Prostacyclin has also 
been implicated in the transmission of pain in the spinal cord, as an upregulation of 
the IP receptor mRNA was observed in the spinal cord following peripheral 
inflammation (Doi et at., 2002). In contrast to pro-inflammatory effects of 
prostacyclins in acute inflammation, recent studies have suggested that the activation 
of the IP receptor suppresses Th2-mediated allergic inflammatory responses (Jaffar et 
al., 2002; Takahashi et al., 2002). 
PGF2a binds to the PGF2a prostanoid (FP) receptor and plays a critical role in 
mammalian reproduction, but unlike the other prostanoid receptors there is little 
evidence that the FP receptor has any role in inflammatory, pain and immunological 
processes (see Hata & Breyer, 2004). 
The prostanoid receptors appear to have diverse and overlapping functions, therefore 
the roles of the individual receptors in pain and inflammation may only become 
apparent dependent on the physiological environment or disease state. 
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The suggestion that prostaglandins directly activate the PPARs originated from the 
discovery that PGJ2 and its derivatives are efficacious activators of PPARa and y 
(Kliewer et al., 1995; Tilley et al., 2001). PPARs are activated by a large number of 
structurally diverse molecules, which do however share some structural similarities, 
including a lipophilic backbone and an acid moiety usually carboxylate (Lehmann et 
al., 1997). In recent years it has been shown that many competitively acting NSAIDs 
at high concentrations (i. e. >10 pM) bind and activate members of the PPAR family 
in tissue culture (Ledwith et al., 1997; Lehmann et al., 1997). Indomethacin 
stimulates the adipogenic cell line TAI to differentiate into mature adipocytes, not 
through the inhibition of cyclooxygenase (Knight et al., 1987) but through the 
activation of PPARcc and y (Lehmann et al., 1997). PPAR agonists have also been 
shown to induce the expression of COX 2 but not COX 1, although this induction 
does not result in an increase in PGE2 synthesis (Lehmann et al., 1997; see Simmons 
et al., 2000). PPARy agonists PGD2, and its metabolites PGJ2 and A12PGJ2 and the 
PGE2 metabolite PGA2, along with a PPARcc agonist were all found to inhibit the 
iNOS pathway to varying degrees in murine macrophages. Therefore suggesting that 
prostaglandin products formed during inflammation may contribute to the resolution 
of inflammation by the activation of the PPAR system (Colville-Nash et al., 1998). 
COX variants and the existence of COX 3 
Paracetamol does not potently inhibit the known COX enzymes, but with advances in 
molecular biology it has become apparent that the genes for COX 1 and 2 have 
multiple polyadenylation/cleavage sites. Therefore the RNA can be cleaved at an 
alternative site giving rise to different length mRNA products and consequently the 
generation of diverse isoforms (Hla, 1996). It has been suggested that paracetamol 
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may act on an alternative splice variant termed COX 3 (Chandrasekharan et at., 2002; 
Simmons et al., 1999), thereby giving rise to a different therapeutic profile from the 
traditional NSAIDs. However there has been some confusion over whether the 
proposed COX 3 is a gene product of COX I or COX 2. Plant & Laneuville (1999) 
detected two COX 2 gene transcripts of 2.8 and 4.5kb, with the 2.8 kb mRNA being 
derived by alternative polyadenylation, although the enzymatic activity or molecular 
structure of this transcript was not determined. Simmons et al (1999) and Botting 
(2000) observed that high concentrations of NSAIDs (e. g.. diclofenac) induced COX 
2 expression and protein levels in a murine macrophage cell line. This NSAID- 
induced COX 2 was more sensitive to paracetamol-inhibition (ICso = 0.1-1.0 mM) at 
concentrations that would not affect LPS-induced COX 2. Diclofenac-induced 
enzyme activity showed a complete insensitivity to aspirin which acetylates the 
original COX 1 and 2 enzymes potently, and suggests that the composition of the 
diclofenac-induced COX 2 active site has been altered (Simmons et at., 1999). COX 
2, induced by IL-1f in cultured lung fibroblasts from COX 1 knockout mice were also 
found to be highly sensitive to inhibition by paracetamol (Botting, 2000). This led to 
the suggestion that paracetamol inhibited the COX 2 splice variant, COX 2b 
(originally termed COX 3) or that COX 2 could exist in different catalytic states 
which exhibit different affinity and sensitivity to paracetamol and other NSAIDs 
(Bujalska & Gumulka, 2001; Simmons et al., 1999). 
In 2002, Chandrasekharan et al described a COX I variant, termed COX 3, as well as 
two smaller COX 1 proteins (partial COX 1 or PCOX 1 proteins). COX 3 contains 
the whole COX 1 transcript, and also retains the intron I sequence (Fig 8. ), which 
significantly alters the enzymatic properties (Chandrasekharan et al., 2002). 
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Fig 8. COX 3, a splice variant of the COX 1 gene: The retention of the 90 
nucleotide intron 1, leads to the production of a protein with an additional 30 amino 
acids inserted into the N-terminal, therefore making it less active than COX 1 (Garcia- 
Blanco et a!., 2004). Figure taken from Garcia-Blanco et al (2004). 
Two PCOX I proteins have been identified, PCOX ]a and PCOX lb, and both 
proteins have an in-frame deletion of exons 5-8 of the COX I mRNA. In addition 
PCOX la, like COX 3 retains the intron I sequence of the COX I gene 
(Chandrasekharan et al., 2002). 
COX 3 and PCOX mRNAs are expressed in the canine cerebral cortex and in lesser 
amounts in other tissues (Chandrasekharan et a/.. 2002). COX 3 was the only splice 
variant found to he enzymatically active in synthesizing prostaglandins from 
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arachidonic acid and possesses 20 % of the activity of COX 1 when expressed in 
insect cells (Chandrasekharan et al., 2002). However, COX 1 only possessed 20 % of 
the activity of COX 2 in the same cell system, therefore suggesting this reduced 
activity may represent an inability of the insect cells to post translationally process the 
active COX 3 in comparison to COX 1 and COX 2 (Chandrasekharan et al., 2002). 
However, the canine COX 3 transfected into insect cells was significantly more 
sensitive to all analgesic/antipyretic drugs tested including paracetamol when 
compared to COX 1 and 2 inhibition (Chandrasekharan et al., 2002). The finding 
that COX 3 is sensitive to analgesic/antipyretic drugs suggest that the COX 1' gene- 
products play an important role in pain and/or fever (Chandrasekharan et al., 2002). 
In humans, COX 3 mRNA is expressed as a larger transcript (approximately 5.2-kb) 
which not only retains intron 1 but is also alternatively polyadenylated, and is found 
most abundantly in the cerebral cortex and other forebrain regions as well as in the 
heart (see Chandrasekharan et al., 2002; Simmons, 2003). However, the intron 1 
sequence in human COX 3 differs by one nucleotide to the intron 1 sequence in 
canine COX 3, and thus shifts the remainder of the protein out of frame. Therefore it 
appears that a catalytically active form of the variant cannot exist in humans (Dinchuk 
et al., 2003; Schwab et al., 2003a). However, COX 3 has been found to be almost as 
abundant as COX 1 in human brain tissue taken from moderate to severely affected 
Alzheimer's disease patients (Cui et al., 2004), which may indicate that there is an 
active enzyme in certain disease states. Northern blot analysis of mouse and rat 
mRNAs shows that rodent tissue and cells, like humans and dogs express a high 
molecular weight COX 1 mRNA that contains intron 1 (see Simmons, 2003). This 
intron I is also out of frame, suggesting that alternative polyadenylation is tied to 
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intron 1 retention and therefore potentially to an alternative processing event that can 
overcome this frameshift to produce a viable protein (see Simmons, 2003). In murine 
spleen and brain tissue and cultured glial cells COX 3 was co-expressed with COX 1, 
although the latter was always in greater abundance (Shaftel et al., 2003). Putative 
COX 3 mRNA was also differentially expressed in various cell types from the rat 
CNS, with the highest expression found in the choroid plexus and spinal cord 
followed by the pituitary gland, hypothalamus, hippocampus, cerebellum and cortex 
(Kis et al., 2004; Kis et al., 2003). In both rat and mouse, like its COX l counterpart, 
COX 3 was not induced in the presence of an inflammatory stimulus such as IL-1f3 
and LPS respectively (Kis et al., 2003; Shaftel et al., 2003). In contrast, Warner et 
al (2004) failed to detect an active protein from COX 3 mRNA in the rat, and 
although RT-PCR showed the expression of mRNA for COX 3, western blot analysis 
suggested that it was a mixture of COX 1 and 2. Furthermore, COX 1 gene knockout 
mice exhibit a greater reduction in nociception and a greater sensitivity to the 
analgesic action of NSAIDs than COX 2 knockout mice (Ballou et al., 2000), which 
may further support the existence of COX 3 as COX 1 knockout mice will also be 
deficient in the COX 3 gene. Thus COX 1 knockout mice should be reassessed 
because they also represent the effects of COX 3, as antibodies and molecular in situ 
hybridization probes do not distinguish between COX 1 and COX 3 (Schwab et al., 
2003b). 
Although COX 3 appears to be more sensitive to paracetamol than any of the other 
isoforms, this inhibition is still only weak, leading to the conclusion that if COX 3 is 
catalytically active in humans, paracetamol only partially mediates its effects through 
the inhibition of this isoform (Schwab et al., 2003b). Paracetamol is also an effective 
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antipyretic and inhibition of COX 3 would not mediate this effect as COX 3 is not 
expressed at sites associated with fever. COX 2 knockout mice, moreover, are unable 
to mount a febrile response to exogenous and endogenous pyrogens, as well as 
exhibiting a drop in core temperature after LPS administration (Li et al., 1999). 
Furthermore, paracetamol administered to these COX 2 knockout mice, fails to 
exhibit an antipyretic effect (Bazan & Flower, 2002). Taken with the evidence that 
paracetamol has been shown to inhibit the COX 2 protein in LPS-stimulated 
microglial cultures (Fiebich et al., 2000; Greco et al., 2003), this would suggest that 
paracetamol inhibits the COX 2 protein to produce antipyresis, although the dose 
required to reduce fever does not appear to inhibit COX 2 (Bazan & Flower, 2002). 
In addition, one of the most effective antipyretics to date is aspirin, which inhibits 
COX 1 preferentially, furthermore the majority of NSAIDs are not selective for either 
isoform and even some COX 2 selective inhibitors only exhibit antipyretic action at 
doses that inhibit the COX 1 isoform too (Toutain et al., 2001). 
Although there is some contention over the existence of COX variants, there is 
increasing evidence for the existence of COX 3, however the mechanism by which 
paracetamol and other NSAIDs inhibit this isoform is still unclear. It has been 
postulated that structural changes evoked by the alteration of the COX 1 N-terminus 
may result in better binding or alternatively, an altered subcellular localization that 
may change the oxidant tone (see Simmons, 2003). In addition if COX 3 was shown 
to be catalytically active in humans its apparent localisation in the brain may support 
the original theory that paracetamol inhibits a central COX enzyme thereby only 
ameliorating central effects such as pyresis and pain (Flower & Vane, 1972). 
However it still needs to be determined whether COX 3 or a variant of COX 2 are 
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pharmacologically active in humans and what role they play in pain and inflammation 
(Fig 9). 
COX 1 gene II COX 2 
COX I COX3 COX2b COX2 COX2 
-constitutive constitutive 
inducible constitutive inducible 
2 selective 
GI tract, PGE2, PGI,, -mucosal protective Inflamed tissue, PGE2 
circulation, PGIZ CNS (PGE2 pain, fever) 
platelet aggregation 
Fig 9. The potential constitutive and inducible COX isoforms and their 
functions. The presence of multiple isoforms may explain why different patients 
benefit from different NSAIDs; different drugs inhibit different isoforms to various 
extents (Warner & Mitchell, 2002). COX 2b proposed by Simmons et al (1999) and 
COX 3 was described by Chandrasekharan et a! (2002). Diagram adapted from 
Warner and Mitchell (2002). 
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1.2.3.2. Paracetamol and Nitric Oxide 
NO structure and isoforms 
Nitric oxide is recognised to be an infra and extracellular mediator influencing cell 
function. NO is synthesized on demand from L-arginine by calmodulin-dependent 
enzymes called nitric oxide synthase (NOS) (Bredt & Snyder, 1990). NOS are 
dimeric in their active form, and contain relatively tightly bound cofactors: (BH4), 
flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and iron 
protoporphyrin IX (haem) (Fig 10. ). 
NADPH 
NADP+ 
Fr 
- ARGININE 
02 
NO 
CITRULLINE 
Fig 10. The synthesis of NO: FAD and FMN accept electrons from NADPH and pass 
them onto the haem and BH4 at the active site, which catalyses the reaction of oxygen 
and arginine, to generate citrulline and NO as products. The electron flow through the 
reductase domain requires the presence of bound calcium and calmodulin. (Alderton 
et al., 2001). 
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There are three quite distinct isoforms, which were cloned and purified between 1991 
and 1994; the constitutive forms neuronal NOS (nNOS) and endothelium NOS 
(eNOS) and the inducible form iNOS (Alderton et al., 2001). Although the human 
isoforms share 51-57% identity (Knowles & Moncada, 1994) they all have different 
genes, localization, regulation and catalytic properties and inhibitor sensitivities 
(Alderton et al., 2001). nNOS is present throughout the brain and spinal cord and 
peripheral nervous system (Moncada & Higgs, 1995) and shares 93 % sequence 
identity in the rat and human (Knowles & Moncada, 1994). The activation of the N- 
methyl-D-aspartate (NMDA) receptor stimulates nNOS, which then mediates a 
variety of functions such as induction and regulation of circadian rhythms and the 
induction of hyperalgesia (Ding et al., 1994; McMahon et al., 1993). eNOS is present 
in vascular endothelial cells and mediates decreases in vascular tone (Alderton et al., 
2001). Both constitutively expressed enzymes generally produce low levels of NO, 
and are key regulators of homeostasis (Moncada & Higgs, 1995). Both enzymes are 
highly dependent on calcium in physiologically relevant concentrations and, 
therefore, are virtually inactive at normal resting cytosolic free Ca 2+ levels (- 50 nM) 
and maximally active at levels of 0.4 -1 µM (Garthwaite, 1991). The most 
important regulator of eNOS and nNOS appears to be free cytosolic calcium, which 
stimulates NOS through the interaction with calmodulin (Fig 10) (see Esplugues, 
2002). Phosphorylation, although less well analysed, constitutes an additional 
mechanism, as there is a reduction in catalytic activity following phosphorylation by 
protein kinase A (PKA) (see Esplugues, 2002). In contrast, iNOS, which resides in 
macrophages and glial cells, can be induced by immunological and inflammatory 
stimuli and is calcium-independent because of its high affinity for calmodulin even 
when unoccupied by calcium (Alderton et al., 2001). Calmodulin increases the rate of 
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electron transfer from NADPH to the reductase domain (Gachhui et al., 1998; 
Gachhui et al., 1996) and also the electron transfer from the reductase domain to the 
haem centre (Abu-Soud et at., 1994) and therefore iNOS can give a sustained rise in 
the release of NO (Garthwaite, 1991; Klein, 2002). iNOS is highly regulated by 
cytokines and plays an important role in inflammation, host defence response and 
tissue repair (Amin et al., 1995; Salvemini et al., 1993), and thus iNOS could be a 
possible target for anti-inflammatory agents. 
iNOS and PGE2 
Naturally occurring PPAR agonists (such as PGD2 and metabolite PGJ2) and PGE2 (at 
high concentrations) can inhibit iNOS, and this inhibition may be mediated by the 
modulation of a stress protein, haem oxygenase 1 (HO 1) (Colville-Nash et al., 1998). 
HO 1 activation may have further effects on inflammation via the production of haem 
breakdown products such as carbon monoxide which may bind and inactivate the 
haem moiety of inflammation producing enzymes such as iNOS or COX (Willis et 
al., 1996). 
Studies by Salvemini et al (1993) have shown that LPS stimulated the synthesis of 
PGE2 and nitrite (NO2) in a RAW 264.7 macrophage cell line, and this stimulation 
was blocked by co-incubation with the NOS inhibitors, NG-monomethyl-L-arginine 
(L-NMMA) and aminoguanidine. Exogenous NO was shown to increase COX 
activity in IL-i 13-stimulated human foetal fibroblasts in a concentration dependent 
manner, and this stimulation was abolished by coincubation with haemoglobin (10 
µM), which binds and inactivates NO, although the soluble guanylate cyclase 
inhibitor, methylene blue, had no effect (Salvemini et al., 1993). It was therefore 
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concluded that NO produced by iNOS modulates the activity of COX through a 
cGMP independent mechanism. 
Exposure of fibroblasts from COX 2 knockout mice to micromolar concentrations of 
NO resulted in an increase in PGE2 without altering COX 1 mRNA or protein 
expression, while in contrast NO inhibited PGE2 production in both LPS stimulated 
macrophages and COX 1 deficient fibroblasts, and this inhibition was associated with 
a reduction in COX 2 expression (Clancy et al., 2000). NO appears to have a 
divergent effect on the COX isoforms, enhancing basal levels of PGE2 in cells derived 
from COX 2 knockout mice with no effect on COX 1 expression, and in contrast NO 
inhibited COX 2 synthesised PGE2, which was associated with a reduction in COX 2 
expression (Clancy et al., 2000). 
Sakai et al (1998) demonstrated that micromolar concentrations of PGE2 stimulates 
NO release in the rat spinal cord via the EP1 receptor, and furthermore it was 
suggested that the NO was released by nNOS as this PGE2-induced NO release was 
inhibited by an NMDA receptor antagonist (MK-801) and a NOS inhibitor (L- 
NAME). Therefore based on the principle that. PGE2 is capable of releasing 
glutamate (Nishihara et al., 1995), PGE2 binds to the EP1 receptor which then 
stimulates glutamate to activate the NMDA receptor, which subsqently activates 
nNOS to produce NO. Milano et al (1995) also observed that in the murine 
macrophage cell line J774, LPS stimulated production of PGE2 capable of stimulating 
TNFa activity, which is a strong inducer of iNOS, although high concentrations of 
LPS stimulated production of endogenous PGE2 which depressed TNFa activity and 
consequently iNOS. 
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Paracetamol at high millimolar concentrations was shown to dose-dependently inhibit 
LPS and IFNy-induced iNOS mRNA expression and NF-Y. 13 binding to the iNOS 
promoter in RAW 264.7 macrophage cells (Ryu et al., 2000). However, Amin et al 
(1995) demonstrated that therapeutic micromolar concentrations of paracetamol failed 
to block nitrite production in LPS-stimulated macrophages, whereas aspirin inhibited 
the expression and production of iNOS at micromolar concentrations. In agreement 
with this, paracetamol at therapeutic and higher concentrations failed to directly 
inhibit either constitutive NOS in the rat cerebellum and human umbilical vein 
endothelial cells or the inducible NOS in RAW 264.7 macrophage cells (Raffa, 2002). 
The involvement of nNOS, NMDA and cGMP in pain 
NO has been implicated as a possible modulator at various levels of nociceptive 
neuronal pathways both peripherally in primary afferent neurones and dorsal root 
ganglia and centrally, in the brainstem and several sensory nuclei within the thalamus 
(Esplugues, 2002). 
NO has been shown to regulate substance P release from the spinal cord in the rat 
(Kamisaki et al., 1995) an effect inhibited by antagonists of the 5HT3 receptor such as 
granisetron. The release was altered by inhibition of NOS with L-NMMA along with 
methylene blue an inhibitor of guanylyl cyclase. It was therefore concluded that 5HT3 
receptors in the spinal cord facilitates substance P transmission, and that the 
intracellular signalling is mediated via the NO-cGMP dependent pathway (Inoue et 
al., 1997). NMDA receptor activation by glutamate has also been shown to result in 
the activation of nNOS with a consequent production of NO (Bredt & Snyder, 1989; 
Montague et al., 1994). It has been suggested that paracetamol mediates its action via 
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a reduction in neuronal NO mechanisms in vivo (Bjorkman, 1995). Björkman (1994) 
observed that pre-treatment with paracetamol inhibited spinal hyperalgesia induced by 
NMDA and substance* P, but, failed to inhibit alpha-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic acid (AMPA)-induced hyperalgesia. This paracetamol-induced 
analgesia was readily reversed by the administration of L-arginine indicating that 
paracetamol may mediate its effect partially through the inhibition of the L-arginine- 
NO pathway (Bjorkman, 1994). Furthermore, selective and nonselective nNOS 
inhibitors administered centrally (i. c. v. and i. t. ) and peripherally (i. p. ) have been 
found to potentiate the antinociceptive activity of paracetamol in the writhing and paw 
pressure tests in rats (Bujaiska, 2003; Bujalska & Gumulka, 2001). 
Nitroparacetamol (NO-paracetamol) 
The production of high levels of NO within the liver, via iNOS, promotes liver 
damage via interference with mitochondrial respiration (Moncada & Erusalimsky, 
2002). However low/physiological amounts of NO (i. e. eNOS or nNOS) in the liver 
have been found to protect the liver against damage induced by TNFa or Fas- 
dependent apoptosis (Fiorucci et al., 2001) and have been shown to inhibit cell 
apoptosis by post-translational inactivation of caspase 1 and' 3 (Dimmeler et al., 
1997). Nitroparacetamol (NO-paracetamol) which is a nitric oxide-releasing 
derivative of paracetamol has been shown to be completely devoid of liver toxicity in 
BALB/c mice, whereas as paracetamol caused a 40 fold increase in aspartate 
aminotransferase plasma levels and extensive centrilobular necrosis due to a fas- 
mediated pathway (Fiorucci et al., 2002) indicating that NO-paracetamol is 
hepatoprotective (Futter et al., 2001). NO-releasing NSAIDs have also been found to 
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be associated with fewer gastrointestinal side effects, due to the NO-mediated 
mucosal vasodilatation (see Keeble & Moore, 2002). 
Al-Swayeh et al (2000) and Romero-Sandoval et al (2002) observed that NO- 
paracetamol exhibited anti-inflammatory activity in the carageenin-induced rat hind 
paw oedema and also reduced electrical stimulation (wind-up)-induced hyperalgesia, 
whereas equal doses of paracetamol were ineffective in these models. Romero- 
Sandoval et al (2002) suggested that NO-paracetamol might negatively modulate the 
activity of the NMDA receptor, by depressing the release of glutamate, on the 
principle that paracetamol inhibits PGE2 synthesis which subsequently suppresses 
PGE2-stimulated glutamate release (Nishihara et al., 1995). 
In addition, NO-releasing compounds have been shown to inhibit COX 2 activity 
selectively in human umbilical vein endothelial cells without altering COX 2 protein 
expression (Kosonen et al., 1998). This has been proposed to be mediated via the NO 
inactivation of the haem group within an enzyme, such as COX, thereby affecting the 
enzymes activation state (Henry et al., 1993). 
1.2.33. Receptor mediated effects 
5HT 
5-Hydroxytryptamine (5HT)/serotonin is a major neurotransmitter involved in pain 
transmission. 5HT-containing neurons in the brain and spinal cord are involved in the 
regulation of nociceptive sensitivity, but different subtypes may play different roles in 
pain regulation and even opposite effects (Eide & Hole, 1993). Stimulation of 5HTi 
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receptors reduces nociceptive sensitivity whereas activation of 5HT2 receptors 
increases nociceptive responsiveness (Eide & Hole, 1993). There is evidence that 
serotonergic pathways are involved in paracetamol-mediated antinociception. 
Lesioning of 5HT pathways with 5,6-dihydroxytryptamine reduced the 
antinociceptive properties of paracetamol in the formalin test in rats (Tjolsen et al., 
1991). Courade et al (2001b) observed a significant increase in 5HT levels in the 
posterior cortex, hypothalamus, striatum, hippocampus and the brainstem but not the 
spinal cord, a reduction in dopamine metabolites in the striatum and an increase in 
noradrenaline levels in the posterior cortex following paracetamol administration. 
Paracetamol-induced antinociception in the hotplate and formalin test in the rat was 
accompanied by a significant increase in 5HT levels and a reduction in the maximum 
number of 5HT2 receptors in the pontine and cortical areas, while 5HTIA receptor 
levels remained unchanged (Pini et al., 1996). Srikiatlhachorn et al (1999; 2000) 
observed in both rats and mice that paracetamol significantly decreased the maximum 
number of 5HT2A binding sites in the frontal cortex but had no effect on receptor 
affinity. This receptor downregulation was observed in acutely (90 mins) and 
chronically (15 and 30 days) treated rodents, but, this down regulation was less 
evident in rats and mice treated for 30 days with paracetamol (Srikiatkhachorn et al., 
1999; Srikiatkhachom et al., 2000). A corresponding increase in latency in the tail 
flick test was also observed in the acute and 15 day treated but not the 30 day treated 
rats (Srikiatkhachorn et al., 1999). Following paracetamol administration for 15 days 
5HT transporters was significantly increased in frontal cortex of the mouse, but this 
upregulation was not as evident in mice treated for 30 days (Srikiatkhachorn et al., 
2000). Therefore it was suggested that the 5HT depletion resulted in the re-adaptation 
of postsynaptic 5HT2A receptors as well as an upregulation of the transporters 
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(Srikiatkhachorn et al., 1999; Srikiatkhachorn et al., 2000). 5HT2 receptors located 
supraspinally may inhibit descending nociceptive transmission, and the receptors 
located spinally modulate nociception differently depending on dose, site of 
administration and stimulus (Alhaider, 1991). 
Paracetamol produced an antinociceptive effect to the hotplate test in mice and this 
effect was potentiated by 5HTJA antagonist WAY 100635 and decreased by a 5HTIA 
agonist in a non dose-dependent manner (Roca-Vinardell et al., 2003). In the same 
study, the 5HTIB antagonist SB216641 induced a dose-related increase in the 
antinociceptive effect of paracetamol and CP93129, a 5HT1B agonist significantly 
decreased the effect of paracetamol (Roca-Vinardell et al., 2003). In addition, 
CP93129 also significantly reduced the antinociceptive effect of paracetamol in both 
hotplate and paw pressure test in rats (Sandrini et al., 2003). Thus paracetamol 
antinociception is increased when 5HT, receptors are antagonised and stimulation of 
these receptors reduces the antinociceptive effect of paracetamol, which could 
indicate that paracetamol partially mediates its effect through the 5HT1 receptor. 
5HT3 receptors are concentrated in the dorsal horn of the spinal cord (Glaum et al., 
1990), but are also present in some CNS areas, including the hippocampus, limbic and 
cortical areas (Laporte et al., 1992). Paracetamol dose-dependently reduced C-fibre 
evoked reflex activity in the rat indicating a central site of action, and this effect was 
totally suppressed by a the 5HT3 antagonist, tropisteron (Pelissier et al., 1995). 
Paracetamol induced significant antinociception in the rat paw pressure test and 
carageenin-treated rats and this effect was also abolished by tropisetron (Alloui et al., 
2002; Pelissier et al., 1996). Unlike tropisetron other 51-IT3 receptor antagonists such 
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as ondansetron and granisetron were unable to reverse the antinociceptive effect of 
paracetamol in both the paw pressure and hot plate tests in rats (Libert et al., 2004; 
Sandrini et al., 2003). In addition, spinal administered antisense 
oligodeoxynucleotides to the 5HT3 receptor did not reverse the antinociceptive effect 
of paracetamol in the rat paw pressure test (Libert et al., 2004). As, 
electrophysiological studies demonstrated that paracetamol had no direct agonist or 
antagonist effects on 5H'T3A receptors and paracetamol also fails to demonstrate any 
binding affinity to the 5HT3 receptor (Sandrini et al, 2003), it was concluded that 
paracetamol mediates its action through a tropisetron-sensitive receptor that is not the 
5HT3 receptor (Libert et at., 2004). 
Courade et al (2001c) observed that the antinociceptive effect of paracetamol in the 
rat paw pressure test was partially inhibited by intrathecal (i. t. ) pre-treatment with the 
5HT antagonists penbutolol (5HTIB), ketanserin (5HT2A) and mesulergine (5HT2C), 
but not by WAY 100635 and granisetron (5HTIA and 5HT3 respectively). 
Others have studied the effects of paracetamol on 5HT3 receptor inherent in anti- 
inflammatory models. The response curve induced by formalin is biphasic, with an 
early phase (phase 1) and a late phase (phase 2). The early phase starts immediately 
and lasts for 3-5 minutes (Tjolsen et al., 1992) and is a direct chemical stimulation of 
nociceptors resulting in an acute and intense activation of C fibres and to a lesser 
extent of A delta afferents (Heapy et al., 1987). There is subsequently a period of 10- 
15 mins when animals display very little behaviour suggestive of nociception, and 
then phase 2 represents a prolonged tonic response in which inflammatory processes 
are involved and neurones in the dorsal horn are activated (Tjolsen et al., 1992). A 
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number of NSAIDs and paracetamol are typically most active in reducing phase 1 and 
the first part of phase 2 responses (Malmberg & Yaksh, 1992). Pini et al (1996) and 
Bonnefont et al (2003) demonstrated that the flinches in all phases are reduced by 
high concentrations of paracetamol while lower concentrations were only active in 
phases 1 and the early part of phase 2. The same trend was seen with the systemic 
administration of paracetamol, where high doses reduced nociceptive behaviour in 
both phases, whereas, lower doses reduced only the second phase (Bonnefont et al., 
2003). WAY 100635 reversed the effect of paracetamol in both phases. However this 
reversal was not seen when paracetamol was administered intrathecally. It was 
therefore concluded that orally administered paracetamol does not exert any local 
action in the fonmalin test but may activate the 5HT pathway (Bonnefont et al., 2003). 
The effect of serotonergic lesions on analgesia can only be demonstrated in the early 
formalin phase and spinal serotonergic pathways do not alter the response in the later 
phase of the formalin test, thereby, indicating that 51-IT is involved in the modulation 
of the first phase (Tjolsen et al., 1992). It was therefore suggested that the effect of 
paracetamol in the late phase is dominated by the influence on peripheral. 
inflammation and therefore the effect of manipulating the central mechanism, i. e. 5HT 
pathways is less predominant (Tjolsen et al., 1991). 
The mechanisms by which paracetamol could induce changes in 5HT levels and 
receptor subtypes is unclear and it is likely that any effect is indirect since Raffa & 
Codd (1996) showed that paracetamol at micromolar concentrations does not bind to 
any of nine receptor subtypes (5HT1p,, 5HT1B, 5HT1D, 5HT2,5HT2c, 5HT3,5HT4, and 
5HT6, and 5HT7) or the neuronal serotonin re-uptake site. In addition Pelissier et al 
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(1996) found no significant affinity of paracetamol for the 5HTIA, 5HTIB, 5HT2a9 
5HT3, and 5HT uptake sites. 
Opioids 
Opioids and the NOP receptor 
Opiates as well as some endogenous peptides exert their effects by acting on the 
classical opioid receptors (It, 8, ic opioid receptors). A more recent addition to the 
opioid receptor family is the nociceptin/orphanin FQ opioid peptide (NOP), 
previously designated the opioid receptor like, ORL 1 receptor. The NOP receptor 
which shares some degree of sequence identity (49-50 %) with the classical opioid 
receptors (Mollereau et al., 1994) and within the transmembrane domains the level of 
identity rises to 61-64 % (Bunzow et al., 1994). All four receptors are negatively 
linked to adenyl cyclase (Bunzow et al., 1994). Initial pharmacology showed that the 
NOP receptor, stably transfected into Chinese hamster ovary cells, could be activated 
by the non-selective opioid receptor agonist etorphine and blocked by the antagonist 
diprenorphine, however the non-selective antagonist, naloxone showed no affinity 
(Mollereau et al., 1994). NOP appears to be highly conserved in mammalian species 
(Mollereau et al., 1994) and in situ hybridization studies have localized cDNA for the 
NOP receptor to be widely but discretely distributed throughout the forebrain, 
brainstem and spinal cord like the classical opioid receptors, (Mollereau et al., 1994; 
Neal et al., 1999). However, in contrast to classical opioid receptor expression, NOP 
is weakly expressed in the striatum (Mansour et al., 1996; Mansour et al., 1994). 
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Nociceptin/orphanin FQ (OFQ) is the endogenous peptide for the NOP receptor, and 
binds with high affinity (Dooley & Houghten, 1996; Reinscheid et al., 1995). 
Specific binding was observed with 125I- [Tyr]-OFQ, whereas t (morphine), 8 
(DPDPE, DADLE) and x (bremazocrine, U69 593) agonists failed to compete for the 
NOP receptor even at micromolar concentrations, and similarly naloxone and the 
endogenous opioid ß-endorphin failed to displace NOP binding (Neal et al., 1999). 
Despite nociceptin sharing a high degree of sequence homology with endorphins, 
enkephalins and in particular dynorphins, nociceptin lacks the amino terminal tyrosine 
required for opioid activity (Sim et al., 1996), and therefore does not show any 
appreciable affinity for µ, S, or x receptors (see Meunier, 1997). 
Early studies showed that nociceptin had a hyperalgesic action in the hotplate test 
(Meunier et al., 1995) and tail flick test (Reinscheid et al., 1995) in mice. However, 
further investigation indicated that nociceptin/OFQ had many effects on nociceptive 
responses, determined by the route of administration, concentration and the species. 
The peptide has been reported to produce hyperalgesia, reversal of opioid-mediated 
analgesia, analgesia and allodynia (Table 3) (see Meunier, 1997). The original 
suggestion that nociceptin produced a hyperalgesic effect in mice when administered 
supraspinally (i. c. v. ) is now thought to be a misinterpretation, in that the i. c. v. 
injection itself caused a stress-induced analgesia which was - reversed by either 
naloxone or nociceptin (Mogil et al., 1996a), and therefore saline-injected animals 
had a prolonged analgesic latency compared to nociceptin-treated animals (Harrison 
& Grandy, 2000). In addition to endogenous opioid antagonism, nociceptin dose- 
dependently reverses the effects of morphine and other opioid agonists, suggesting 
that nociceptin is an anti-opioid (Mogil et al., 1996a). 
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Table 3. The effects of Nociceptin/OFQ on nociceptive responses 
Species Route Test Dose of Outcome Reference 
nocice tin 
Mouse i. c. v. TF 0.3-10 nmol Hyperalgesia (naloxone- (Reinscheid et al., 
insensitive) 1995) 
Mouse i. c. v. HP 20 µg/day Hyperalgesia (naloxone- (Meunier et al., 1995) 
insensitive) 
Mouse i. c. v. TW, 49°C 2.5-25 nmol Antagonizes DAMGO 
(0.01-0. lnmol), DPDPE 
(Grisel et al., 1996; 
Mogil et al., 1996a; 
(10-50 nmol), U50 488H Mogil et al., 1996b) 
(100-1000 nmol) and 
morphine analgesia 
Mouse i. c. v. TF 10 nmol Hyperalgesia (Citterio et al., 2000) 
Reversal of morphine and 
dynorhin A-mediated 
analgesia 
Rat i. c. v. TW 49°C 400 fmol-50 Antagonizes morphine (Tian et al., 1997a) 
nmol analgesia 
Rat i. c. v. TF 0.1-10 nmol Antagonizes EA-analgesia (Tian etal., 1997b) 
Rat i. t. Spinal 1,10µg Depression of reflex (Xu et al., 1996) 
nociceptive 
flexor reflex 
Rat i. t. TF 1,10 Analgesia (Xu et al., 1996) 
Rat i. t. TF 1,10 µg and Analgesia (Tian et al., 1997a; Xu 
3,10 nmol et al., 1996) 
Rat i. t. TF 1,10 nmol Potentiates morphine (Tian et al., 1997a) 
analgesia 
Mouse Lt. TW, 49°C 10 nmol No effect (Grisel et al., 1996) 
Rat i. t. TF 1-10 nmol Analgesia, potentiates EA- (Tian et al., 1997b) 
analgesia 
Mouse i. t. TF 20µg Naltrexone-reversible (King et al., 1997) 
analgesia 
EA electro-acupuncture (100 Hz), HP hotplate test, TW tail withdrawal, TF tail flick 
test. Adapted from Harrison et al (2000) 
Paracetamol and the opioid system 
In competition experiments paracetamol demonstrated a low micromolar affinity in 
the cortex and in the pons for [3H]naloxone binding sites, suggesting that paracetamol 
only binds directly to the receptor at high concentrations (Pini et al., 1997). Pre- 
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treatment with naloxone abolished the antinociceptive activity of paracetamol in both 
the hotplate and the first phase of the formalin test, without affecting the serum 
concentration of paracetamol in rats (Pini et al., 1997). Naloxone also prevented the 
paracetamol-induced reduction in 5HT2 receptors and the consequent rise in 5HT 
(Pini et al., 1997). This study implicated a link between the serotonergic and 
opioidergic systems in paracetamol-mediated analgesia. 
Sandrini et al (2001a) also found that pretreatment with naloxone attenuates 
antinociceptive activity of paracetamol in the hotplate test and the first phase of the 
formalin test. In addition, pretreatment with the u antagonist [2(-)-2-(3 furylmethyl)- 
normetazocine] (MR 2226) attenuates the antinociceptive action of paracetamol in the 
hotplate and both phases of the formalin test (Sandrini et al., 2001a). Dynorphin A 
has also been implicated in paracetamol-induced analgesia, as evident by a significant 
reduction in dynorphin A levels in the frontal cortex accompanying paracetamol- 
mediated antinociception (Sandrini et al., 2001a). 
When paracetamol and morphine are administered in combination the antinociceptive 
effect was significantly greater than either drug administered alone in the hotplate test 
in the rat (Sandrini et al., 2001b). Antinociception was accompanied by a reduction 
in dynorphin levels in the frontal cortex but only when the two drugs were 
administered in combination was the effect abolished by pre-treatment with the ic- 
opioid receptor antagonist MR2226 and the non-selective opioid antagonist naloxone. 
However the reduction in dynorphin levels was only partially attenuated by MR2226, 
and not at all by naloxone (Sandrini et al., 2001b). The decrease in levels of 
dynorphin A in the frontal cortex by high concentrations of paracetamol alone and 
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low doses of paracetamol in combination with morphine suggests that both drugs may 
act through similar mechanisms. This mechanism may involve the opioidergic system 
and alteration of dynorphin release, which in turn may increase 5HT levels and could 
consequently produce analgesia (Pini et al., 1997). 
Raffa et al (2000) specifically examined the administration of paracetamol into spinal 
and supraspinal sites to determine whether paracetamol elicits two-site synergism. 
When administered spinally paracetamol produced a dose-dependent antinociception 
in the writhing test in mice (Raffa et al., 2000), however when administered 
supraspinally paracetamol was ineffective. When paracetamol was coadministered at 
lower concentrations at both sites the resulting antinociception was equivalent to that 
produced by a high dose of paracetamol administered at one site suggesting a self- 
synergistic interaction between the brain and spinal cord. Spinal administration of 
naloxone reverted the synergistic interaction to an additive relationship. However, in 
contrast when injected supraspinally naloxone had little effect on the synergistic 
effect of paracetamol (Raffa et al., 2000). When administered orally paracetamol 
produced antinociception which was also significantly attenuated by pretreatment 
with naloxone. It was therefore concluded that the opioid system may contribute to 
some extent at the spinal level to the antinociceptive mechanism of paracetamol and 
antinociception following systemic administration results from a synergy between 
supraspinal and spinal sites (Raffa et al., 2000). Endogenous opioids and their 
pathways have been further implicated in the antinociception of paracetamol, as 
subtype-selective opioid antagonists, (3-funaltrexamine (µ), naltrindole (S) and nor- 
binaltorphimine (x) attenuated this paracetamol-induced self-synergy in mice (Raffa 
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et al., 2004). However, the involvement of the opioid system must be indirect due to 
lack of affinity of paracetamol for µ, 6 and x receptors (Pelissier et al., 1996). 
1.2.3.4. Other possible mechanisms 
Voltage-dependent Na' channels in sensory nerves contribute to the control of 
membrane excitability and underlie the generation of action potentials, and some Na' 
channel subtypes have been implicated in pain states that are associated with nerve 
injury and inflammation (Baker & Wood, 2001). It has been suggested that sensory 
neuron-specific tetrotoxin-resistant Na+ channels are involved in pain pathways and 
that the blockade of expression or function may produce analgesia (Akopian et al., 
1999). A variety of hyperalgesic mediators (PGE2, adenosine and serotonin) dose- 
dependently modulate tetrodotoxin-resistant currents by increasing the magnitude of 
the current, shifting its conductance-voltage relationship in a hyperpolarized direction 
and therefore increasing the rate of activation and inactivation (Baker & Wood, 2001; 
Gold et al., 1996). Antagonising these mediators could therefore produce an 
antinociceptive effect. 
Acidosis observed in inflammatory conditions such as chronic joint inflammation, 
contributes greatly to pain and hyperalgesia. This acid sensitivity of nociceptors is 
associated with the activation of voltage-gated H+ channels (Voilley et al., 2001). 
Voilley et al (2001) observed that NSAIDs prevented the inflammation-induced 
expression of acid-sensing ion channels in sensory neurons, and in addition some 
NSAIDs, such as asprin and diclofenac, directly inhibited these currents. However 
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compounds such as paracetamol, indomethacin and the COX 2-selective inhibitor 
rofecoxib failed to inhibit voltage-gated H+ channels in these neurons. 
Calcium has a physiological role in the control of pain either through a direct action, 
modulating of membrane excitability, which is dependent on the passage of calcium 
through membrane channels or transport through an ion pump, or through modulation 
of the analgesic activities of other endogenous substances such as transmitters, 
peptides, hormones via a transient increase in cytoplasmic calcium (Koleva & 
Dimova, 2000). Assi (2001) observed that co-administration of the calcium channel 
blockers nifedipine and verapamil enhanced the analgesic effect of paracetamol 
against mechanical (tail clip) and chemical stimuli (writhing test) pain in mice. 
Nifedipine, and verapamil, as well as the calmodulin antagonist trifluoperazine 
administered orally, are antinociceptive alone and also potentiate the effect of 
paracetamol in the writhing test in mice (Koleva & Dimova, 2000). The potentiation 
is most probably due to the individual effects of the antagonists and paracetamol on 
different mechanisms thereby leading to additive effects. 
Paracetamol administered peripherally and systemically both produced 
antinociception in the tail flick test in mice and this antinociception was antagonised 
by the ai-adrenoreceptor antagonist, prazosin but not by the a2-adrenoreceptor 
antagonists yohimbine (Pinardi et al., 2002). Therefore it was postulated that 
paracetamol-induced antinociception might be due to the central activation by ai- 
adrenoreceptors of the descending noradrenergic inhibitory system (Pinardi et al., 
2002). 
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13. Adenosine 
The physiological importance of adenosine has been widely reported since 1929 
(Drury & Szent-Gyorgyi, 1929). It is now accepted that the majority of its biological 
effects are mediated via the activation of G protein-coupled receptors (Collis & 
Hourani, 1993; Fredholm et al., 1994; Fredholm et al., 2001; Ralevic & Burnstock, 
1998). These receptors interact with several effector systems, primarily the inhibition 
and stimulation of adenylate cyclase, but also cGMP, phosphodiesterases, 
phospholipase A2, phosphinositidase and calcium and potassium channels (Ralevic & 
Burnstock, 1998). Adenosine has important diverse effects on biological processes, 
and dependent on the receptor subtype activated these effects can be conflicting as 
outlined below (Collis & Hourani, 1993; Daval et al., 1989; Dubey et al., 1996; 
Feoktistov & Biaggioni, 1997; Feoktistov et al., 1998; Fredholm, 1995; Kaiser & 
Quinn, 1999; Ralevic & Burnstock, 1998). 
13.1. Adenosine receptors and transporters 
At present four distinct adenosine receptors, A1, AZ, e,, A2B and A3, have been cloned 
and characterised in several species (Table 5) and can be characterised 
pharmacologically (see Fredholm et al., 2001). 
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Table 5. Summary of classification of adenosine receptors. 
At Ain Als A3 
'Affinity for adenosine - 70 nM - 150 nM - 5100 nM - 6500 nM 
`G protein G; and Go GS and Gaf G, and Gq G13 and Gq 
'Transduction .. CAMP 
T cAMP T cAMP I cAMP 
mechanism T K+, 1P3, PLC TCat+, PLC, T,, Ca2+, PLC 
IN 
°Selective agonists R-PIA, CPA CGS21680 Metrifudil IB-MECA, 
CI-IB-MECA 
bSelective antagonists DPCPX ZM241385, Enprofylline, MRS 1191 
SCH58261 PSB 1115 
a. k d Distribution High levels: Predominately' Widely Widely 
Cortex, expressed in the distributed, distributed, 
cerebellum, periphery. High present at a low present at a 
hippocampus levels: spleen, density in the low density in 
and the dorsal thymus, brain the brain 
horn. Lower leukocytes, 
levels: in other platelets. 
brain regions Restricted 
and peripheral expression in 
tissues CNS; striatum, 
nucleus 
accumbens, 
olfactory 
tubercle 
`Caffeine affinity (Kd) 
Rat 20 pM 8.1 pM 17 pM 190 pM 
Human 12 µM 2.4µM 13 µM 80 µM 
1, decrease; T, increase; IP3, Inositol triphosphate; PLC, Phosphodiesterase C; CPA, 
N6-cyclopentyladenosine; CGS 21680,2-p-(2-Carboxyethyl) Phenethylamino-5'-N- 
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ethylcarboxamidoadenosine Hydrochloride; DPCPX, 1,3-dipropyl-8- 
cyclopentylxanthine; IB-MECA, 2-chloro- N6 -(3- iodobenzyl) adenosine-5 -N- 
methylcarboxamide; MRS 1191,3-Ethyl-5-benzyl-2-methyl-4-phenylethynyl-6- 
phenyl-1,4-(±)-dihydropyridine-3,5-dicarboxylate; PSB 1115,1 -propyl-8p-sulfo 
phenylxanthine; R-PIA, N6-(R-phenylisopropyl)-adenosine; SCH58261,5-amino-7- 
(2-phenylethyl)-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolol[ 1,5-]pyrimidine; 
ZM241385,4-[2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]- triazin-5-ylamino] 
ethyl]phenol. Adapted from aDunwiddle & Masino (2001), bFeoktistov & Biaggioni 
(1997) and `Fredholm et al (1996), d Fredholm et al (2001) Jarvis & Williams (1989) 
Rivkees et al (2000). 
1.3.1.1 Al receptor 
The A, receptor has ubiquitous expression within the CNS and is primarily linked to 
the inhibition of adenylyl cyclase, the activation of K+ channels and the inhibition of 
Ca2+ channels through inositol phosphate and PLC transduction systems (see 
Dunwiddle & Masino, 2001). Al receptors are linked to the inhibition of the release 
of nearly every classical neurotransmitter including glutamate, gamma aminobutyric 
acid (GABA), acetylcholine, noradrenaline, 5HT and dopamine (see Dunwiddle & 
Masino, 2001). This inhibition of neurotramsmitter release plays an important 
neuroprotective role in hypoxia and ischamic conditions (see Ralevic & Burnstock, 
1998). The inhibitory modulation of transmitter release primarily appears to reflect 
the inhibition of Cat+channels in nerve endings (Fredholm & Dunwiddie, 1988). The 
action of adenosine at the Al receptor has also been implicated in sedation, 
anticonvulsant activity, anxiolytic, antinociceptive and locomotor depressant effects, 
all of which have been confirmed in knockout mice (Johansson et al., 2001). There is 
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considerable evidence for a link between adenosine Ai receptors and dopamine D1 
receptors (Ferre et al., 1991), with the anatgonism of adenosine A, receptors, 
enhancing the motor effects of D1 receptor agonists (Ward et al., 1991). In the 
kidney the activation of the Al receptor mediates vasoconstriction, a reduction in 
glomerular filtration and the inhibition of rennin secretion (see Fredholm et al., 2001) 
and in the heart the A, receptor mediates cardiac depression causing bradycardia (see 
Ralevic & Bumstock, 1998). 
1.3.1.2. A2A receptor 
The A2A receptors are predominantly expressed in the periphery, but there is also a 
very high and restricted expression in the brain (Table 5) (Jarvis & Williams, 1989). 
The A2A receptor is predominantly coupled to the stimulation of adenylyl cyclase. 
A2A receptor-mediated excitatory neurotransmitter release has been observed in the 
central (Brown et al., 1990; Spignoli et al., 1984) and the peripheral nervous system 
(Correia-de-Sa et al., 1991). A2A receptors also interact with inotropic and 
metabotropic glutamate receptors and GABAB receptors to regulate cAMP formation. 
In the vasculature, A2A receptors 'are found on the smooth muscle and endothelium, 
where there are associated with vasodilation (Ralevic & Burnstock, 1998). A2A 
receptors have been implicated in platelet aggregation, nociception and in the 
maintenace of blood pressure and heart rate (Ledent et al., 1997). Negative 
interactions have been observed between A2A and D2 receptors, in that the A2A 
receptors alter the binding characteristics of D2 receptors for their agonists in rat 
striatal slices (Ferre et al., 1997; Ferre et al., 1991). Several studies have suggested 
that A2 receptors are physiologically relevant in cerebral ischaemia, neurological 
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disorders and neurodegenerative processes such as Parkinson's disease (see Kaiser & 
Quinn, 1999). 
13.13. A2B receptor 
The A2B receptors are ubiquitously expressed throughout the brain and periphery 
(Dixon et al., 1996; Stehle et al., 1992). The A2B receptor is predominantly coupled 
to the stimulation of adenylyl cyclase and the consequent rise in cAMP, although 
other intracellular signalling pathways are also coupled to the A2B receptor. 
Feoktistov & Biaggioni (1995) demonstrated that in the human mast cell line, HMC-1 
A2B receptors were coupled to phospholipase C via a cholera and pertussis toxin 
insensitive G-protein, presumably Gq. Activation of the A213 receptor coupled- 
phospholipase C in HMC-1 increases diacylglycerol levels and subsequently activates 
protein kinase C. Phospholipase C can also stimulate interleukin 8 secretion, and this 
effect was blocked by antiasthmatic drugs, enprofylline and theophylline, thereby this 
pathway offers a possible explanation for the involvement of adenosine in 
bronchoconstriction in humans (Feoktistov & Biaggioni, 1995). The involvement of 
A2B receptor in HMC-1 activation was further confirmed by the inhibition of mast cell 
activation by the A2B receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (Feoktistov 
et al., 2001). The A2B receptors are also involved in smooth muscle relaxation in the 
vasculature and intestine where the A2A receptor does not predominate (see Ralevic & 
Burnstock, 1998). 
-63- 
1.3.1.4. A3 receptors 
In 1992, Zhou et al cloned and characterised the fourth adenosine receptor, the A3 
receptor. This receptor is ubiquitously expressed, however, high expression was 
found in the testes and mast cells (Zhou et al., 1992). The A3 receptor is 
predominantly coupled to the inhibition of adenylyl cyclase but is also coupled to 
other intracellular signalling pathways such as the cholera and pertusis toxin 
insensitive Gq G-protein. In contrast to humans, the A3 receptor appears to play a 
role in enhancement of mediator release from mast cells in rodents, since inosine, a 
metabolite of adenosine that accumulates in ischaemic tissue and can trigger mast cell 
degranulation, binds to the A3 receptor in the rat, and therefore suggested that inosine 
binding to this subtype may stimulate degranulation (Jin et al., 1997). Furthermore, 
A3 receptor knockout mice exhibited an attenuated response to adenosine-induced 
bronchoconstriction, and show significantly less degranulation of mast cells than their 
wildtype controls (Tilley et al., 2003). There is some uncertainty as to the subtype 
involved in adenosine-induced mast cell degranulation, this could be due to the cross- 
selectivity of the adenosine analogues used, or different signalling pathways in 
different tissues and/or species. The A3 receptor may also be cardioprotective in 
ischaemia, in isolated cardiac myocytes cardioprotection was shown to require the 
activation of the Al and A3 receptors (see Mubagwa & Flameng, 2001; Wang et al., 
1997). There may also be a role for the A3 receptor in locomotion as the systemic 
administration of IB-MECA depresses locomotor activity in mice (Jacobson et al., 
1993). 
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1.3.1.5. Adenosine transporters 
Most physiological actions of adenosine are mediated by the adenosine receptors, and 
the availability of adenosine for processes including adenosine uptake/transport, 
release, production and degradation (Geiger, 1987) govern these sites. Extracellular 
concentrations of adenosine are regulated by rapid transport into cells by transporters, 
where it is either phosphorylated to AMP by adenosine kinase (Km = ca. 100 nM) or 
degraded to inosine by adenosine deaminase (Km = 20-100 µM) (see Fredholm et al., 
1996). In the 1980's it was established that nucleoside transport occurs via two 
distinct processes; facilitated diffusion and Na+-dependent (see Cass et al., 1999; 
Geiger, 1987; Geiger et al., 1985; Geiger & Nagy, 1985). Since then it has been 
recognised that there are multiple carriers for the transport of nucleosides, that are 
either equilabrative nucleotide transporters (ENT), which are facilitated 
bidirectionally carrier proteins or the concentrative nucleotide transporters (CNT) 
which are inwardly directed Na+-dependent/cotransporters (see Kong et al., 2004). 
Equilabritive facilitated diffusion appeared to occur via two distinct transporters, 
which were functionally differentiated by their sensitivity to the transport inhibitor 
nitrobenzylthioinosine (NBTI). The equilibrative-sensitive transporter (es), is 
inhibited by nanomolar concentrations of NBTI, whereas the equilibrative-insensitive 
transporter retains full activity until exposed to micromolar concentrations of NBTI 
(Thorn & Jarvis, 1996). These two ENT systems have been cloned and characterised 
from mammalian cells and are designated ENT 1 (es) and ENT 2 (ei) (Crawford et al., 
1998; Griffiths et al., 1997; Yao et at., 1997). The ENT systems (ei and es) are 
expressed in most cell types (see Baldwin et al., 1999) and transport both pyrimidine 
and purine nucleosides and in addition ei transports nucleobases (see Ritzel et al., 
2001 a). 
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To date three CND' systems have been cloned from human and rodents; CNT I (cit 
system) generally pyrimidine nucleoside selective (Huang et al., 1994), CNT 2 (cif 
system) which is purine nucleotide and uridine selective (Che et al., 1995) and more 
recently CNT 3 (cib system), this transporter differs from CNT 1/2 in its functional 
activities and transports both pyrimidine and purine nucleosides (Ritzel et al., 2001b). 
The CNT systems are primarily expressed in specialized epithelial cells such as 
intestine, kidney, testes and liver (see Lu et al., 2004; Ritzel et al., 2001a). 
1.3.2. Adenosine and pain 
It has been observed that peripheral administration of adenosine produces pronounced 
pro-nociceptive effects, whereas centrally administered adenosine produces 
antinociceptive effects (Sawynok & Yaksh, 1993). Therefore centrally administered 
adenosine agonists would enhance antinociception and centrally administered 
antagonists like caffeine should produce nociception. Adenosine A, agonists, CPA, 
R-PIA, NECA and 2-chloroadenosine (CADO) all produce a dose-related inhibition 
of acetylcholine-induced writhing in mice, and this antinociception is comparable to 
morphine and more potent when the drugs are administered by 
intracerebroventricular, suggesting a central site of action (Herrick-Davis et al., 
1989). It has also been observed that NECA, the non-selective A, /A2A agonist was 
antinociceptive when administered through central and peripheral routes (Holmgren et 
al., 1986). In addition, NECA was 15 times more potent than the A, agonists N6- 
cyclohexyladenosine (CHA) and L-PIA, therefore it was suggested that NECA 
activated both Ai and A2A receptors at central and peripheral sites to produce 
antinociception (Holmgren et al., 1986). In humans, the Al receptor activation has 
also been shown to have analgesic and anti-inflammatory actions, and GR79236 a 
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highly selective A, receptor agonist has been shown to inhibit trigeminal nerve firing, 
which plays a pivitol role in migraine in animals and humans (Giffin et al., 2003). 
Holmgren et al (1986) also observed that itrathecally administered agonists were 
more potent than peripherally administered agonists in the tail flick assay in mice. 
The spinal antinociceptive effects of A, and A2 agonists have also been investigated in 
the carrageenan-induced thermal hyperalgesia model in the rat, where the A, agonist 
CHA produced a dose-dependent antinociception in the inflamed and non-inflamed 
paw (Poon & Sawynok, 1998). CGS21680 only produced antinociception at high 
nanomolar doses in the inflamed paw (Poon & Sawynok, 1998) but adenosine kinase 
inhibitors 5-amino-5'-deoxyadenosine (NH2dAD) and 5-iodotubercidin produced 
dose-dependent antinociception (Poon & Sawynok, 1998). This antinociception 
produced by adenosine agonists and adenosine kinase inhibitors were all reversed by 
the administration of caffeine and the A, antagonist cyclopentyl-1,3- 
dimethylxanthine (CPT), however an A2A antagonist failed to reverse this 
antinociception, suggesting the activation of the spinal Al receptors mediates 
antinociception (Poon & Sawynok, 1998). Peripheral administration of NH2dAD was 
also antinociceptive in the rat formalin test, this antinociception was again reversed by 
the administration of caffeine and CPT (Sawynok et al., 1998). It has been suggested 
that A2A activation facilitates the activity of the nucleoside transporters, as CGS21680 
facilitated adenosine uptake in hippocampal synaptosomes. This increase in uptake 
modulates the extracellular adenosine levels available which may in turn activate Al 
receptors (Pinto-Duarte et al., 2005). This mechanism may provide a possible role for 
peripheral A2A receptors in nociception. The stimulation of A2 receptors does not 
appear to produce antinociception in rodents, however the selective antagonism of the 
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A2A receptor by SCH58261 and the A2B receptor by novel antagonists results in 
antinociception in the writhing and hotplate tests in the mouse (see section 3.1.2) 
(Abo-Salem et al., 2004; Bastia et al., 2002). 
The different involvement of Al and A2A receptors in antinociception has been further 
demonstrated in adenosine receptor knockout mice. The response of A2A knockout 
mice to acute pain stimuli was much slower and they exhibited hypoalgesia compared 
to heterozygous and wildtype mice (Ledent et al., 1997). AI knockout mice exhibited 
hyperalgesia providing substantial evidence that these receptors are involved in 
nociception (Johansson et al., 2001). 
Opioid interaction with adenosine and the involvement of pain 
One of the first indications that adenosine may contribute to the spinal actions of 
morphine was the observation that intrathecal administration of methylxanthines 
inhibited morphine-induced antinociception in the hotplate and tail flick test in mice 
(DeLander & Hopkins, 1986). Subsequently morphine was shown to release 
adenosine in in vivo and in vitro spinal cord preparations (Sweeney et al., 1987a; 
Sweeney et al., 1987b). This release was found to be Cat+-dependent and capsaicin- 
sensitive (Sweeney et at., 1987b; Sweeney et al., 1989). This capsaicin-sensitivity 
supported the hypothesis that the spinal analgesic action of morphine was due to the 
activation of the opioid receptors on small-diameter primary afferent-nerve terminals, 
which released adenosine which subsequently activated the A, and A2 adenosine 
receptors to suppress transmission of nociceptive information (Sawynok et al., 1989). 
The release of adenosine occurred via a bi-directional nucleoside carrier, which was 
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insensitive to NBTI blockade of adenosine uptake but sensitive to NBTI inhibition of 
adenosine release, suggesting a heterogeneous carrier molecules involved in uptake 
and release of adenosine in the spinal cord (Sweeney et al., 1993). 
Adenosine is released by nanomolar concentrations of µ-opioid agonists, but S-opioid 
ligands only released adenosine at high micromolar concentrations, although both 
were calcium-dependent, whereas high micromolar concentrations ic-opioid agonists 
release adenosine in a calcium-independent manner. Caffeine did not block 8 agonist- 
induced antinociception, and it was suggested that the µ receptor subtype was 
responsible for the caffeine-sensitive opioid-induced antinociception in the spinal 
cord in the rat (Cahill et al., 1995). Simultaneous activation of µ-and-S-opioid 
receptors was shown to generate a synergistic release of adenosine from rat spinal 
cord synaptosomes (Cahill et al., 1996). More recently caffeine has also been shown 
to attenuate the antinociceptive effects induced by µ and 8 agonists but not a x- 
agonist in the hotplate test in mice (Pharr et al., 2003). It has also been proposed that 
t and 8 receptor agonists inhibit adenosine uptake thereby increasing the adenosine 
concentration in the brain (Halimi et al., 2000). 
De Lander & Keil (1994) observed that when spinally co-administrated A, or A2 
receptor selective agonists produced additive interactions in combination with µ- 
opioid agonists and a synergistic interaction in combination with 8 agonists and that a 
synergistic relationship existed between the ic-agonist and AI receptor agonists. The 
t-adenosine interaction was consistent with previous data, however the x and 8 
results contrast with previously demonstrated 1d6 opioid receptor-mediated release of 
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adenosine (De Lander & Keil, 1994). Furthermore, it has also been demonstrated 
autoradiographically that formalin administration significantly alters µ-opioid 
receptor density in the superficial laminae of the spinal cord, and this modification is 
counteracted by the administration of CPA and CGS21680 (Borghi et al., 2002). 
Zhang et al (2005) also showed DPCPX, a Ai antagonist reversed the effects of 
morphine-induced reversal of hypersensitivity to mechanical stimuli, thereby 
providing evidence that morphine reduces allodynia via the activation of the A, 
receptor. 
Biogenic amines have also been shown to release adenosine in the spinal cord; 
Sweeney et al (1990) observed that 5HT released adenosine from capsaicin-sensitive 
primary afferent nerve terminals in the spinal cord via a receptor-mediated, Cat+- 
dependent mechanism. Spinal administration of noradrenaline has also been shown to 
release a nucleotide that is converted to adenosine, and is methyxanthine sensitive, 
which may indicate that adenosine, contributes to spinal adrenergic analgesia 
(Sweeney et al., 1987b). 
1.4. Caffeine 
Caffeine and other methylxanthines exert a variety of pharmacological effects on a 
diverse number of peripheral and central sites. Methylxanthines have antiasthmatic 
actions, cause smooth muscle relaxation, stimulate the CNS and cardiac muscle and 
produce diuretic actions (Arnaud, 1987). Initially the pharmacological actions of 
methylxanthines were considered to be due to phosphodiesterase inhibition. This 
hypothesis was attractive because ubiquitous expression of the phosphodiesterase 
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enzymes could explain the varied action and variety of tissues that methylxanthines 
effect (Fredholm, 1980). However, phosphodiesterase inhibition, calcium 
mobilisation and 5'-nucleotidase inhibition require a concentration in excess of 100 
µM (Astrup et al., 1990; Sawynok & Yaksh, 1993). Following therapeutic doses or 
ingestion of caffeine via beverages, plasma levels are generally between 5- 50 µM 
(Lelo et al., 1986b; see Sawynok & Yaksh, 1993). However, these potential 
mechanisms should not be dismissed because certain local routes of administration 
might encounter considerably higher concentrations or they may also contribute to the 
toxic actions of caffeine (see Sawynok & Yaksh, 1993). 
1.4.1. History of Caffeine and its consumption 
Caffeine was isolated and its structure identified in 1875 by Meridus as 1,3,7- 
trimethylxanthine, which closely resembles important endogenous metabolites such as 
purines, xanthines and uric acid (see Arnaud, 1987). Caffeine is present in the human 
diet in a variety of foods and beverages (see Arnaud, 1987). Caffeine is still being 
used in over-the-counter pharmaceuticals such as diuretics, cold remedies, weight 
control products and analgesics (Barone & Roberts, 1996; Fredholm et al., 1996). 
However, the contribution of caffeine to the efficacy of any of these pharmaceuticals 
has failed to be properly evaluated (see Sawynok & Yaksh, 1993). In the late 1950s 
clinical studies were carried out in order to examine the effects of caffeine and 
analgesic combinations. However, the subject population was limited and controls 
were often lacking, which lead to controversial findings and made the contribution of 
caffeine difficult to determine (see Sawynok & Yaksh, 1993). In the last fifteen years 
a number of clinical trials (with the appropriate population and controls) have 
produced evidence that caffeine may contribute to the amelioration of some pain 
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states (see section 1.4.3) (Ghelardini et al., 1997; Laska et al., 1984; Laska et al., 
1983; Ward et al., 1991). 
The average consumption of caffeine in tea and coffee is approximately 200 mg/day 
which is equivalent 3-4 cups/day of coffee, and the median concentration of caffeine 
per cup of coffee is approximately 74 mg (Gilbert et al., 1976). The amount of 
caffeine in a cup of coffee varies dependent on the cup size and preparation technique 
used; ranging from 75 % in boiled coffee, 80 % in an espresso and 85 % in percolated 
coffee to nearly 100 % in filter coffee (see Fredholm et al.; 1996). It could be 
assumed that the average 70 kg person drinks 4 cups of coffee/day, and therefore the 
intake of caffeine per day ranges from 200 -700 mg which is the equivalent to 3-10 
mg/kg/day (Carter et al., 1995). 
1.4.2. Absorption, distribution, metabolism and excretion 
Caffeine is rapidly absorbed from the gastrointestinal tract and reaches 99 % 
absorbtion in humans approximately 45 min after ingestion (Bonati et al., 1982; 
Marks & Kelly, 1973). In animals similarly, caffeine absorption is also almost 
complete (Arnaud, 1985). The pharmacokinetics of caffeine are independent of the 
route of administration, as plasma concentration curves are superimposable following 
oral or intravenous administration suggesting there is no pronounced first pass 
metabolism effect (see Arnaud, 1987). The hydrophobic properties of caffeine allow 
it to pass through all biological membranes including the blood brain barrier in the 
adult or foetal animal (see Arnaud, 1987; Fredholm et al., 1996). Kinetic studies on 
rodents have shown that the plasma concentration of caffeine closely relates to the 
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concentrations of caffeine in the brain, suggesting that caffeine simply crosses the 
blood brain barrier by simple diffusion (Zhi & Levy, 1990). However McCall et al 
(1982) suggested that caffeine also enters the brain by carrier-mediated transport, as 
caffeine transport was saturable and caffeine also inhibited adenine uptake. A 
possible explanation for this saturable (carrier mediated) transport of caffeine is its 
structural similarity to the nucleic acid precursors purines and purine nucleosides. 
Caffeine undergoes virtually complete metabolism in all species so far examined with 
only 1-5 % being excreted unchanged (see Sawynok & Yaksh, 1993). Metabolism 
occurs primarily by oxidative N-demethylation to paraxanthine (1,7-dimethylxantine) 
in humans, this conversion being mediated by CYP450 family 1A2 (CYP1A2) (Fig 
11). Paraxanthine then undergoes further transformations one of which is 8- 
hydroxlation to 1,7 dimethyluric acid. The other routes involve a 7-demethylation 
followed by acetylation to generate 5-acetylamino-6-formylamine-3-methyluracil. 
Alternatively paraxanthine undergoes a 7-demethylation to form 1-methylxanthine 
which is subsequently 8-hydroxylated to form the excretable product 1-methylurate 
(Price & Gale, 1987; Sawynok & Yaksh, 1993). This route is the main metabolic 
pathway in humans -(Labedzki et al., 2002). Initial demethylation to paraxanthine 
accounts for the majority of caffeine metabolism, however caffeine can also be 
demethylated to theophyline and theobromine before further metabolism to excretable 
products. However, these represent minor metabolic conversions accounting for 4% 
and 12 % of caffeine methylation respectively (Lelo et al., 1986a). 
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Figure 11. Metabolic pathways of caffeine In man. The major metabolic pathway 
of caffeine in man is CYP450 metabolism to paraxanthine, although minor metabolic 
routes also exist. 1) N-demethylation to paraxanthine by CYP1A2; 2) 8-hydroxlation 
(by CYP3A4) to 1,7 dimethyluric acid or 3) 7-demethylation (by CYP1A1 OR 
CYP2D6) followed by acetylation (by N-acetyltransferase) to generate 5-acetylamino- 
6-formylamine-3-methyluracil, alternatively 4) paraxanthine undergoes 7- 
demethylation (by CYP1A1 OR CYP2D6) to form 1-methylxanthine 5) subsequent 8- 
hydroxylation (by xanthine oxidase) forms the excretable product 1-methylurate. 
Adapted from Arnaud (1987), isoforms taken from Ha et al (1996). 
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Similar routes of metabolism have been reported in rabbit (Fabro & Sieber, 1969), rat 
(Bonati et al., 1984) and mouse (Burg & Stein, 1972), although the distribution of 
metabolites are more diffuse in rodents (Bonati et al., 1984). For instance, in the rat 
paraxanthine is the major metabolite in the plasma (Fredholm et al., 1996), and in the 
mouse, paraxanthine primarily is demethylated to 1 methylxanthine (Labedzki et al., 
2002). However, 40 % of caffeine metabolites are trimethyl derivatives and thus do 
not involve demethylation pathways, while in comparison less than 5% of these 
metabolites are found in humans (see Arnaud, 1987). Caffeine metabolism, like most 
drugs metabolised by enzymes, is also subject to polymorphism (Grant et at., 1983a; 
Grant et al., 1983b; Kalow, 1985). This polymorphism is in the form of fast and slow 
acetylators, with slow acetylators having problems metabolising caffeine if 
administered in large doses (Grant et al., 1983a; Grant et al., 1983b; Kalow, 1985). 
1.4.3. Caffeine and pain 
Headache 
The effect of caffeine on cerebral blood flow and on cerebral vascular tone provides a 
plausible explanation for its effectiveness in treating headache (Mathew et al., 1983). 
In migraine, caffeine acts as a vasoconstrictor in cerebral blood vessels via the 
antagonism of endogenous adenosine, which is a highly potent dilator of the cerebral 
blood vessels (Engelhardt et al., 1997). In some headache and pain paradigms, 
caffeine may produce direct adjuvant analgesic properties but in other headache 
conditions it may simply be effective in alleviating a manifestation of caffeine- 
withdrawal (Sawynok et al., 1995; Sjaastad & Bakketeig, 2004; Spencer, 2002). 
Under certain conditions of pain caffeine could also have an indirect effect by 
elevating mood and alertness (Sawynok & Yaksh, 1993). It has been shown that 
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caffeine (65 and 130 mg) alone has an analgesic effect that is equivalent to 
paracetamol in patients with non-migrainous headache (Ward et al., 1991). Caffeine 
also appears to be effective in combination with paracetamol and aspirin in migraine, 
but there is no substantial evidence that this is due to the caffeine ingredient (Lipton et 
al., 1998). However, headaches are not easily interpreted, as they can be caused by 
caffeine-withdrawal therefore administration of caffeine immediately relieves the 
withdrawal symptoms of headache (Granados-Soto & Castaneda-Hernandez, 1999). 
Caffeine as analgesic adjuvant 
An adjuvant is a substance/compound that enhances the analgesic effect of another 
substance/compound (Hersh et al., 2000). The rationale for using drug combinations 
is the enhancement of analgesia and the reduction of adverse effects by using drugs 
with differing mechanisms of action (Beaver, 1984). Although the effects of caffeine 
as an adjuvant are generally associated with headache, the analgesic effects of 
caffeine have been demonstrated in other pain models including oral surgery and 
postpartum cramping (Laska et al., 1984; Laska et al., 1983; Zhang, 2001). The 
adjuvant action of caffeine was not demonstrated before 1975, as due to the low doses 
of caffeine (< 60 mg) used it was difficult to assess efficacy of caffeine (see Sawynok 
& Yaksh, 1993). Most of these early studies also failed to demonstrate 
reproducibility, due to different methods and scoring sytems (Beaver, 1984). In 1984 
Laska et al evaluated the adjuvant ability of caffeine by evaluating clinical trials with 
caffeine combinations over the last twenty years (Laska et al., 1984). There was a 
lack of statistical significance observed among the multiple doses studied by Laska et 
al (1984), although overall the conclusion was that the potency of an NSAID or 
paracetamol without caffeine requires a dose 40 % greater than one with caffeine to 
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obtain the same response. Combinations of caffeine and NSAIDs have been shown to 
be more efficacious than equal doses of NSAIDs, and it appears that between 65 and 
130 mg of caffeine must be administered before a significant enhancement is seen 
(see Sawynok & Yaksh, 1993). To put this into perspective a strong cup of coffee 
contains between 70 and 100 mg of caffeine (Granados-Soto et al., 1993; Hersh et al., 
2000). Laska et al, (1983) concluded that not only was the analgesic efficacy of 
paracetamol (500 mg) in combination with caffeine (65 mg) more effective in 
postpartum and dental extraction pain than paracetamol alone, but the onset of 
analgesia was also faster. In agreement Ward et al (1991) observed that caffeine and 
paracetamol combinations were more effective than either drug alone in headache 
pain. However, others (Zhang & Li Wan Po, 1996) have reported that caffeine added 
little to the analgesic efficacy of paracetamol in post-surgical pain. 
Siegers (1973) observed that in rats, caffeine alone was analgesic in mechanical- 
induced nociception and had an additive influence on paracetamol-induced analgesia. 
Sawynok et al (1995; 1996) also showed that systemic administration of caffeine 
alone produced a dose-related antinociception in the hot plate test and formalin test in 
rats. Peripheral co-administration of caffeine with formalin did not produce an 
antinociceptive effect, and it was suggested that the analgesic effect of caffeine is due 
to a central action only (Sawynok, 1995). Several other studies in rodents have 
looked at the effect of caffeine on NSAIDs, more specifically the adjuvant nature of 
caffeine, and found that caffeine potentiates NSAID-induced antinociception, through 
an unknown mechanism (summarised in Table 6). 
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Pharmacokinetics/phannacodynamics 
It has been suggested that caffeine may increase the bioavailability of NSAIDs by 
increasing the absorption or impairing the elimination of these drugs (Sawynok & 
Yaksh, 1993). This is based on the observation that caffeine lowers gastric acidity by 
directly stimulating the parietal cells (Debas et al., 1971) and can modify gastric and 
hepatic blood flow (Onrot et al., 1986). It has been suggested that this effect is 
mediated via the inhibition of adenosine receptors, which increase the basal H+ 
secretion (Gil-Rodrigo et al., 1990). This lowering of pH would facilitate the 
diffusion of agents whose pKa rendered them unionizable in an acidic environment 
e. g. aspirin (Sawynok & Yaksh, 1993). Caffeine has been shown to increase 
absorption of paracetamol or aspirin in rats (Engelhardt et al., 1997). However the 
opposite was seen by Siegers (1973) who demonstrated that caffeine inhibited the 
absorption of paracetamol and thus lowered the serum concentration of paracetamol 
presumably by reducing the rate at which paracetamol was transported to the small 
intestine. This reduction in absorption rate of paracetamol from the stomach was due 
to the relaxing action of caffeine on gastric smooth muscle (Siegers, 1973). 
Presumably a slower absorption of paracetamol would extend the half-life of the 
paracetamol. This has been shown in mice, as the half-life of paracetamol was 
prolonged when caffeine and paracetamol were coadministered (Price & Gale, 1987). 
Slight changes were also observed in the paracetamol conjugates excreted, and it was 
concluded that caffeine might protect the liver against paracetamol-induced 
hepatotoxicity by reducing the rate of formation of NAPQI (Price & Gale, 1987). 
However, in contrast, the addition of caffeine in vitro stimulated the oxidative 
metabolism of paracetamol in rat liver microsomes, resulting in an increased 
formation of paracetamol-GSH conjugates and increased covalent binding to 
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microsomal proteins, thereby increasing the formation of NAPQI (Nouchi et al., 
1986). However, the high millimolar concentration of caffeine used in this study 
may not be therapeutically relevant. Lee et al (1996a) showed that methylxanthines 
did not alter the formation of NAPQI in control mice, but activated CYP450 enzymes 
when mice were treated with CYP450 inducers such as ethanol or phenobarbitone. 
Therefore paracetamol and caffeine combinations only appear to be a risk in alcohol- 
enhanced paracetamol hepatotoxicity (DiPetrillo et al., 2002). However, not all 
studies have found a change in pharmacokinetic parameters (Castaneda-Hemandez et 
al., 1994; Castaneda-Hernandez et al., 1992; Gayawali et al., 1991) and many of these 
authors propose that caffeine's potentiation of paracetamol is due to a 
pharmacodynamic interaction.. 
1.4.4. Involvement of adenosine in caffeine-induced antinociception 
As discussed previously caffeine has a variety of physiological effects, however the 
only known mechanism that is significantly affected at therapeutic concentrations of 
caffeine is the competitive antagonism of the adenosine receptors (10-100 µM) (see 
Fredholm, 1980). Caffeine exhibits a Ki of 50 tM at the A, receptors in the brain, 
and a Ki of approximately 27 µM and 30 µM at A2A in striatal membranes and A2B 
receptors in brain slices respectively from the rat (Daly et al., 1983). The functional 
antagonism of these receptors will depend both on local levels of adenosine and the 
affinity for adenosine for the receptors, as antagonism by caffeine results in 
competitive inhibition (Daly et al., 1983). 
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Pain 
Sawynok and Reid (1996) showed that caffeine and the A, antagonist CPT in the 
formalin test in rats produced antinociception but the A2 antagonist 3,7-dimethyl-l- 
propargylxanthine (DMPX) could only produce significant antinociception at 
concentrations that antagonised the adenosine receptors unselectively. Therefore it 
was suggested that the ability of caffeine to produce antinociception was dependent 
on the antagonism of the Al receptor (Sawynok & Reid, 1996). However, it has been 
suggested that caffeine has a central site of action as caffeine has not demonstrated 
any antinociceptive properties when administered locally (Doak & Sawynok, 1995), 
presumably because of the antagonism of opposing receptors in peripheral nerve 
terminals, and thus the activation of the A2 receptors produces pronociceptive effects 
(Taiwo & Levine, 1990). Therefore caffeine would be antinociceptive, but peripheral 
antagonism of Al receptors would produce the opposite effect. However, supraspinal 
and spinal admininstration of adenosine agonists can also produce antinociception 
(see section 1.3.2), and thus the nature of caffeine antagonism of specific adenosine 
receptor subtypes remains unclear. 
Caffeine also increases the turnover of several monoamine transmitters including 
dopamine, 5HT, and noradrenaline (Bickford et al., 1985; Grant & Redmond, 1982; 
Hadfield & Milio, 1989). Ghelardini et al (1997) observed that the antinociceptive 
effect of caffeine in the hotplate test in mice was inhibited by the muscarinic 
antagonist pirenzepine, the acetylcholine depletor HC-3 and the Al agonist CPA. In 
addition HC-3 also inhibited caffeine-induced antinociception in the paw pressure test 
in the rat (Ghelardini et at., 1997). The Al receptor agonist CPA has also been shown 
to counteract caffeine-induced acetylcholine release in the rat hippocampus (Carter et 
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al., 1995). It was concluded that caffeine antinociception was dependent on 
cholinergic activation, which may be mediated via Al receptor antagonism 
(Ghelardini et al., 1997). 
Caffeine has been shown to inhibit PGE2 release in stimulated rat microglial cells in 
the absence and presence of paracetamol and aspirin (Fiebich et al., 2000). It has 
been suggested that this inhibition is indirect and due to inability of caffeine to inhibit 
the conversion of arachidonic acid to prostaglandin in the bovine brain in vitro 
(Engelhardt et al., 1997). Caffeine does however diminish the amount of COX 2 
protein in a concentration-dependent manner suggesting that caffeine inhibits COX 2 
induction rather than its activity (Fiebich et al., 2000). At the concentrations of 
caffeine (10 µM-1 mM) used in this study caffeine acts as a non-selective antagonist 
of adenosine Al and A2 receptors. Since A2A receptors are responsible for the 
induction of intracellular signalling events that cause an upregulation of the COX 2 
gene and the release of PGE2 (Fiebich et al., 1996), it is plausible that caffeine inhibits 
the induction of the COX 2 gene by the antagonism of the A2A receptor, thereby 
suppressing pain and inflammation caused by COX 2 induction. 
Locomotion 
Caffeine produces a biphasic effect on locomotion, stimulating at low doses 
(Sawynok & Reid, 1996) and having a depressant effect at higher doses (El Yacoubi 
et al., 2000). This could be explained by the blockade of the A2A receptor by low 
doses of caffeine stimulating locomotion, and at higher doses of caffeine the Al 
receptor is blocked and a depressant effect on locomotor activity is observed (El 
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Yacoubi et al., 2000). In A2A knockout mice caffeine-induced locomotor stimulation 
was lost, demonstrating that the blockade of the A2A subtype is important to the 
stimulatory effects of caffeine (Ledent et al., 1997). This was in agreement with 
Halldner et al (2004) who showed that low doses of caffeine did not induce locomotor 
stimulation in A2A knockout mice whereas, Al knockout and A2A heterozygous mice 
produced biphasic locomotor effects to caffeine. Ledent et al (1997) also observed 
that a stimulatory dose of caffeine had a depressant effect on locomotion which they 
attributed to other biological effects such A, blockade. In contrast, as the locomotor 
depressant dose of caffeine is less in mice completely lacking the A2A receptor and 
double knockout mice A2A/Al than in wildtype animals, it has been suggested that the 
depressant effects of caffeine are not mediated by either receptor (Halldner et al., 
2004). NO has also been implicated in caffeine-induced locomotor activity in mice, 
due to the inhibition of caffeine-induced locomotor effects by L-NAME. This NOS 
inhibition of caffeine induced-locomotion has been shown to be reversed by the 
administration of L-arginine (Kayir & Uzbay, 2004). 
1.5. Summary 
Paracetamol has been used therapeutically for over one hundred years, and was 
originally assumed to have a similar mechanism to the NSAIDs, like aspirin. 
Although paracetamol alleviates moderate pain, due to the mechanism by which 
paracetamol produces its effects appears to perplex researchers today as much as it 
did a century ago. 
Reports that caffeine is an analgesic in its own right are controversial; the effects of 
caffeine appear to vary with different experimental conditions and pain intensities. 
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Therefore several factors may influence the apparent activity of caffeine, including 
dose, test stimulus i. e. pain state and intensity and the characteristics of the co- 
administered drug (see Sawynok & Yaksh, 1993). There are many possible reasons 
why caffeine may enhance the analgesic effect of paracetamol and other NSAIDs. 
Many studies have confirmed that caffeine increases mental alertness, decreases 
drowsiness and fatigue (Laska et al., 1984), thereby the mood-altering effects of 
caffeine, may alleviate the psychological (affective) component of pain (see Sawynok 
& Yaksh, 1993). There is also the possible interference with absorption and 
metabolism of these NSAIDs. However, since at therapeutic concentrations caffeine 
is an adenosine antagonist, it is also plausible that an antinociceptive effect of caffeine 
may be due to the selective antagonism of an adenosine receptor subtype. 
1.5.1 Aims of the project 
1. Competition binding studies have been used to rule out potential target 
receptors and transport systems for paracetamol (Raffa & Codd, 1996). 
However, both opioid and adenosine systems have been hypothesised as 
targets for the actions of paracetamol and the recently characterised opioid 
receptor, NOP and the NBTI-sensitive adenosine transporter have yet to be 
studied. Competition binding studies have been carried out to determine if 
paracetamol binds to either of these two sites. One study has directly searched 
for binding sites using radiolabelled paracetamol (Courade et al., 2001a), but 
the concentration of [3H]paracetamol (30 nM) may not have been sufficient to 
detect specific binding. Therefore in studies described in this thesis 
[3H]paracetamol was used, at a concentration relevant to in vivo activity 
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(3µM), to determine whether paracetamol demonstrates any specific binding 
in the brain and spinal cord of mice. 
2. A2A antagonists have been shown to produce antinociception, and A2A receptor 
gene knockout mice display hypoalgesia. As caffeine may antagonise the 
adenosine A2A receptor to produce antinociception, the use of A2A knockout 
mice allows this possibility to be addressed. To determine whether caffeine 
enhances paracetamol-induced antinociception via an action at the A2A 
receptor, the effects of paracetamol and caffeine on nociception in wildtype 
and adenosine A2A receptor knockout mice have been studied. In addition, the 
effect of subtype-selective A2A and A2B antagonists on antinociceptive 
responses of paracetamol have also been investigated. 
3. NO has been implicated in pain pathways for many years, and more recently it 
has been suggested that NO may have a role to play in paracetamol-induced 
analgesia in the spinal cord. Therefore mouse spinal cord slices were used to 
determine whether paracetamol inhibited NOS, and whether caffeine had any 
effect on this pathway. 
4. Whether paracetamol inhibits the COX enzymes and their products is not 
clear, and if it does there is also the possibility that caffeine inhibits COX 2 
induction via adenosine antagonism to produce an additive effect. Therefore 
to determine whether paracetamol reduces LPS-stimulated PGE2 synthesis and 
to identify whether caffeine potentiates this inhibition by the antagonism of 
the A2A receptor, the levels of PGE2 were measured, in murine microglia 
cultured from wildtype and A2A adenosine knockout mice. 
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Chapter 2 
An investigation of binding sites for paracetamol in the 
mouse brain and spinal cord. 
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2.1. Introduction 
Numerous receptors and transporters have been proposed as targets for the 
mechanism of action of paracetamol, but there is no strong evidence for an interaction 
between paracetamol and any pathway involved in pain transmission that conclusively 
identifies a single target. 
2.1.1. Paracetamol and opioid interactions 
It has been suggested that paracetamol may relieve pain through the opioid system 
(Sandrini et al., 2001b). Further, Raffa et at. (2000) have suggested that paracetamol- 
induced antinociception involves a "self-synergistic" interaction between spinal and 
suspraspinal sites and, that this involves an endogenous opioid pathway. Although 
previous work by Raffa & Codd (1996) failed to show any significant binding of 
paracetamol to the µ, S or x opioid receptors at micromolar concentrations, others 
have demonstrated that paracetamol has a low micromolar affinity for [3H]naloxone 
binding sites, suggesting that direct receptor interactions can occur at high 
concentrations (Pini et al., 1997). Also, pretreatment with naloxone has been shown 
to abolish paracetamol-induced antinociceptive activity in the hotplate test and the 
first phase of the formalin test (Pini et al., 1997; Sandrini et al., 2001a). Miranda et al 
(2004) has also demonstrated that coadministration of paracetamol and morphine 
produced a synergistic antinociception which was antagonized by the µ-antgonist, 
naltrexone and the S-antagonist, naltrindole. 
An opioid related receptor (NOP) has now been characterized (Mollereau et al., 1994) 
and this receptor shows low affinity for naloxone (Meunier, 1997). As the 
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endogenous peptide, nociceptin, for the NOP receptor has been shown to have a role 
in nociceptive pathways (see Table 2) (Calo et al., 2000; Citterio et al., 2000) we 
hypothesized that the NOP receptor could be a another potential opioid related target 
for the analgesic effects of paracetamol. 
2.1.2. Adenosine and pain 
Adenosine is a ubiquitous autocoid that has also been implicated in pain pathways. 
Peripheral administration of adenosine has been shown to produce pronounced pro- 
nociceptive effects whereas centrally administered adenosine produces 
antinociceptive effects (Sawynok & Yaksh, 1993) and A, adenosine receptors have 
been shown to modulate pain transmission at the spinal level (Sawynok, 1998). The 
analgesic effects of adenosine are enhanced by inhibitors of uptake or metabolism 
(Sawynok & Liu, 2003), and thus inhibition of adenosine uptake might also be 
responsible for some of the analgesic effects of paracetamol. Nitrobenzylthioinosine 
(NBTI) binding sites have been shown to be highly expressed in the spinal cord and 
brainstem of the rat, which serve sensory functions, and these sites are also located on 
unmyelated primary afferent fibres (Geiger & Nagy, 1985). Therefore adenosine 
receptors and its transporter may serve as possible targets for the analgesic effects of 
paracetamol. Added to this there is a large body of evidence indicating that effects of 
opioids are partly mediated by adenosine, and that adenosine is released from spinal 
sites following opioid stimulation (Sawynok, 1998). A small but significant 
reduction in [3H]NBTI-sensitive binding was also detected in the brains of µ-opioid 
receptor deficient mice, leading to the conclusion that NBTI may have a functional 
interaction with the µ-opioid receptor in the brain (Bailey et al., 2002). Therefore if 
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paracetamol inhibited adenosine transport, with a downstream opioid effect, it may 
explain the indirect interaction between paracetamol and the opioid receptors. 
2.13. Paracetamol binding 
Competition binding studies have been mostly used to rule out target receptors for 
paracetamol (Raffa & Codd, 1996), although one study has directly searched for 
binding sites using radiolabelled paracetamol (Courade et al., 2001). This study used 
[3H]paracetamol (50 Ci/mmol) at 30 nM, a concentration more than 1000-fold below 
the plasma concentration required to induce an analgesic response in laboratory 
animals and so it may not have been sufficient to detect specific binding (Prescott, 
1996). 
The first aim of the experiment described in this chapter was to determine by 
quantitative autoradiography in mouse brain whether paracetamol competes for 
binding to NOP receptors or to the NBTI-sensitive adenosine transporter; two targets 
that have hitherto not been examined. The second aim was to determine by 
quantitative autoradiography whether [3H]paracetamol, at a concentration relevant to 
in vivo activity (3 µM), demonstrates any specific binding in the brain and spinal cord 
of mice. 
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2.2. Autoradiographic procedures 
2.2.1. Tissue preparation for binding 
Adult male CD1 mice (Charles River) were housed three per cage in an air conditioned unit 
maintained at 20-22 °C and 50-60 % humidity and were allowed free access to standard 
rodent chow and water. Lighting was controlled on a 12 hr cycle. Mice (6-8 weeks) were 
killed by decapitation and intact whole brains and spinal cords were removed. Following 
decapitation the spinal column was carefully extracted and placed in an ice-cold Petri dish of 
0.9 % w/v pH 7.4 saline. The intact column was then cut into four identifiable parts (cervical, 
thoracic and sacral and lumbar regions). Each of these sections were inserted into a piece of 
rubber tubing measuring 5 mm diameter, 35 mm length and then connected to a 10 ml syringe 
containing ice cold saline (0.9 % w/v, pH 7.4). The spinal cord was then ejected with 
hydraulic pressure from the syringe into a Petri dish containing fresh ice-cold saline. All 
tissues were then rapidly frozen in isopentane at -20-30 °C and stored at -80 °C for up to one 
month prior to sectioning. 
2.2.2. Tissue sectioning 
2.2.2.1. Sectioning of brains 
Sections were cut at -21 °C using a cryostat (Zeiss Microm 505 E); whole brains were 
mounted on a stage with the use of an embedding medium (O. C. T compound). 20 µm 
frozen coronal and sagittal sections were cut at 300 µm intervals. The sections were 
thaw-mounted onto pre-cleaned and gelatine-subbed ice-cold microscope slides. 
Adjacent sections were cut for the determination of total and non-specific binding of 
each ligand. For competition binding studies adjacent sections were taken for the 
determination of [3H]NBTI binding to the NBTI-sensitive adenosine transporter and 
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[3H]nociceptin binding to the NOP receptor in the presence of 0 µM, 1 µM, 10 µ1V1 
and 100 µM paracetamol. Extra sections were cut at the level of the caudate for early 
developments and scrape binding. The sections were dried using anhydrous calcium 
sulphate (Dreirite BDH chemicals, Poole, U. K) in an airtight container at 4 °C for 2 hr 
to prevent the formation of ice-crystals before storing at -20 °C for seven days. 
2.2.2.2. Sectioning of spinal cords 
The frozen regions of the spinal cord were fixed in embedding medium (O. C. T) and 
mounted on a stage prior to sectioning. 20 µm thick sections were cut throughout the 
spinal cord regions at -21 °C using a cryostat (Zeiss Microm 505 E). Adjacent 
sections were cut for the determination of total and non-specific binding. Separate 
slides were prepared for scrape binding as described above. The sections were dried 
using anhydrous calcium sulphate (Dreirite) in an airtight container at 4 °C for 2 hr to 
prevent the formation of ice-crystals before storing at -20 °C for seven days. 
2.2.2.3. Cleaning and subbing of microscope slides 
Microscope slides were soaked overnight in a1% detergent solution (Decon). All 
slides were then rinsed with hot running water for 10 min followed by cold distilled 
water for a further 15 min. The slides were then left to soak in a 10 % HCI: 90 % 
ethanol for 20 min before they were rinsed with distilled water for 15 min. The slides 
were then soaked in a1% gelatin: 0.05 % chromimum potassium sulfate solution for 
2 min and then left to dry overnight. 
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2.2.3 Radioligand binding 
2.2.3.1. NOP and NBTI competition binding 
Adjacent frozen coronal (20 pm) sections were cut at 300 pm intervals for the 
determination of [3H]NBTI binding to the NBTI-sensitive adenosine transporters and 
[3H]nociceptin binding to the NOP receptor in the presence of 0 µM, 1 µM, 10 pM 
and 100 µM paracetamol. The concentration of [3H]NBTI (4.5 nM, 26 Ci/mmol) was 
approximately 10 times the value of Kd (0.46 ± 0.14 nM (Snell et al., 2000)) and was 
previously used by Bailey et al (2002) to ensure all NBTI-sensitive transporters were 
bound. Non-specific binding was determined on adjacent sections by carrying out 
binding in the presence of 10 pM unlabelled NBTI. The concentration of 
[3H]nociceptin (0.4 nM, 164 Ci/mmol) was approximately 3 times the Kd (0.13 nM) 
as determined by Neal et al (1999) and the non-specific binding was determined on 
adjacent sections by carrying out binding in the presence of 1 µM unlabelled 
nociceptin. The sections were defrosted and then preincubated for 30 min in 50 mM 
Tris-HCI (pH 7.4 at 25 °C) supplemented with 2 U/ml adenosine deaminase type VIII 
and 0.9 % NaCl for the binding of [3H]NBTI and [3H]nociceptin respectively. The 
sections were then incubated in 50 mM Tris-HCI (pH 7.4 at 25 °C) containing either 
[3H]NBTI (4.5 nM) or [3H]nociceptin (0.4 nM) for 30 and 180 min respectively to 
determine total binding. Adjacent sections were also incubated in the presence of 
[3H]ligand supplemented with 1 µM, 10 tM and 100 1M paracetamol to determine 
whether paracetamol displaced ligand binding. Non-specific binding was determined 
by incubating further adjacent sections with [3H]ligand with an excess of the 
corresponding unlabelled ligand. For the [3H]NBTI binding, sections were washed 
three times for 10 min in ice-cold rinse buffer containing 50 mM Tris-HCI pH 7.4 at 
0-4 °C and dipped for 30 sec in ice-cold reverse osmosis water. The sections bound 
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with [3HJnociceptin were washed for 5 min in rinse buffer containing 50 mM Tris- 
HCl supplemented with 3 mM MgC12 and 0.1 % w/v bovine serum albumin fraction V 
(pH 7.4 at 0-4 °C). 
2.2.3.2. [3H]Paracetamol binding 
Adjacent frozen coronal, sagittal and spinal cord sections (20 µm) were cut at 300 µm 
intervals for the determination of total and non-specific binding of [3H] paracetamol. 
The sections were defrosted prior to a 15 min pre-incubation in 50 mM Tris-HCI, pH 
7.4 at 25 °C and incubated for 60 min in fresh buffer supplemented with 3 µM 
[3H]paracetamol (32 Ci/mmol). Sections were incubated in the presence of 3 µM 
[3H]paracetamol and adjacent sections treated additionally with 3 mM unlabelled 
paracetamol for the determination of non-specific binding. Sections were then 
washed twice for 10 min in ice-cold rinse buffer (50 mM Tris- HC1, pH 7.4 at 0 °C) 
and immersed for 5 sec in ice-cold reverse osmosis water. 
Following the wash step, sections were rapidly dried for 2 hr in a cold air stream. 
Dehydration was continued for a further seven days at room temperature in airtight 
boxes containing anhydrous calcium sulphate (Drierite). 
2.2.5. Scrape binding 
To determine if binding was successful prior to apposition of the slides to film, scrape 
binding was carried out. As previously mentioned (section 2.2.2.1) additional slides 
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were also prepared for scrape binding (one for non-specific and one for total per 
brain/spinal cord sectioned). These sections were treated identically to the other 
slides processed during radioligand binding. However following the rinse step the 
sections from these scrape slides are wiped off using a piece of filter paper 
(Whatmann, GFB filter) and placed in scintillation vials with 0.5 ml of tissue 
solubiliser NCS-II, and 4 ml Unisolve E scintillation fluid. Scintillation counting was 
then carried out 24 hr later using a Wallac (1410 model) liquid scintillation counter. 
The specific binding was established by subtracting the non-specific counts from the 
total counts. 
2.2.6. Apposition to Hyperfilm and early developments 
Autoradiographic [3H]microscales in the range of 0.07-3.4 nCi/mg were apposed to 
[3H]Hyperfilm together with the sections from NBTI and ORL-1 binding. For the 
brain and spinal cord sections exposed to [3H]paracetamol, standards were not used 
due to the high level of radioactivity used to achieve binding therefore when analysed 
total and non-specific binding were compared using relative optical density. The 
Hyperfilm was laid emulsion side down directly onto the sections inside a Hyperfilm 
cassette (under red light conditions in a dark room). The cassettes were sealed with 
insulation tape to exclude light and were stored flat until development. 
The exposure time of the sections to the Hyperfilm varied according to the ligand and 
has been previously determined (see Table 7). However due to a the discontinuation 
of the Hyperfilm. by the common supplier, a different source of Hyperfilm was used 
which was found to be less sensitive and therefore the apposition to the sections had 
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to be determined by early developments (several small sections of film apposed to 
microscope slides of sections, developed sequentially over a period of weeks to 
determine when full exposure was reached). 
Table 7. Exposure times of radioligand bound brain and spinal cord sections to 
[3H]-sensitive Hyperfilm 
Ligand Exposure and reference New film exposure time 
[ H]NBTI 4 weeks (Bailey et al., 2002) 8 weeks 
[ H]leucyl nociceptin 3 weeks (Neal et al., 1999) 4 weeks 
[ H]paracetamol 9 months (Courade et al., 2001) 4 weeks (brains) 
5 weeks (cords) 
2.2.7. Film development 
Films were developed in a dark room using 50 % Kodak D19 developer for 3 min. 
The film was then placed in stop solution (distilled water and glacial acetic acid) for 
30 sec before fixing the images for 2 min (Kodak rapid fix solution). The films were 
then rinsed in fresh running reverse osmosis (RO) water for 30 min and dried 
overnight in a fume cupboard. 
2.2.8. Quantitative analysis and statistical procedures 
Quantitative analysis of autoradiographic films was carried out as detailed previously 
(Kitchen et al., 1997) using video-based computerised densitometry i. e. MCID. Brain 
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and spinal cord structures were identified by reference to the mouse and rat atlases of 
Paxinos and Franklin (2001) and Paxinos and Watson (1986) respectively. Specific 
receptor binding was determined by subtraction of non-specific binding from total 
binding. Specific binding was expressed in fmol/mg tissue (± S. E. M) as determined 
by the [3H]-microscales laid down with the [3H]NBTI and [3H]nociceptin sections. 
For the brain and spinal cord sections bound with [3H]paracetamol, standards were 
not employed due to the high level of radioactivity used to achieve binding, therefore 
analysis was carried out by comparison of relative optical density (ROD). 
Measurements for quantitative analysis of coronal sections were taken from left and 
right hemispheres therefore representing a duplicate determination. All areas of the 
spinal cord were analysed using free hand drawing tools. Comparison of quantitative 
measurements of autoradiographic binding was carried out using two-way analysis of 
variance (ANOVA; region and +/- paracetamol) for [3H]NBTI and [3H]nociceptin and 
[3H]paracetamol. One-way ANOVA for comparison of total and non-specific binding 
of paracetamol was performed on all spinal cord segments. Comparison of individual 
brain regions and spinal cord laminae was made using Fisher's LSD post hoc test. 
2.2.9. Materials 
[3H]nociceptin and unlabelled nociceptin were dissolved in 50: 50 methanol: 0.1 N 
HCl which was then further diluted 1: 64 methanol/ 0.1 N HCI: incubation buffer (50 
mM Tris-HCI, 3 mM MgC12,0.1 % w/v bovine serum albumin fraction V, bacitracin 
1260 U/L and 0.2 mM ethylene glycerol-bis (2-amino ethylether)-N, N, N', N' 
tetraacetic acid (EGTA), pH 7.4 at 25 °C). [3H]NBTI and [3H]paracetamol were 
dissolved in 50 mM Tris-HCI (pH 7.4 at 25 °C). Unlabelled NBTI and paracetamol 
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were dissolved in 50: 50 DMSO: incubation buffer and 1: 20 ethanol: incubation 
buffer, respectively. Both were then further diluted 1: 100 with 50 mm Tris-HC1 (pH 
7.4 at 25 °C). [3H]nociceptin and [3H]paracetamol were purchased from Amersham 
(Buckinghamshire, UK). [3H]NBTI was purchased from New Life Sciences 
(Cambridge, UK) and unlabelled nociceptin was supplied by Bachem Ltd 
(Merseyside, UK). All other compounds were purchased from Sigma-Aldrich (Dorset, 
UK). 
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2.3. Results 
23.1. Quantitative autoradiography of NBTI-sensitive adenosine transporters 
and the NOP receptor in the brains of mice in the absence and presence of 
paracetamol. 
23.1.1 NBTI-sensitive transporter 
Quantitative autoradiography showed a widespread distribution of NBTI-sensitive 
adenosine transporters in coronal sections throughout the fore-, mid-and hindbrain of 
mice with quantitative levels similar to those previously reported (Bailey et al., 2002) 
(Table 8). High levels (200-400 fmol/mg) of [3H]NBTI binding were found in 
regions such as vertical limb of diagonal band, medial and lateral septum, central 
lateral and medial thalamic nuclei, reunions thalamic nuclei, habenula, dorsal and 
ventromedial hypothalamic nuclei, periaqueductal grey layer, substantia nigra and the 
superficial grey layer of superior colliculus. Moderate levels of binding (100-200 
fmol/mg) were detected in the granular layer of the olfactory bulb and the anterior 
olfactory nucleus, caudate putamen, nucleus accumbens, auditory and caudal 
somatosensory cortex, globus pallidus, amygdala and the stratum molecular of the 
hippocampus. Lower levels (<100 fmol/mg) of [1H]NBTI binding were found in the 
hippocampus, rostral somatosensory, visual, retrosplenial and motor cortex along with 
the olfactory bulb (Table 8). 
The density of NBTI-sensitive adenosine transporters sites was not significantly 
altered in the presence of paracetamol (Table 8, Fig 12). There were however some 
small quantitative differences with a maximum percentage increase of 27 % in the 
-98- 
presence of paracetamol. This change was not concentration-dependent. Furthermore 
two-way ANOVA did not demonstrate a significant quantitative difference overall 
(P> 0.05) in the binding of [3H]NBTI in the presence of paracetamol. 
23.2. NOP receptor binding 
Quantitative analysis revealed a wide distribution of [3Hjnociceptin (0.4 nM) binding 
throughout the fore-, mid- and hindbrain regions with quantitative levels similar to 
those previously reported (Clarke et al., 2001; Slowe et al., 2001) (Table 9). 
Moderate to high levels of binding (50 -120 fmol/mg) were observed throughout all 
parts of the cortex. In non-cortical structures high levels of binding (>70 fmol/mg) 
were detected in structures such as the amygdala, anterior olfactory bulb, 
hippocampus and dentate gyrus. Moderate levels (40-70 fmol/mg) of binding were 
detected in nucleus accumbens, habenula, suprachiasmatic nucleus, superior 
colliculus periaqueductal grey, hippocampus, thalamus and hypothalamus. The 
substantia nigra, zona incerta, triangular septal nucleus and bed nucleus of striatal 
terminalis exhibited low levels (<40 fmol/mg) of binding (Table 9). 
The density of [3H]nociceptin receptors did not alter significantly in the presence of 
paracetamol (Fig 13). There were however some small quantitative differences. 
Paracetamol reduced the binding in the majority of regions but this change was not 
concentration-dependent and two-way ANOVA did not demonstrate a significant 
quantitative difference overall (P> 0.05) in the binding of [3H]nociceptin in the 
presence of paracetamol. 
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23.3. Quantitative autoradiography of the [3H]paracetamol in the brains of mice. 
2.33.1 Sagittal sections 
In sagittal sections, [3H]paracetamol (3 µM) bound throughout the fore-, mid-and 
hindbrain with a ubiquitous distribution (Table 10, Fig 14). Specific binding at levels 
between 10 and 20 % were detected in the substantia nigra, cerebellum, and external 
cortex of inferior colliculus, hippocampus, retrosplenial agranular cortex, amygdaloid 
complex and the caudate. Low levels of specific binding (<10 %) were observed in 
the dentate gyrus, hypothalamus, thalamus and nucleus accumbens. Two-way 
ANOVA (for the factors region and ± unlabelled paracetamol) showed no significant 
difference (P >0.05) between regions or between total and non-specific binding. 
2.3.3.2. Corona) sections 
Quantitative analysis revealed a homogenous distribution of [3H]paracetamol (3 µM) 
binding throughout the fore-, mid- and hindbrain regions (Table 11, Fig 15). 
Moderate (20-35 %) levels of specific binding were observed in the retrosplenial 
agranular cortex, thalamus and hypothalamus, hippocampus and the habenula. Low 
levels (<5 %) of specific binding were detected in all other regions analysed including 
periaqueductal grey, substantia nigra, nucleus accumbens and the septum. 
Two-way ANOVA (for the factors region and +/- unlabelled paracetamol) showed no 
significant difference between regions (P >0.05) but a significant difference between 
total and non-specific binding (P <0.001). Post-hoc analysis (Fisher's LSD test) of 
-106- 
individual regions showed that total and non-specific binding was significantly 
different (P <0.05) only in the retrosplenial agranular cortex. 
23.4. Quantitative autoradiography of the [3H]paracetamol in the spinal cords of 
mice 
Quantitative analysis showed a wide distribution of [3H]paracetamol (3 µM) binding 
throughout the spinal cord (Table 12, Fig 16). Specific binding was typically around 
10 % with the exception of thoracic regions where specific binding were around 20 
olo, Two-way ANOVA (for the factors region and ± unlabelled paracetamol) showed 
a significant difference between total and non-specific binding (P <0.0001). Further 
analysis (for factors segment and region) showed no significant difference (P >0.05) 
between regions but a significant difference (P <0.001) between segments. One-way 
ANOVA was performed on all segments and showed that paracetamol binding was 
significantly higher in thoracic segments when compared to lumbar (P <0.05) and 
cervical segments (P <0.01) but not sacral segments. 
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Table 10. Quantitative autoradiography of [3 H]paracetamol binding 
in sagittal sections of the brains of male mice. 
Relative optical density 
Region Lateral 
Coordinates 
(mm) Total NSB % 
Specific 
Binding 
Cortex 
Retrosplenial agranular 0.24 0.63 ± 0.08 0.54 ± 0.08 14.1 
Motor 1.44 0.58 ± 0.10 0.52 ± 0.08 10.7 
Thalamus 0.24 0.51 ± 0.10 0.49 ± 0.09 4.0 
Hypothalamus 0.24 0.52 ± 0.11 0.49 ± 0.09 6.2 
Nucleus accumbens 1.44 0.52 ± 0.08 0.49 ±0.07 6.2 
Hippocampus 1.44 _ 0.52 ± 0.08 0.48 ± 0.06 19.0 
External cortex of inferior colliculus 1.68 0.58 ± 0.08 0.51 ± 0.06 13.1 
Caudate putamen 1.44 0.52 ± 0.10 0.46 ± 0.06 11.9 
Cerebellum 1.44 0.61 ± 0.13 0.52 ±0.08 15.2 
Substantia nigra 1.68 0.61+0.10 0.51 ± 0.07 15.1 
Dentate gyrus 1.68 0.62 ± 0.10 0.57 ± 0.09 7.6 
Amygdala 1.68 0.55 ± 0.12 0.48 ± 0.08 13.0 
The mean binding in relative optical density (1z=3 ± SEM) of 3 µM [3H]paracetamol 
in 20 µm sagittal sections of the brains of mice. Non-specific binding was determined 
with unlabelled paracetamol (3 mM). Measures in the regions were carried out at the 
lateral co-ordinates taken from the mouse atlas of Paxinos & Franklin (2001). Two- 
way ANOVA (for factors binding and region) showed no significant difference 
between regions (P >0.05) 
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Figure 14. Distribution of [3H]-paracetamol binding in sagittal sections 
of CD1 mice. 
Total NSB 
Representative computer-enhanced autoradiograms of 20 µm sagittal sections from the 
brains of CD1 mice from lateral coordinates 0.36 mm to 2.52 mm, which were cut at 300 
µm apart (n=3), showing total binding of 3µM [3H]-paracetamol and NSB determined in 
the presence of 3 mM unlabelled paracetamol. The colour bar shows a pseudo-colour 
interpretation of the relative density of black and white film images calibrated in a relative 
optical density (ROD). 
Table 11. Quantitative autoradiography of [3 H]paracetamol binding 
in coronal sections of the brains of male mice. 
Relative optical density 
Region Bregma 
Coordinates 
(mm) 
(ROD) 
Total NSB % 
Specific 
Binding 
Anterior Olfactory nucleus 3.20 0.65 t 0.15 0.5210.11 18.7 
Cortex 
Motor 2.46 0.72: t 0.11 0.61: t 0.09 15.3 
Retrosplenial agranular 1.10 0.68 ± 0.15 0.44 ± 0.09 35.6 
Nucleus accumbens 1.34 0.58 ± 0.06 0.51 ± 0.08 12.8 
Caudate putamen 1.34 0.55 ± 0.06 0.50 ± 0.08 8.1 
Septum 0.86 
Lateral 0.57 ± 0.08 0.48 ± 0.07 13.9 
Medial 0.62 ± 0.08 0.53 ± 0.07 14.6 
Vertical limb of diagonal band 0.86 0.64 ± 0.09 0.55 ± 0.06 14.6 
Globus pallidus -0.10 0.51 ± 0.07 0.46 ± 0.06 9.4 
Thalamus -1.70 0.51 ±0.10 0.37 ± 0.10 27.2 
Hypothalamus -1.70 0.51 ± 0.10 0.38 ± 0.10 26.1 
Hippocampus -2.46 
Stratum oriens 0.63 ± 0.12 0.43 ± 0.10 31.3 
Stratum radiatum 0.58 ± 0.10 0.41 ± 0.08 30.3 
Stratum molecular 0.58 ± 0.08 0.38 ± 0.07 34.4 
Amygdala -1.70 0.56 ± 0.11 0.43 ± 0.11 23.0 
Habenula -1.70 0.59 ± 0.12 0.42 ± 0.09 28.3 
Dentate gyrus -2.46 0.46 ± 0.08 0.38 ± 0.08 16.6 
Substantia nigra -3.40 0.53 ± 0.14 0.42 ± 0.09 21.6 
Periaqueductal grey -3.40 0.47 ± 0.10 0.38 ± 0.08 19.9 
Superficial grey layer of superior colliculus -3.40 0.53 ± 0.11 0.43 ± 0.10 19.0 
External cortex of inferior colliculus -4.16 0.49 ± 0.09 0.45 ± 0.10 7.3 
Intercollicular nucleus -4.16 0.46 ± 0.10 0.43 ± 0.11 6.2 
Cerebellum -6.84 0.63 ± 0.11 0.51 ± 0.10 18.1 
The mean binding in relative optical density (n=4 ± SEM) of 3µM [3H]paracetamol in 
20 µm coronal sections of the brains of mice. Non-specific binding was determined 
with unlabelled paracetamol (3 mM). Measures in the regions were carried out at the 
bregma co-ordinates taken from the mouse atlas of Paxinos & Franklin (2001). 
Regional determinates were made from both left and right sides of the sections which 
were cut 300 tM apart. Binding was carried out in a completely paired protocol. 
Two-way ANOVA (for the factors binding and region) showed no significant 
difference between regions (P >0.05), but a significant difference -was observed 
-110 - 
between total and non-specific binding (P <0.001). Post-hoc analysis (Fisher LSD 
test) of individual regions showed only one region where total and non-specific 
binding was significantly different (*P, <0.05). 
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Table 12. Quantitative autoradiography of 0 H]-paracetamol binding 
in the spinal cords of male mice. 
Region 
Relative Optical Density (ROD) 
Segments Total NSB % Specific 
Binding 
Cervical Cl & C6 
Laminae 1-111 0.935 ± 0.066 0.858 ± 0.039 8.32 
Laminae IV-VII 0.863 ± 0.055 0.787 ± 0.068 8.81 
Laminae VIII-IX 0.846 ± 0.059 0.785 ± 0.071 7.22 
Laminae X 0.946 ± 0.064 0.120 ± 0.030 12.66 
Intermediomedial 0.860 ± 0.094 0.832 ± 0.056 3.19 
cell column 
White matter 0.612±0.059 0.619±0.039 -1.14 
Ti &T3 
Thoracic 
Laminae I-III 
Laminae IV-VII 
Laminae VIII-IX 
Laminae X 
Intermediomedial 
cell column 
White matter 
L3&L5 
Lumbar 
Laminae I-III 
Laminae IV-VII 
Laminae VIII-IX 
Laminae X 
Intermediomedial 
cell column 
White matter 
S4 
Sacral 
1.025 ± 0.033 0.819 ± 0.062 20.05 * 
0.928 ± 0.014 0.782 ± 0.047 15.69 * 
0.938 ± 0.023 0.771 ± 0.039 17.78 * 
0.949 ± 0.030 0.809 ± 0.061 14.78 * 
0.953 ± 0.033 0.780 ± 0.061 18.16 * 
0.707 ± 0.015 0.578 ± 0.036 18.28 * 
0.924: k 0.076 0.840: E 0.036 9.07 
0.834: t 0.059 0.763 ± 0.049 8.55 
0.819±0.072 0.764 ± 0.047 6.82 
0.872 ± 0.081 0.793 ± 0.062 9.02 
0.794 ± 0.092 0.774 ± 0.062 2.58 
0.742 ± 0.074 0.644 ± 0.645 13.16 
Laminae 1-111 0.852: k 0.059 0.832 ± 0.056 2.31 
Laminae IV-VII 0.830 ± 0.048 0.737 ± 0.068 11.23 
Laminae VIII-IX 0.712 ± 0.038 0.687 ± 0.079 15.30 
Laminae X 0.855 ± 0.065 0.736 ± 0.067 13.95 
Intermediomedial 0.877 ± 0.065 0.728 ± 0.065 16.98 
cell column 
White matter 0.616 ± 0.030 0.529 ± 0.043 14.04 
The mean binding in relative optical density (n=6 f SEM) of 3µM [3H]paracetamol in spinal 
cord regions of male mice. Non-specific binding was determined with unlabelled 
paracetamol (3 mM). Measures in the regions were carried out at the bregma co-ordinates 
taken from the rat atlas of Paxinos & Watson (1986). Regional determinates were made from 
both left and right sides of the sections which were cut 300 gm apart. Binding was carried out 
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in a completely paired protocol. Comparison of total and non-specific binding across all 
regions showed a significant difference (P <0.0001, ANOVA) Post hoc analysis (Fisher's 
LSD test) of individual laminae showed a significant difference between total and NSB for 
paracetamol in all laminae of thoracic segments (P <0.. 05), and the specific binding was 
significantly different from the lumbar (P <0.05) and cervical segments (P <0.01) but not 
sacral segments (P >0.05). 
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2.4. Discussion 
2.4.1. Ligand binding to NBTI-sensitive adenosine transporters and NOP 
receptor in the absence and presence of paracetamol. 
Pelissier et al (1996) and Raffa & Codd (1996) have previously shown a lack of 
affinity of paracetamol for a number of receptors, uptake systems and transporters. 
They showed that paracetamol lacks affinity for nine receptor subtypes of 5HT 
(5HTIA. 5HT1B, SHTID, 5HT2,5HT2C, 5HT3,5HT4, and recombinant 5HT6, and 5HT7), 
the neuronal 5HT re-uptake site, and several other receptors or uptake sites including, 
a1, a2,01 and 12 adrenoceptors, Di and D2 dopamine, M2 muscarinic, NK2 neurokinin, 
t and ic-opioid receptors, neuropeptide Y and sigma receptors and the noradrenaline 
re-uptake site (Raffa & Codd, 1996). In addition, Pelissier et al (1996) showed no 
significant interaction with adenosine A, and A2A receptors, 5HT2A, NMDA 
receptors, NK1, and the dopamine uptake site. However, the affinity of paracetamol 
for the NBTI-sensitive transporter and the NOP receptor has not previously been 
established. The qualitative and quantitative pattern of NBTI-binding was similar to 
previous studies in the mouse and rat brain (Bailey et al., 2002; Ekonomou et al., 
2000; Geiger, 1987; Geiger et al., 1985; Geiger & Nagy, 1985). Paracetamol did not 
have a marked effect on binding, suggesting that paracetamol does not bind to the 
NBTI-sensitive transporter. Its analgesic effects are, therefore, unlikely be due to 
interference with adenosine uptake, unlike opioid-induced analgesia which has been 
suggested to occur at least partially by this mechanism (Pini et al., 1997; Sandrini et 
al., 2001 a; Sandrini et al., 2001b). 
The diffuse distribution pattern of the NOP receptor is consistent with previous data 
(Clarke et al., 2001; Slowe et al., 2001) and reflects the wide physiological role of 
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this receptor system and its role in nociception. Once again paracetamol had no 
significant effect on binding, suggesting that the analgesic effects of paracetamol are 
not mediated by an interaction with the NOP receptor. 
2.4.2. [3H]paracetamol distribution in the mouse brain 
The autoradiographic study of Courade et al (2001) using [3H]paracetamol at 30 nM 
failed to show any specific binding to murine brains, but because this concentration is 
more than 1000 fold below the plasma concentration required to elicit an analgesic 
response in man (70-132 pMA) and in laboratory animals, the current study has been 
carried out using a similar autoradiographic procedure but with a concentration more 
relevant to in vivo levels (3 µM) Prescott (1996). This study confirms the results of 
Courade and colleagues (2001), showing that paracetamol binding is ubiquitous and 
that, although there is some indication of specific binding overall, the level of specific 
binding in most regions failed to reach statistical significance. However, if 
paracetamol binds to any system with a low affinity it is possible that during the wash 
stages used herein and by Courade to remove non-specifically bound paracetamol, 
that this low affinity binding would also be lost. In addition sagittal sections did not 
demonstrate the small level of specific-binding achieved in the coronal sections, 
which presumably reflects the limited discrimination of thoses structures showing 
specific-binding in the coronal sections by sagittal sectioning. 
In the spinal cord [3H]paracetamol also demonstrated specific binding, although again 
this binding was found to be homogenous throughout the laminae. However, specific 
binding was significantly higher in thoracic segments when compared to lumbar and 
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cervical segments, suggesting that paracetamol may have a direct effect on 
nociception in the spinal cord, supporting the suggestions of a spinal site of action for 
paracetamol (Bjorkman, 1994; Pelissier et al., 1996). In addition to this spinal site of 
action, paracetamol could be binding to the recently discovered COX I variant 
(termed COX 3), which is expressed in the canine cerebral cortex and in lesser 
amounts in other tissues, and was selectively inhibited by paracetamol 
(Chandrasekharan et al., 2002). This variant has also been shown to be expressed in 
rats and mice, and the highest abundance has been found in the central nervous 
system (Kis et al., 2003; Shaftel et al., 2003). 
In conclusion, the analgesia induced by paracetamol is not mediated through the NOP 
receptor or the NBTI-sensitive adenosine transporter. Paracetamol does show some 
specific binding in the brain and spinal cord but the binding was not region-specific, 
suggesting that the binding is not related to any particular neurotransmitter system. 
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Chapter 3 
Modulation of paracetamol-induced antinociception by 
adenosine antagonists in wildtype and adenosine A2A 
knockout mice. 
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3.1. Introduction 
3.1.1 Site of action of paracetamol and adenosine 
Paracetamol has been shown to produce analgesia in rats and mice in numerous 
analgesic tests (Engelhardt et al., 1997; Hunskaar et al., 1985; Miranda et al., 2001; 
Miranda et al., 2004; Srikiatkhachorn et al., 1999; Tjolsen et al., 1992). There is 
evidence to indicate that paracetamol has a central mechanism of action as opposed to 
a peripheral one (Bannwarth et al., 1995; Bonnefont et al., 2003; Flower & Vane, 
1972; Pelissier et al., 1995). It has been suggested that the action of paracetamol is 
spinal due to the low dose required to elicit an antinociception when administered 
spinally (i. t), compared to the higher doses required to elicit a similar response when 
the drug is administered peripherally (i. p) in the tail flick test in mice (Pinardi et al., 
2003). 
Adenosine has a dual effect on nociception; within the spinal cord it acts to suppress 
nociceptive signalling, which is partially mediated via the A, and possibly A2A 
receptors (DeLander & Hopkins, 1986; Holmgren et al., 1986), and in the periphery it 
has algogenic activity which has been suggested to be mediated via a A2 receptor 
subtype (McQueen & Ribeiro, 1986; see Sawynok & Yaksh, 1993). 
3.1.2 Caffeine as an analgesic, an adenosine antagonist and analgesic adjuvant 
Caffeine is a non-specific adenosine antagonist and binds A, and A2 receptors with 
equal affinity, but does not bind A3 receptors (see Fredholm & Lindstrom, 1999). It is 
frequently used in combination with NSAIDs and paracetamol for its analgesic 
adjuvant properties (Sawynok & Yaksh, 1993). In humans, the analgesic effect of 
paracetamol has been shown to be enhanced by caffeine in postpartum and dental pain 
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(Laska et al., 1983). In rats, caffeine produces a significant enhancement of 
paracetamol antinociception in the writhing nociception test (Granados-Soto et al., 
1993). Further, caffeine has been shown to increase paracetamol antinociception in 
thermal nociceptive models in the mouse (Engelhardt et al., 1997). When used alone 
caffeine was found to produce a dose-related antinociception in the rat, with a 
predominantly central site of action (Sawynok et al., 1995), and in the mouse it has 
also been found to be significantly antinociceptive in the hot plate test (Abo-Salem et 
al., 2004; Ghelardini et al., 1997). 
Although it is unclear how caffeine produces its analgesic effect, it is likely that its 
mechanism of action is mediated through adenosine receptor antagonism, although 
the subtype responsible has not yet been identified (Fredholm et al., 1996). The 
analgesic adjuvant effects of caffeine cannot be due to Al receptor blockade as 
stimulation of A, receptors is known to be antinociceptive (Sawynok & Liu, 2003), 
genetically modified mice lacking the Ai receptor are hyperalgesic (Johansson et al., 
2001; Wu et al., 2005) and Ai antagonists are pronociceptive (Bastia et aL, 2002) or 
ineffective in animal models of pain (Abo-Salem et al., 2004). Abo-Salem et al 
(2004) demonstrated that novel selective A2B adenosine receptor antagonists produced 
a similar antinociception to caffeine in the hot plate test in mice, raising the possibility 
that part of the action of caffeine might be mediated at the A2B receptor. Although 
they also reported that adenosine A2A antagonists were not antinociceptive (Abo- 
Salem et al., 2004), others have shown antinociceptive effects of A2A antagonists in 
the writhing test (Bastia et al., 2002). Further, adenosine A2, receptor gene knockout 
mice do display hypoalgesia (Ledent et al., 1997) and this raises the possibility that 
both A2 subtypes can be involved in nociceptive modulation. 
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Therefore the aim of this study was to determine whether caffeine enhances 
paracetamol-induced antinociception via an action at the A2A receptor. To address 
this the effects of paracetamol and caffeine in wildtype and adenosine A2A receptor 
knockout mice have been studied, using the hot plate and tail immersion nociceptive 
tests. In addition, the effect of subtype selective A2A and A2B antagonists (Abo-Salem 
et al., 2004; Fredholm et al., 1998) on antinociceptive responses to paracetamol has 
been investigated. 
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3.2. Methods 
3.2.1. Adenosine A2A receptor knockout and wild type mice 
Adenosine A2A receptor gene deficient mice (Ledent et al., 1997) were bred at the 
University of Surrey. Mating between heterozygote (+/-) animals produced wildtype 
(+/+), heterozygote (+/-) and homozygote (-I-) animals in the expected Mendelian 
frequency. The genotype of the animals was established at 21 days by tail tipping and 
DNA amplification using PCR (Ledent et al., 1997). DNA from 0.4-0.6cm lengths 
of tail were extracted using a DNeasy kit according to the manufacturers instructions, 
tail samples were incubating overnight at 55 °C with a lysis agent, proteinase K. 
Once samples were completely lysed, samples were transferred to a DNeasy mini 
column and collecting tube, where the DNA could selectively bind to the silica gel 
membrane while contaminants pass through during a1 min spin at 6000 g (8000 
rpm). Wash buffer was then added to the column and eluted during a further 1 min 
centrifuge at 6000 g. A second wash buffer was then added and the column 
centrifuged for 3 min at 6000 g. This step dried the DNeasy membrane, prior to 
elution of the purified DNA by centrifuging columns for I min at 6000 g with elution 
buffer. The purified DNA was then amplified using PCR using 6 µ1 of DNA extract, 
14 µl of RNAse free water and 2 µl of each of the three primers A2R3, NEOR3 and 
A2D3 (see Ledent et al, 1997 for details of primers used) was added to PureTaq 
Ready-to-go PCR beads. The PCR programme consisted of a precycle of 94 °C for 2 
min followed by 40 cycles of 94 °C for 30 s (denature), 56 °C for 1 min (anneal) and 
72 °C for 1 min 15 s (elongation). Following DNA amplification, samples were run a 
1.2 % agarose E-gel for 30 mins and viewed under UV light (Fig 17). 
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Fig 17. DNA extracted from murine tail tips run on 1.2 % agarose E-gel. 
Heterozygous animals have two bands (229 bp and 570 bp), wildtype animals only 
have the lower band (229 bp) and knockout mice have the higher band (570 bp). 
After weaning, all animals were housed three per cage in an air conditioned unit 
maintained at 20-22 °C and 50-60 % humidity and were allowed free access to 
standard rodent chow and water. Lighting was controlled on a twelve-hour cycle, 
lights on at 07.00 hr. Animals were acclimatised to the procedure room for 2 hr prior 
to testing at 11.00 hr. All protocols were carried out in accordance with the Animals 
(Scientific Procedures) Act, 1984 and approved by a local ethical committee. 
3.2.2. Drug treatment 
Mice weighing 25-30 g received paracetamol, caffeine, PSBI115 (1-propyl-8-p- 
sulfophenylxanthine) or SCH58261 (5-amino-7-(ß-phenylethyl)-2-(8-furyl)pyrazolo 
[4,3-e]-1,2,4-triazlol[1,5-c]pyrimidine) alone or in combination. All drugs were 
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injected intraperitoneally (i. p. ) in a volume of 8 ml/kg. Control groups were given 
drug vehicle (see Materials) in an equal volume. 
3.23. Tail immersion test 
Mice were restrained in a plastic tube with the tail exteriorised and a thermal stimulus 
was applied by immersion of approximately 3 cm of the tip of the tail in a 
thermostatically controlled water-bath kept at a temperature of 53 ±1 °C. Latencies 
for tail withdrawal were recorded for each animal before and after drug administration 
using a hand-held stopwatch. A 10 sec cut-off time was imposed to avoid tissue 
damage. 
3.2.4. Hot plate 
In a modification of the method of Chen (1951) a3 mm aluminium plate was placed 
in a thermostatically controlled water-bath kept at a constant temperature of 55 ± 1°C. 
The latency for nociceptive response (defined as paw licking or jumping) was 
recorded for each animal before and after drug administration using a hand-held 
stopwatch. A 30 sec cut-off time was imposed to avoid tissue damage. 
3.2.5. Statistical analysis 
Statistical comparison of the drug-treated groups was performed using two-way 
ANOVA (for factors treatment and time) with repeated measures, followed by 
Scheffe's or Fisher's LSD post hoc tests for unequal or equal group sizes, 
respectively. Comparison between wildtype and knockout responses was performed 
using Student's t-test. 
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3.2.6. Materials 
Paracetamol and caffeine were purchased from Sigma-Aldrich (Dorset, UK) and 
dissolved in warmed PBS (Oxoid, Hampshire, UK). SCH58261 (Sigma-Aldrich, 
Dorset, UK) was dissolved in DMSO (5 mg/ml) which was further diluted in PBS to 
give a final concentration of 15 % DMSO (Fischer Scientific, Loughborough, UK) in 
the drug injection solution. PSB1115 was dissolved in PBS and was a kind gift fröm 
Prof. Christa Müller (Bonn University, DM). DNeasy kit and the PureTaq ready-to- 
go PCR beads were purchased from Qiagon (Crawley, UK) and Amersham 
Plc(Buckinghamshire, UK)- respectively. 1.2 % agarose E-Gel was purchased from 
Invitrogen (Paisley, UK). The primers A2R3 (5'-CTCCACCATGATGTACACCG- 
3'), NEOR3 (5'-AAGGAAGGGTGAGAACAGAG-3') and A2D3 (5'- 
CATGGTTTCGGGAGATGCAG-3') were purchased from Sigma-Genosy.: -Ltd 
(Haverhill, UK) 
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3.3. Results 
33.1. Antinociceptive effect of paracetamol in the tail immersion test and the 
effect of caffeine and adenosine receptor antagonists. 
3.3.1.1. Wildtype mice. 
The basal response latency of all mice prior to drug administration was 2.23 ± 0.15 s. 
Paracetamol (50-200 mg/kg) administered alone produced significant antinociception 
(P< 0.01) at all time points, while 10 mg/kg paracetamol was without effect (Fig 
18A). Caffeine (10 mg/kg) administered alone produced a pronociceptive effect 
which was significant at 15 and 30 min (Fig 18B). Caffeine (10 mg/kg) abolished the 
antinociceptive effect of paracetamol (50-200 mg/kg) (Fig 18B, C). In contrast a high 
dose of caffeine (40 mg/kg) produced an antinociceptive effect when administered 
alone (Fig 18B, C). 
33.1.2. Adenosine A2A receptor knockout mice. 
The basal response latency of all knockout mice prior to drug administration was 3.40 
± 0.16 s and this was significantly higher than the wildtype control. Paracetamol 
(100-200 mg/kg) and caffeine (10 mg/kg) administered alone, or in combination 
failed to elicit additional significant antinociception, except for 100 mg/kg 
paracetamol alone at 15 mins (Fig 19A). Caffeine (10 mg/kg) administered alone also 
failed to produce a significant effect (Fig 19A). 
- 127 - 
Fig 18. Antinociceptive effects of paracetamol in the tail immersion 
test and the effect of caffeine in wildtype mice. 
5 
4.5ý (A) 
v 
4 
3.5 
cl 3- 
2.5 
0 cý. 
] 
2 
1.5 
o PBS 
O 10mg/kg paracetamol 
  50mg/kg paracetamol 
A 100mg/kg paracetamol 
f 200mg/kg paracetamol 
1 
0.5 
0 
-10 15 30 45 
5- time (min) 
4.5 (B) 
4 
3.5 * 
3- 
2.5- 
2- 
= 1.5- 
I 
0.5- 
0 
-10 15 30 45 
5-1 time (min) 
4.5- (c) 
4 
3.5- 
3- 
2.5- 
0 2 
1. 
1 
## 
o PBS 
" 10mg/kg caffeine 
" 40 mg/kg caffeine 
o l Omg/kg paracetamol + 
10mg/kg caffeine 
  50mg/kg paracetamol + 
10mg/kg caffeine 
100mg/kg paracetamol + 
10mg/kg caffeine 
f 200mg/kg paracetamol + 
10mg/kg caffeine 
o PBS 
" Paracetamol 
0 10 mg/kg caffeine 
f Paracetamol + 
10mg/kg caffeine 
0 40 mg/kg caffeine 
0 10 100 1,000 
Dose (mg/kg) 
-128- 
Legend for Fig 18. 
The mean nociceptive response latency (± S. E. M;, control n=18-21, treated groups 
n=6 ) in the tail immersion test (53 t 1°C) prior and subsequent to the administration 
of (A) paracetamol (10-200 mg/kg) and (B) paracetamol (10-200 mg/kg) + caffeine 
(10 mg/kg), (C) dose response curve at peak nociception (30 min) subsequent to the 
administration of drugs. PBS= phosphate buffered saline. * Treatment vs PBS; # 
paracetamol vs paracetamol + caffeine (P<0.05, ANOVA, Scheffe's post hoc test). 
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Fig 19. Antinociceptive effects of paracetamol in the (A) tail 
immersion and the (B) hotplate test and the effect of caffeine in the 
adenosine A2A knockout mice. 
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3.3.1.3. The effect of SCH58261 and PSB1115 on the antinociceptive response to 
paracetamol in wildtype mice. 
Paracetamol (50 mg/kg) produced significant antinociception at 30 min. The A2A 
antagonist, SCH58261 (3 mg/kg), administered alone produced significant 
antinociception at 30 min (Fig 20A). SCH58261 (3 mg/kg) in combination with 
paracetamol (50 mg/kg) also elicited a significant antinociceptive effect at 30 min, 
and the effect was no greater than the effect of paracetamol alone (Fig 20A). The AZB 
antagonist PSBI115 (10 mg/kg), administered alone, did not produce significant 
antinociception at any time point measured, but abolished the effect of paracetamol 
(50 mg/kg) at 30 min, a time that reflects peak antinociception in wild-type animals 
(Fig 20B). 
3.3.2. Antinociceptive effect of paracetamol in the hot plate test and the effect of 
caffeine and adenosine receptor antagonists. 
3.3.2.1. Wildtype mice. 
The basal response latency of all mice prior to drug administration was 8.03 ± 0.39 s. 
Paracetamol administered alone (10-400 mg/kg) produced significant antinociception 
(P< 0.01) at 30 min (Fig 21A). A low dose of caffeine (10 mg/kg) administered alone 
had no effect on nociceptive response latencies (Fig 21B) but attenuated the 
antinociceptive effect of paracetamol (50-200 mg/kg) and this effect was significant 
(P< 0.05) for the highest dose (200 mg/kg) of paracetamol (Fig 21B, D). In contrast 
the high dose of caffeine (40 mg/kg) administered alone produced an antinociceptive 
effect at all time points measured (Fig 21C). The high dose of caffeine also 
attenuated the effect of paracetamol (50-200 mg/kg) but to a greater extent, and this 
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effect was significant (P< 0.05) for the higher doses (100- 200 mg/kg) of paracetamol 
(Fig 21C, D). 
3.3.2.2. Adenosine A2A receptor knockout mice. 
The basal response latency of all knockout mice prior to drug administration was 
11.35 ± 0.41 s and was significantly higher than the wildtype control. Paracetamol 
(100-200 mg/kg) administered alone or in combination failed to alter nociceptive 
response latencies at all time points (Fig 19B). Caffeine (10 mg/kg) administered 
alone prodUiced antinociception at 45 mins only (Fig 19B). 
3.3.2.3 The effect of SCH58261 and PSB1115 on the antinociceptive response to 
paracetamol in wildtype mice. 
Paracetamol (50 mg/kg) produced significant antinociception at 30 min after drug 
administration. The A2A antagonist SCH58261 (3 mg/kg) produced significant 
antinociception at all time points measured (Fig 22A). Paracetamol (50 mg/kg) 
antinociception was only potentiated in the presence of SCH58261 (3 mg/kg) at the 
15 min time point (Fig 22A). The A2B antagonist PSBI115 (10 mg/kg) administered 
alone produced significant antinociception at 45 min. The combination of paracetamol 
(50 mg/kg) and PSB1115 (10 mg/kg) produced significant antinociception at all time 
points measured (Fig 22B), which, was significantly greater than paracetamol alone at - 
30 mins (peak nociception) (Fig 22B). 
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Fig 20. The effect of SCH58261 and PSB1115 on the antinociceptive 
response to paracetamol in wildtype mice in the tail immersion test. 
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post hoc tests). 
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Fig 21. Antinociceptive effects of paracetamol in the hotplate test and 
the effect of caffeine in wildtype mice. 
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Fig 21 continued 
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subsequent to the administration of drugs. PBS= phosphate buffered saline. * Treatment vs 
PBS; # Caffeine vs PBS (P<0.05, ANOVA, Scheffe's post hoc test). 
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Fig 22. The effect of SCH58261 and PSB1115 on the antinociceptive 
response to paracetamol in wildtype mice in the hotplate test. 
20 1 (A) 
15 
0 PBS 
***  
50mg/kg paracetan 1 
***v 3mg/kg SCH58261 
10 v 50mg/kg paracetamol + 
3mg/kg SCH58261 
0 cý. 
5 
o---r-ýý 
-10 15 30 45 
20 
1 time 
(min) 
(B) 
v 15 # 
0PBS 
2 
10 
N 50mg/kg paracetamol 
0 10mg/kgPSB1115 
ail ie 11 -0- --o 
oL V 50mg/kg paracetamol 
5+ 10mg/kgPSB1115 
0 
-10 15 30 45 
time (min) 
The mean nociceptive response latency (± S. E. M; control n= 6-9, treated groups n=6) in the 
hotplate test (55 ± 1°C) prior and subsequent to the administration of paracetamol (50 mg/kg) 
± A2 antagonists; (A) SCH58261 (3 mg/kg) and (B) PSB1115 (10 mg/kg). PBS= phosphate 
buffered saline. * Treatment vs PBS; # PSB1115 + paracetamol vs PSB1115 or paracetamol 
alone (P<0.05, ANOVA, Scheffe's or Fischer LSD post hoc tests). 
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3.4. Discussion 
Although other studies have reported the effect of high doses of paracetamol (400 
mg/kg) (Bonnefont et al., 2003; Pini et al., 1996; Sandrini et al., 2001; 
Srikiatkhachorn et al., 1999), initial experiments in this study showed an 
antinociceptive effect was also achieved at 200 mg/kg, and therefore it was felt 
unnecessary to continue to use doses above 200 mg/kg because of the known toxic 
effects (Gardner et al., 2002; Tee et al., 1987). Caffeine at a concentration of 40 
mg/kg has previously been shown to have an antinociceptive effect in the hot plate 
test when combined with paracetamol (Engelhardt et al., 1997). We also found an 
antinociceptive effect of 40 mg/kg caffeine in the tail immersion and hot plate test but 
doses at this level have questionable relevance to its use as an analgesic adjuvant in 
humans. As lower doses of caffeine have also been shown to exert an antinociceptive 
effect (Abo-Salem et al., 2004; Ghelardini et al., 1997; Sawynok et al., 1995), and 10 
mg/kg has been shown to be maximally effective at potentiating the effect of 
analgesics in mice (Gayawali et al., 1991), 10 mg/kg caffeine was chosen for the 
majority of the experiments. 
3.4.1. Antinociceptive effects of paracetamol in nociceptive tests and the effect of 
caffeine in wildtype mice 
In these experiments paracetamol produced an antinociceptive effect in both the tail 
immersion and the hot plate tests at concentrations between 10-200 mg/kg. Caffeine 
(10 mg/kg) administered alone in the tail immersion test produced a pronociceptive 
effect and abolished the antinociceptive effect of paracetamol. In contrast high doses 
of caffeine (40 mg/kg) produced antinociception in the tail immersion test. In the hot- 
plate test low doses of caffeine (10 mg/kg) alone also did not produce an 
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antinociceptive effect in contrast to the results reported by Abo Salem et al (2004). 
The studies differ in both mouse strain and the temperature of the thermal stimulus, 
factors that could underlie the discrepancy in the two studies. However, a high dose 
of caffeine (40 mg/kg) administered alone produced significant antinociception at all 
time points in agreement with Sawynok et al (1995). When administered in 
combination with paracetamol, caffeine (10 and 40 mg/kg) again inhibited the effects 
of paracetamol, in contrast to results reported by Engelhardt et al (1997) in which 
caffeine (40 mg/kg) potentiated the effect of paracetamol. Again both studies differ in 
mouse strain and the temperature of the thermal stimuli, as well as the route of 
administration. In both nociceptive tests therefore caffeine at 10 mg/kg is not 
antinociceptive and inhibits rather than enhances the effects of paracetamol. Siegers 
(1973) also observed the dual effect of caffeine on paracetamol in the paw pressure 
test in rats, as caffeine (10 mg/kg) significantly reduced the antinociceptive effect of 
paracetamol (200 mg/kg), but, a higher dose of caffeine (50 mg/kg) potentiated the 
effect of paracetamol (200 mg/kg). Caffeine (10 mg/kg) alone had no effect on 
analgesia, although the higher dose of caffeine (50 mg/kg) had an antinociceptive 
effect (Siegers, 1973). This suggests that, at low doses, caffeine acts preferentially at 
the A, receptor to produce a pronociceptive effect but at high doses (40 mg/kg) 
caffeine alone acts preferentially at the A2 receptor. In support of this caffeine (5-20 
mg/kg, i. p. ) has also been seen to attenuate the antinociceptive effects of other drugs 
such as carbamazepine and oxocarbazepine in paw-inflammatory hyperalgesia in rats, 
and this attenuation of antinociception was also seen with the administration of the Al 
antagonist, DPCPX (0.4,0.8 mg/kg, i. p. ) (Tomic et al., 2004). 
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3.4.2. Involvement of the A2 receptor subtypes 
In the A2A knockout mice the basal nociceptive responses was increased in both 
nociceptive tests in agreement with the hypoalgesia reported previously (Bailey et al., 
2002; Ledent et al., 1997). Although the antinociceptive effects of opioid agonists 
have been observed in these mice (Bailey et al., 2002), the relatively weak 
antinociceptive effects of paracetamol were not detectable. The use of A2A knockout 
mice, was therefore not helpful in clarifying the involvement of the A2A receptor in 
the interaction between paracetamol and caffeine, so subtype specific A2 antagonists 
were used. 
SCH58261 is a specific antagonist of the adenosine A2A receptor (Fredholm & 
Lindstrom, 1999; Zocchi et al., 1996) that has been shown to have antinociceptive 
effects in CD1 mice in the hot plate test (52 °C), but only when administered 
intrathecally, and not when administered intraperitoneally (Bastia et al., 2002). 
However in the experiments reported here SCH58261 (3 mg/kg) produced 
antinociception in the hot plate test (55 °C), and this discrepancy may reflect the 
temperature used or the nociceptive end point used, as we chose paw licking rather 
than jumping. Paw licking is a more sensitive nociceptive response than jumping 
(Mogil et al., 1999). We also observed antinociceptive effects of SCH58261 in the 
tail immersion test (53 °C) when administered intraperitoneally in both tests, 
SCH58261 (3 mg/kg) did not alter the antinociceptive effect of paracetamol. The lack 
of additivity of the antinociceptive effects of paracetamol and SCH58261, and the 
lack of an additional effect of paracetamol in the A2A knockouts, may point to a 
possible A2A involvement in the mechanism of action of paracetamol. 
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PSB1115 is a specific antagonist with 450-fold selectivity for the human adenosine 
A2B receptor compared to the rat adenosine A2A receptor (Hayallah et al., 2002). 
Abo-Salem et al (2004) reported that PSB1115 at 10 mg/kg did not produce 
significant antinociception by itself in the hot plate test, but significantly potentiated 
the effects of morphine. In agreement with these results we found no significant 
antinociception of PSB 1115 alone at 10 mg/kg in either the hot plate or the tail 
immersion test. However, PSB 1115 significantly potentiated the effect of 
paracetamol in the hot plate test, as has been seen with morphine (Abo-Salem et al., 
2004), but in contrast, it abolished the response to paracetamol in the tail immersion 
test. As the tail immersion test is predominantly a spinal reflex, the inhibition by 
PSB1115 of the response to paracetamol suggests that the paracetamol-induced 
antinociception in this test involves spinal A2B receptors. The hot plate test, in 
contrast, is predominantly mediated at higher centres, so the enhancement by 
PBS1115 of paracetamol-induced antinociception in this test may be due to an 
interaction with A2B receptors in the brain. However, due to the polar sulphonate 
group in PSB 1115, this compound is probably prevented from penetrating the blood 
brain barrier (Baumgold et al., 1992) and paracetamol and PSBI115 produce 
antinociception by acting at two different sites, central and peripheral respectively. 
Overall, the opposing effects of the A2B antagonist on paracetamol-induced 
antinociception in the two tests points to opposing roles for A2B receptors downstream 
from spinal and supraspinal sites. There are examples of this for other nociceptive 
systems and opposing effects at spinal and supraspinal nociceptive sites have been 
reported for the nociceptin receptor, NOP (Tian et al., 1997). 
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In conclusion, paracetamol is antinociceptive in both spinal and supraspinal tests and 
the co-administration of caffeine does not enhance the effect of paracetamol, and even 
reduces it, suggesting that the mouse is not a good model for studying the effects of 
caffeine in humans as an analgesic adjuvant. The hypoalgesic nature of the A2A 
knockout mice and the antinociceptive effect of the AZ, a, antagonist SCH58261 in both 
spinal and supraspinal tests, support the existence of pronociceptive A2A receptors in 
pain pathways. The inability of paracetamol to cause an antinociceptive effect in A2A 
knockouts, or in the presence of an A2A antagonist, may also point to an A2A receptor 
involvement in the mechanism of action of paracetamol. The opposing effects of the 
A2B receptor antagonist, PSB1115, on paracetamol-induced antinociception in the hot 
plate and tail immersion tests also suggest a role for the A2B receptor in the action of 
paracetamol that is dependent on the pain pathways activated. 
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Chapter 4 
An investigation into the effect of paracetamol and 
caffeine on nitric oxide synthase in the mouse spinal 
cord. 
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4.1 Introduction 
4.1.1 Nitric oxide, glutamate and the NMDA receptor 
Glutamate is the main excitatory neurotransmitter in the CNS and mediates fast 
neurotransmission at the majority of excitatory synapses via two classes of glutamate 
receptors: ionotrophic (directly coupled to cation channels); NMDA, AMPA-kainate 
receptors, and the metabotropic receptors (G-protein-coupled receptors) (Nakanishi, 
1992). Glutamate provokes central sensitization by increasing the excitability of 
spinal neurons. This is primarily mediated via the NMDA receptor, and the 
subsequent C fibre stimulation to yield a highly augmented response (wind-up) 
(Davies & Lodge, 1987; Dickenson & Sullivan, 1987; Haley et al., 1990; Woolf & 
Thompson, 1991). Furthermore, NMDA receptor antagonists have been shown to 
both reverse and prevent hyperalgesia (Eide et al., 1994; Ma & Woolf, 1995). 
Therefore, the activation of NMDA receptors by glutamate is thought to be essential 
in the development of spinal sensitization and hyperalgesia (Meller & Gebhart, 1993). 
The production of NO by nNOS is closely related to the activation of the NMDA 
receptor (East & Garthwaite, 1990; Garthwaite et al., 1989a), and the level of NO 
around the nNOS-containing synapses reflects the activity of glutamate-mediated 
neurotransmission (Kiss & Vizi, 2001). Gorbunov & Esposito (1994) observed that 
glutamate provokes a NMDA receptor-mediated mobilization of calcium from 
intracellular stores, which stimulates NOS activity by forming calcium/calmodulin 
complexes. Both glutamate superfused directly onto the rat spinal cord and 
intraperitoneal administration of NMDA produced a rapid increase in NO, which was 
abolished by the non-competitive NMDA channel blockers, ketamine and MK-801 
(Rivot et al., 1999). 
- 143 - 
4.1.2. NO and pain 
NO has various roles in the mediation of pain and inhibition of its formation can have 
different effects dependent on the pain stimulus; however, inhibition of NO has an 
antinociceptive effect when pain stems from a chemical or thermal insult. A number 
of authors have shown that intrathecal administration of L-NAME blocks thermal 
hyperalgesia in rats and mice, and this effect is reversed by the administration of L- 
arginine (Kitto et al., 1992; Malmberg & Yaksh, 1993; Yamamoto & Shimoyama, 
1995). Both formalin injection and NMDA perfusion have been shown to 
significantly increase the release of NO metabolites in the periphery, and this release 
was significantly suppressed by the administration of L-NMMA and the NMDA 
antagonist D, L-2-amino-5-phosphonovaleric acid (Omote et al., 2000). In addition, 
L-arginine (i. t. and i. p. ) has also been shown to reverse the inhibitory effect of L- 
NAME (i. t. ) on the nociceptive response to formalin (Malmberg & Yaksh, 1993; 
Sakurada et al., 2001). Hyperalgesia induced by acetic acid in the writhing test in 
mice, has also been found to be reversed by NOS inhibitors (i. p) (Duarte & Ferreira, 
2000). The NOS inhibitors, L-NAME (unselective) and L-N6(1-iminoethyl)lysine 
(iNOS selective) have been shown to reverse hyperalgesia induced by polyarthritis in 
the rat, L-NAME being more effective than L-N6(1-iminoethyl)lysine (Tedesco et al., 
2002). It has therefore been suggested that the NO contributes to hyperalgesia by 
activating the NO/cGMP pathway and that the release of NO is mediated via the 
activation of the NMDA receptor in the periphery (Omote et al., 2000). 
In contrast, the blockade of NO synthesis has been shown to exacerbate pain in 
models of mechanical hyperalgesia (Zhuo et al., 1993) and NOS inhibitors failed to 
affect mechanical allodynia (Tedesco et al., 2002). The effect of NO on drug-induced 
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antinociception is also unclear. For example, NOS and cGMP inhibitors attenuate the 
antinociceptive effect of (3-endorphin in the tail flick test in mice (Xu & Tseng, 1995). 
Similarly NOS and cGMP inhibitors reduce the antinociceptive effect of the a2- 
adrenorceptor agonist, clonidine in rats and mice in the formalin and tail flick assays 
respectively (de Moura et al., 2004). In contrast, the antinociceptive effect of 
morphine is potentiated by NOS and cGMP inhibitors in the mouse tail flick test (Xu 
& Tseng, 1995; Zhu & Barr, 2001). In addition, Ulugol et al (2002) demonstrated 
that subthreshold doses of L-NAME co-administered with morphine resulted in an 
increase in the antiallodynic effect of morphine, which was reversed by the 
administration of L-arginine in rats. This potentiation of antinociception is also seen 
with intrathecal co-administration of NOS inhibitors with µ, S- and to a lesser extent, 
x agonists, in both acute (tail flick and paw pressure tests) and prolonged formalin 
pain in rats (Machelska et al., 1997). 
Morphine administered in high doses (520 nM, i. t. ) produces agitation and 
volcalisation in rats (Woolf, 1981; Yaksh et al., 1986) and nociceptive-related 
behaviour such as scratching, biting and licking in mice that resemble the behavioural 
effects of spinally administered NMDA (Sakurada et al., 1996). This effect resulted 
in an increase in NO metabolites and glutamate release and was inhibited by the pre- 
treatment with the NMDA and NOS inhibitors MK801 and L-NAME respectively, 
therefore it was concluded that the excitatory action of high doses of morphine were 
mediated via the NMDA-NO cascade in the spinal cord (Watanabe et al., 2003). 
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4.13. NO and paracetamol 
In rats, NO inhibitors administered intraperitoneally have been shown to potentiate 
the antinociceptive activity of paracetamol in the paw pressure and writhing tests. 
The non-selective inhibitor, L-NAME potentiated and prolonged the analgesic action 
of paracetamol at all doses in both tests, whereas the nNOS specific inhibitor 7- 
nitroindazole only potentiated the activity of low doses of paracetamol in the writhing 
test. It appears that NO may only be involved in certain types of pain as the evidence 
suggests that there is no effect on mechanically-induced pain. L-N6(1- 
iminoethyl)lysine, which is a relatively selective iNOS inhibitor, had no effect on the 
antinociception-induced by paracetamol in either test (Bujalska & Gumulka, 2001). 
The antinociceptive effect of paracetamol was also potentiated when L-NAME was 
administered centrally, therefore it was concluded that nNOS may be involved in both 
the peripheral and the central action of paracetamol (Bujalska, 2003). Bjorkman 
(1994) observed that pretreatment with paracetamol inhibited NMDA or Substance P- 
induced hyperalgesia, and that this inhibition was attenuated by the administration of 
the NOS substrate, L-arginine suggesting that paracetamol competitively inhibits the 
NMDA-NO pathway. 
These findings suggest that the analgesic action of paracetamol could be partially 
mediated through the inhibition of NO synthesis in the spinal cord. The aim of this 
study was therefore to determine whether paracetamol inhibited NOS in the mouse 
spinal cord and whether caffeine had any effect on this pathway. 
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4.2. Methods 
4.2.1 [3]g]citrulline production as a marker for Nitric oxide 
CD1 male mice, adult (6-8 weeks old, 6 per experiment) and pups (10 day old, 6-8 per 
experiment) were killed by decapitation and the brains and spinal cords rapidly 
removed. The cerebella and spinal cord (see section 2.2.1) were dissected free, 
washed in magnesium-free, ice-cold Krebs-bicarbonate buffer (composition (mM) 
NaCl, 118; KCI, 4.7; KH2PO411.2; NaHCO3,25.0; glucose, 11.0 and CaC12,2.0, 
continuously gassed with 95 % 02/5 % C02) and immediately cross-chopped (0.4 x 
0.4 mm) on a Mcllwain tissue chopper. Tissue slices were suspended in 250 ml 
buffer, and incubated at 37 °C for 15 min. The buffer was then decanted off and 
replaced with 250 ml fresh buffer and incubated at 37 °C for a further 60 min. The 
slices were then allowed to settle under gravity, the buffer decanted off and fresh 
buffer added. This wash step was carried out twice. The slices were then allowed to 
settle and 50 µl of packed slices were transferred to 5 ml polypropylene tubes 
containing 200 µl Krebs buffer and buffer or test substance (final concentrations: 100 
µM L-NAME, 100 µM paracetamol, 30 µM caffeine or 100 µM paracetamol + 30 pM 
caffeine, total vol. 280 µl). Tubes were gassed, capped and incubated at 37 °C for 15 
min. Glutamate (5 mM) plus glycine (10 µM) or an equal vol. of buffer (30 µl) was 
then added to the relevant tubes prior to the addition of [3H]L-arginine (3 tCi/m1,20 
µl)), giving a final vol. of 330 t1. The tubes were then gassed and capped and 
incubated at 37 °C for a further 15 min. 
The assay was terminated by the addition"of 750 tl ice-cold Krebs buffer containing 4 
mM EDTA/5 mM L-arginine, and then centrifuged (4,000 xg at 4 °C for 5 min). The 
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pellet was then resuspended in 1 ml of 1M trichloroacetic acid -and left on ice to 
precipitate the protein. The samples were then treated in accordance with the method 
of Bredt & Snyder (1989) as follows. The samples were recentrifuged (4,000 xg at 4 
°C for 5 min) and the supernatant was removed. Trichloroacetic acid was extracted 
three times with 2 ml of water-saturated diethyl ether and then neutralised with 2 ml 
of 20 mM Hepes (pH 6.0). The neutralized samples were applied to 2 ml columns of 
Dowex AG50WX-8 (Na+ form) and eluted with 2 ml of distilled water. [3H]Citrulline 
(formed stoichiometrically with NO from [3H]Arginine) in the eluate was quantified 
by adding 1 ml aliquots of eluates to 3 ml of Unisolve E and counting the mixture for 
tritium on a Wallace 1410 scintillation spectrometer. 
4.2.2. Statistical analysis 
Results were expressed as disintegrations per minute (dpm) of [3H]citrulline (mean ± 
S. E. M). Statistical analysis was performed by one-way ANOVA (for the factor 
treatment), followed by Scheff's post hoc test. 
4.23. Measurement of nitrite release from synaptosomes/slices using the Greiss 
method. 
Cerebellum and spinal cord slices were obtained using the McIlwain tissue chopper 
(see above) and synaptosomes according to the method of Gray et al (1962) and 
Gorbunov et al (1994) were incubated with 0.5 mM ß-nicotinamide adenine 
dinucleotide phosphate (NADPH) and 100 µM L-arginine, in the absence and 
presence of glutamate (final concentration 1 mM) or paracetamol (final concentration 
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100 µM) for 1 hour at 37°C with 95% 02/ 5% CO2 gas. The reaction was then 
stopped using concentrated NaOH (final pH 9) and synaptosomes/slices were pelleted 
and the supernatants were assayed using the Greiss reaction (Green et al., 1982). 
Nitrite standards produced a measurable standard curve although all unknown 
samples did not produce enough nitrite to extrapolate back to the standard curve 
therefore a more sensitive method was employed. 
4.2.4. Materials 
[3H]arginine (40 Ci/mmol) was purchased from Tocris Cookson Ltd (Bristol, UK). 
Dowex AG50WX-8 and HEPES were supplied by Biorad Laboratories Ltd 
(Hertfordshire, UK) and Calbiochem Merck Biosciences (Nottingham, UK) 
respectively. Unlabelled arginine, EDTA, L-NAME, glutamate, paracetamol and 
caffeine were obtained from Sigma Aldrich (Dorset, UK). NaOH, glucose, glycine 
were obtained from VWR International (Lutterworth, UK). All other chemicals were 
purchased from Fisher Scientific (Loughborough, UK). All solutions were made up 
in magnesium-free Krebs bicarbonate buffer. 
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4.3 Results 
4.3.1 [3H]citrulline production in the mouse cerebellum. 
The basal production of [3H]citrulline in cerebella slices from male adult mice was 
722 ± 229 dpm. None of the drugs tested (glutamate plus glycine, L-NAME or 
paracetamol) stimulated or inhibited the basal production of [3H]citrulline when 
incubated with the slices (Fig 23A). 
The basal production of [3H]citrulline in cerebella from 10 day old mice was 2769 ± 
110 dpm. Glutamate (5 mM) plus glycine (10 µM) produced a significant increase in 
the production of [3H]citrulline, which was abolished by preincubation with L-NAME 
(100 µM). L-NAME (100 µM) alone did not alter the basal production of 
[3H]citrulline. Paracetamol (100 µM) did not alter the basal production of 
[3H]citrulline, and had no effect on the glutamate/glycine-induced increase (Fig 23B). 
43.2. [3H]citrulline production in the mouse spinal cord. 
The basal production of [3H]citrulline in spinal cord slices from male adult mice was 
430 ± 71 dpm. None of the drugs tested (glutamate plus glycine, L-NAME, caffeine 
or paracetamol) stimulated or inhibited the basal production of [3H]citrulline when 
incubated with the slices (Fig 24A). 
The basal production of [3H]citrulline in spinal cord from 10 day old mice was 625 ± 
107 dpm. L-NAME (100 µM), paracetamol (100 µM) and caffeine (30 µM) alone or 
in combination did not alter the basal production of [3H]citrulline. Glutamate (5 mM) 
plus glycine (10 µ1v1) produced a significant increase in production of [3H]citrulline, 
which was significantly attenuated by preincubation with L-NAME (100 µM). In 
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the presence of paracetamol (100 µM) or caffeine (30 µM) alone there was no 
significant stimulation of [3H]citrulline production by glutamate (5 mM) plus glycine 
(10 µM). There was a significant difference between glutamate (5 mM) plus glycine 
(10 µM) alone and glutamate (5 mM) plus glycine (10 µM) in the presence of a 
combination of paracetamol (100 µM) and caffeine (30 µM) (Fig 24B). 
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Figure 23. The effect of paracetamol on the production of NO in 
cerebella slices from (A) adult and (B) 10 day old mice. 
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Figure 24. The effect of paracetamol on the production of NO in 
spinal cord slices from (A) adult and (B) 10 day old mice. 
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4.4 Discussion 
The mechanism of NO synthesis and its inhibition has been studied in the cerebellum 
(Bredt & Snyder, 1989; Garthwaite & Garthwaite, 1987; Garthwaite et al., 1989a; 
Grima et al., 1997; Southam et al., 1992; Toms & Roberts, 1994) and the 
hippocampus (Bhardwaj et al., 1995; Sequeira et al., 1997) due to the high levels of 
nNOS present in these structures. The NOS activity in the spinal cord has been 
evaluated in vivo and by patch cell clamping, however NOS activity in the cord has 
not been previously evaluated using the stoichiometric conversion from [3H]Arginine 
to [3H]Citrulline. Therefore, the cerebellum was also used to check the suitability of 
the assay. 
Cerebella and spinal cord slices from adult animals exhibited no significant response 
to stimulation by glutamate/glycine and therefore inhibition of NOS by L-NAME, 
paracetamol or caffeine could not be measured. The basal levels of NO release were 
lower in comparison to the 10 day-old mice. This is indicative of lower nNOS levels 
or receptor levels. Garthwaite et al (1985) used pups cerebellum, as the NMDA-NO 
pathway mediates most, if not all, of cGMP response to exogenous glutamate in the 
developing rat cerebellum. However, others have demonstrated that the activity of 
nNOS does not show any age-related changes in the cerebellum (Siles et al., 2002; 
Vallebuona & Raiteri, 1995). 
Glutamate (5 mM)/glycine (10 µM) produced a significant increase (85 % from 
control) in cerebella slices from 10 day-old mice, in agreement with Bredt & Snyder 
(1989) who observed a increase (300 %) from the basal production of NO in the 
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presence of glutamate (2 mM) in the rat cerebellum. Preincubation with L-NAME 
(100 µM) completely abolished the glutamate/glycine-induced stimulation showing 
that this method was sensitive enough to detect a possible reduction in NO production 
by paracetamol. The inhibition by L-NAME would indicate that the synthesis of NO 
in the cerebellum was mediated via the NMDA pathway since L-NAME has been 
shown to inhibit the NMDA-induced synthesis but not the AMPA-induced synthesis 
of NO (Yamada & Nabeshima, 1997). However, Garthwaite et a! (1989b) observed 
that the non-NMDA agonist kainite induced a large accumulation of cyclic GMP 
which was, calcium dependent augmented by arginine and inhibited by L- 
N°monomethylarginine in the young rat cerebellum, however it was not inhibited by 
NMDA antagonists. 
Paracetamol did not alter the basal or the glutamatefglycine-induced release of NO 
from the 10 day-old mouse cerebellum in agreement with Raffa (2002) who found no 
evidence that paracetamol (0.01-10 mM) directly inhibited nNOS in the rat 
cerebellum. 
The basal production of NO was significantly stimulated (185 % from control) in the 
presence of glutamate (5 mM)/glycine (10 µM) in spinal cord slices from 10 day-old 
mice. This stimulation was significantly attenuated by the preincubation with L- 
NAME as in the cerebellum (Fig 23B). Paracetamol attenuated the 
glutamate/glycine-induced synthesis of NO, but had no effect on the basal release of 
NO. Caffeine (30 µM) also attenuated the glutamatelglycine-induced stimulation, but 
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had no effect on basal production. Caffeine is a non-selective antagonist of adenosine 
Ai and A2 receptors. In the hippocampus of rats A, receptor stimulation has been 
shown to attenuate basal and NMDA-induced synthesis of NO, which is consistent 
with presynaptic A, receptor mediated inhibition of excitatory amino acid release and 
consequent decrease of NO production (Bhardwaj et al., 1995). Therefore Al 
antagonism might be expected to increase basal production of NO, however, these 
experiments show no effect on basal production of NO and a potentiation to 
glutamate-stimulated NO production suggesting that caffeine may be acting via one of 
the A2 receptors rather than the Al receptor, or that only the A2 receptors are involved 
in NMDA-induced stimulation. 
When paracetamol (100 µM) and caffeine (30 µM) were preincubated with spinal 
cord slices in combination they abolished the glutamate/glycine-induced stimulation 
to a greater extent than paracetamol and caffeine alone. There is however no 
evidence that these effects are mediated through the NMDA receptor. 
In conclusion, in the 10 day-old but not the adult mouse cerebellum and spinal cord 
glutamate/glycine treatment induces the generation of NO (Bredt & Snyder, 1989). 
Paracetamol and caffeine alone and in combination do not affect the basal synthesis of 
NO but attenuated glutamatelglycine-induced NO synthesis in the spinal cord but not 
the cerebellum. The lack of inhibition of NO synthesis in the cerebellum is to be 
expected, as it is not a major pain structure. The inhibition of NOS in the spinal cord 
by paracetamol supports the suggestion by Bjorkman (1994) that paracetamol 
mediates its effect through the spinal inhibition of hyperalgesia-induced NO release. 
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It is also apparent that caffeine has an inhibitory effect on spinal NOS, and that this 
should be investigated further. However, due to the limitations of this method the 
effects of paracetamol and caffeine on the synthesis of NO in the adult mouse are 
inconclusive. This method may not be sensitive enough to show the smaller increases 
in NOS production and therefore the adult tissue failed to show appreciable 
stimulation. Also the higher amounts of white matter and more defined tissue 
structure in the adult tissues not only made them harder to cross chop but may have 
interfered with the assay. 
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Chapter 5 
An investigation into the effect of paracetamol and 
caffeine on PGE2 synthesis in cortical and striatal 
microglia from wildtype and A2A knockout mice. 
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5.1 Introduction 
5.1.1 Paracetamol and COX 
Paracetamol exhibits effective analgesia (Dahl & Raeder, 2000; de Craen et al., 1996; 
Hahn et al., 2003; Hyllested et al., 2002; Skjelbred & Lokken, 1979; van der Marel et 
al., 2003; Zhang, 2001) and antipyresis (Drwal-Klein & Phelps, 1992; Kramer et al., 
1991), however it appears to lack the ability of NSAIDs to inhibit inflammation. 
The majority of NSAIDs inhibit the COX 2 enzyme preferentially to produce 
analgesia, antipyresis and the suppression of inflammation. The COX 2 isoform is the 
inducible form of the enzyme and is expressed transiently in response to growth 
factors, tumor promoters and cytokines (Malkowski et al., 2000), but it is 
constitutively expressed in the brain (Versteeg et al., 1999). 
It has been established that aspirin is ten times more potent than paracetamol as a 
peripheral COX inhibitor, in the dog spleen. However, paracetamol was equipotent 
with aspirin as a central COX inhibitor, in the rat brain (Flower & Vane, 1972). It 
was therefore hypothesized that paracetamol may inhibit prostaglandin synthesis in 
the CNS specifically. This central inhibition was also demonstrated by the marked 
difference in the increased COX activity in microglial cells, compared to the lower 
activity in peripheral cells such as macrophages and monocytes in response to 
paracetamol (Vane & Botting, 1995). In in vitro, paracetamol appears to inhibit both 
the COX isoforms weakly (see section 1.2.3.1), but again NSAIDs such as aspirin and 
Indomethacin are ten times more potent towards COX 2 (Mitchell et al., 1993). 
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5.1.2. The inhibition of PGE2 synthesis 
Although the inhibition of COX in vitro appears to be weak, paracetamol markedly 
inhibits PGE2 synthesis in vivo and in vitro. Muth-Selbach et al (1999) and 
Malmberg & Yaksh (1992) have both reported a paracetamol-inhibitable PGE2 release 
from the spinal cord in the rat. In vitro, COX 2 activity following stimulation by IL- 
I and NSAIDs has been shown to be highly sensitive to inhibition by paracetamol, 
in a murine monocyte cell lines (J774.2) and cultured lung fibroblasts (Botting, 2000; 
Simmons et al., 2000). Tordjman et al (1995) observed that in non-adherent 
peritoneal macrophages from the mouse, paracetamol reduced PGE2 synthesis with a 
50 % subsequent reduction in COX 2 levels, although there was no effect on COX 2 
mRNA levels. In contrast, Greco et al (2003) observed in rat microglia that 
paracetamol inhibited LPS-stimulated (100 ng/ml) PGE2 synthesis without affecting 
COX 1 and 2 expression. Furthermore paracetamol had no effect on basal or LPS- 
stimulated [3Hjarachidonic acid release, or the conversion of PGH2 to PGE2; therefore 
it was suggested that paracetamol inhibits at the COX site, blocking the conversion of 
PGG2 to PGH2 (Greco et al., 2003). Low doses of paracetamol have also been shown 
to stimulate prostaglandin production (PGE2 and PGI2) in J774.2 macrophages and 
stomach mucosa homogenates, but in contrast at higher concentrations this 
prostaglandin production is inhibited (Swierkosz et al., 2002). 
5.13 Adjuvant ability of caffeine 
Caffeine is frequently combined with NSAIDs as an analgesic adjuvant; although its 
ability to additively/synergistically induce analgesia is in some contention (see 
sections 1.4.3 and 1.4.4. ). 
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Adenosine and its agonists have been shown to upregulate the COX 2 enzyme and its 
mRNA, with a subsequent increase in PGE2 production, in human granulocytes 
(Pouliot et al., 2002). Fiebich et al (1996) observed a similar effect in rat microglia 
cultures with the adenosine A2A selective agonist CGS21680 and the non-selective 
agonist NECA, both inducing COX 2 mRNA with a subsequent increase in PGE2 
synthesis. The A2A antagonist KF17837 inhibited CGS21680-induced COX 2 
expression and its subsequent PGE2 synthesis (Fiebich et al., 1996). In contrast, the 
adenosine Ai agonist, CPA and the A3 agonist, APNEA only showed marginal effects 
on the agonist-stimulated COX enzyme (Fiebich et al., 1996). These findings 
suggested that the A2A receptor mediated intracellular signalling events that cause 
COX 2 gene upregulation (Fiebich et al., 1996), and therefore caffeine may inhibit 
this induction to produce an synergistic effect on the analgesic ability of the NSAIDs 
to inhibit COX activity (Fiebich et al., 2000). 
The mechanism by which paracetamol produces an analgesic response, and the 
mechanism by which caffeine potentiates this effect is still unclear. The A2A receptor 
knockout mice provide a useful tool to study the antagonism of the A2A receptor by 
caffeine, and its potential to inhibit the upregulation of PGE2 synthesis and enhance 
the effect of paracetamol. Therefore the aim of this study was to determine whether 
paracetamol reduces PGE2 synthesis in murine wildtype and knockout microglia 
cultures and to identify if caffeine potentiates this inhibition via the A2A receptor. 
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5.2. Methods 
5.2.1. Inhibition of synthesis of prostaglandin E2 
5.2.1.1. A2A knockout receptor and wildtype mice 
Purebred breeding of homozygotes was employed due to the age the litters were used 
(1-3 days), and these animals were too young for genotyping and therefore, traditional 
breeding from heterozygotes. Homozygous wildtype male and female mice or 
homozygous A2A knockout male and female mice were mated to produce purebred 
litters. All animals were housed in breeding pairs and postpartum mated, in an air 
conditioned unit maintained at 20-22 °C and 50-60 % humidity and were allowed free 
access to food and water. 
5.2.1.2. Cell culture preparation 
1-3 day old-wildtype (+/+) and knockout (-/-) neonates were dipped in 96 % ethanol 
and decapitated into cold previously filtered (0.20 µm filter) minimum essential 
medium (MEM) containing 10 mM Hepes, pH 7.4 at 4°C. The brains were removed 
from the skull along with the meninges. The cortex and striatum were dissected out 
and dissociated by trypsinsation (0.05 % trypsin; 0.02 % ethylene diamine tetraacetic 
acid (EDTA) in Dulbecco's modified Eagle's medium (DMEM)); pipetted gently up 
and down once with a 10 ml Pasteur pipette before a5 min incubation at 37 °C. The 
trypsin was then deactivated by addition of 10 ml of culture medium, which saturates 
the trypsin cleavage sites (DMEM supplemented with 10 % heat inactivated foetal 
calf serum (FCS), 2 mM L-glutamine, 25 tg/ml gentamicin). The deactivated trypsin 
mixture was then repeatedly pipetted -until a homogenous suspension was achieved. 
The suspension was then passed through a 40 µm filter and centrifuged at 150 g for 5 
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min. The supernatant was removed and the pellet resuspended in fresh culture 
medium, and seeded in T80 flasks (12.5 ml per flask) and placed in an incubater (37 
°C, 5% C02/95 % humidified air). The culture medium was changed every three 
days until the 15th day when the microglia were removed from the astrocyte bed 
(Szczepanik et al., 2001) by gently shaking them on a rotary shaker at 200 rpm at 37 
°C for I hr. The medium was removed and spun at 95 g for 5 min. The supernatant 
was then discarded and the pellet resuspended in 2 ml of fresh culture medium. A 
sample (10 µl) was then taken and placed on a haemocytometer, and the number of 
cells calculated. The cells were then seeded in 96 well plates at a concentration of 
2x105 cells/well and left to adhere for 24 hr before dosing with test substance. 
5.2.1.3. Determination of Prostaglandin E2 concentration 
Following the 24 hr incubation the culture medium was removed and replaced with 
fresh culture medium. The microglia were then pre-incubated with paracetamol (1 
µM-100 µM) and/or caffeine (30 µM) for 30 minutes at 37 °C, 5% C02/95 % 
humidified air. The cells were then treated with lipopolysaccharide (100 ng/ml) for 
24 hr to stimulate PGE2 production. 
Microglia were also seeded in 96 well plates and incubated at 37°C in 5% C02/95 % 
humidified air for 24 hr. They were then incubated with 2-[p-(2-carbonyl-ethyl)- 
phenylethylamino]-5'-N-ethylcarboxamidoadenosine (CGS 21680) (0 nM-1000 nM) 
and either 30 nM (4-[2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]-triazin-5- 
ylamino] ethyl]phenol (ZM241385) or vehicle (0.02 % DMSO) for a further 24 hr. 
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Following the incubation with the test substances the medium was harvested and 
centrifuged at 9500 g for 10 minutes. The supernatant was then removed, vortexed 
and the levels of PGE2 were measured by enzyme linked immunoassay according to 
the manufacturer's instructions (Amersham Plc) (Fig 25). 
Addition standard/ Addition of 
of assay unknown i substrate 
reagent 
I 
Goat Mouse 
and- anti- 
Mouse PGE2 
PGE, peroxidase 
Ig 6rý 
ý 
v 
I 
ý+ % 
PGE, 
+ TMB -* Stop reaction 
measure optical 
density at 
450nm 
Wash X4 
-4 
Incubate 1 hr 1 I Incubate 30 min 
Fig 25. Protocol summary for the measurement of PGE2. Standards and unknown 
samples are incubated with antibody and conjugate for 1 hr. The wells are then 
washed with washing buffer before the addition of the substrate 3,3', 5,5'- 
Tetramethylbenzidine Dihydrochloride Hydrate (TMB) and a further 30 min 
incubation. The reaction was stopped by the addition of 1M sulphuric acid to all 
wells, and the optical density (450 nm) analysed using a Multiscan 351 photometer 
(Labsystems, Helsinki, Finland). Taken from manufacturer's instructions. 
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Standards were made up in the assay buffer provided, and 50 µl duplicate samples of 
blanks, standards and supernatant were added to the microtitre plate. All wells were 
incubated with the antibody and conjugate for 1 hr. Each well was then washed with 
washing buffer'before the addition of the substrate and a further 30 min incubation. 
The reaction was stopped by the addition of 1M sulphuric acid to all wells (Fig 25. ). 
The concentration of the unknown samples was estimated from a standard curve 
ranging from 50-6400 pg/ml. The standard curve was constructed using the 
normalized percentage bound PGE2 (B/B0) which was calculated using the non 
specific binding (NSB) optical density and the optical density from standard zero: 
Unknown optical density - NSB optical density 
x 100=%B/Bo 
Standard zero optical density -NSB optical density 
Fig 26. Example of the standard curve for PGE2 
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5.2.2. Protein determination 
Following the removal of medium for analysis of PGE2, NaOH (0.2 M, 100 µl) was 
added to each well and incubated for 12 hr at room temperature. The concentration of 
cell protein in each well was determined by means of the Bradford (1976) method, 
using bovine serum albumin solutions as standards. Bradford reagent (5 ml) was 
added to 100 t1 of blank, standards and unknown samples and incubated for 5 min at 
room temperature. The solutions were analysed on an Uvikon 860 spectrophotometer 
(595 nM) (Kontron Instruments, Milton Keynes, UK). The protein concentration of 
the unknown samples were estimated from a standard curve ranging from 50-1000 µg. 
5.23. Statistical analysis 
Results were expressed as pg/pg of protein (mean ± S. E. M. ). Statistical analysis was 
performed by two-way ANOVA in the LPS-stimulated microglia (for factors 
genotype and treatment) and the CGS21680-stimulated micorglia (for factors of ± 
antagonist and concentration). Both analyses ere followed by Scheffe's post hoc test 
for individual group comparison. 
5.2.4. Materials 
PGE2 ELISA kit was purchased from Amersham Plc (Buckinghamshire, UK). MEM, 
DMEM, FCS and gentamicin were purchases from Invitrogen (Paisley, UK). 
ZM241385 (3 mM stock) was supplied by Tocris Cookson Ltd (Bristol, UK) and 
dissolved in 20 % DMSO: 80 % MQ water prior to a serial dilution. CGS 21680 (1 
mM) was purchased from Sigma-Aldrich (Dorset, UK) and was dissolved in 0.7 % 
ethanol, prior to a serial dilution in MQ water. Bradford reagent was diluted 1: 4 
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Bradford reagent concentrate: MQ water and was supplied by BIO-RAD Laboratories 
(Hertfordshire, UK). All other chemicals were purchased from Sigma-Aldrich 
(Dorset, UK) and were diluted in MQ water. 
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53 Results 
53.1. The effect of paracetamol and caffeine on the LPS-stimulated synthesis of 
PGE2 
The basal synthesis of PGE2 in +/+ and -/- cortical microglia was 0.068 ± 0.045 pg/µg 
of protein and 0.125 ± 0.042 pg/µg of protein respectively. When cortical microglia 
were incubated in the presence of LPS there was a 16-18-fold increase in PGE2 
synthesis, although this failed to reach significance. Paracetamol (1-100 µM) 
decreased stimulated-synthesis of PGE2 in cortical microglia in both genotypes, 
however individual treatments did not reach statistical significance, although this 
trend was observed at all concentrations of paracetamol. Caffeine (30 µM) alone (ca. 
50 %) and in combination with paracetamol also decreased stimulated synthesis of 
PGE2 in +/+ and -/- cortical cultures, but again individual treatments did not reach 
statistical significance (Fig 27A). Overall a significant difference (ANOVA, P< 
0.05) was found between the treatments in all cultures, and between the two 
genotypes, however there was no significant interaction between treatment and 
genotype and the post hoc test failed to find any significant differences. 
The basal synthesis of PGE2 in +/+ and -/- striatal microglia was 0.18 ± 0.13 pg/ tg of 
protein and 0.69 ± 0.31 pg/µg of protein respectively, although due to the high 
experimental variability this did not yield a significant difference. When striatal 
microglia were incubated in the presence of LPS the synthesis of PGE2 was not as 
marked as the increase in PGE2 synthesis from cortical cultures, with a 9-fold increase 
in wildtype cultures and only a 2-fold increase in knockout cultures, and this increase 
was not found to be statistically significant. Paracetamol (1-100 µM) decreased 
stimulated-synthesis of PGE2 in striatal microglia was seen in both genotypes, 
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however individual treatments did not reach statistical significance, although this 
trend was observed at all concentrations of paracetamol. Caffeine (30 µM) alone did 
not have any effect on the stimulated synthesis in cultures from either genotype, 
however in the presence of paracetamol, a decrease in stimulated synthesis of PGE2 
was seen +/+ and -/- striatal cultures, but again individual treatments did not reach 
statistical significance (Fig 27B). Overall a significant difference (ANOVA, < 0.05) 
was found between the treatments in all cultures, and between the two genotypes, 
however there was no significant interaction between treatment and genotype and the 
post hoc test failed to find any individual significant differences. 
5.3.2. The effects of CGS21680 and ZM241385. 
To establish whether A2A receptors are present on murine microglia, striatal and 
cortical microglia from wildtype (+/+) and A2A knockout (-/-) mice were cultured and 
incubated with the A2A agonist, CGS21680 (0-1000 nM) in absence and presence of 
the A2A antagonist, ZM241385 (30 nM) or vehicle (0.02 % DMSO). In the presence 
of the vehicle and ZM241385 (30 nM) alone the PGE2 levels produced by +/+ cortical 
microglia were 0.43 ± 0.19 pg/µg of protein and 0.58 ± 0.19 pg/µg of protein 
respectively. In the presence of the vehicle and ZM241385 (30 nM) alone the PGE2 
levels produced by -/- cortical microglia were 0.37 ± 0.2 pg/µg of protein and 
ZM241385 (30 nM) alone produced 0.36 ± 0.15 pg/jig of protein. There was no 
significant difference between cortical cultures from wildtype and knockout mice. 
The PGE2 levels produced by the +/+ striatal microglia in the presence of vehicle or 
ZM241385 (30 nM) alone were 0.15 ± 0.11 pg/gg of protein and 0.33 ± 0.13 pg/µg of 
protein respectively. The -/- striatal microglia when incubated in the presence of the 
vehicle alone produced PGE2 levels of 0.23 ± 0.11 pg/gg of protein and ZM241385 
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(30 nM) alone produced PGE2 levels of 0.45 ± 0.09 pg/µg of protein. There was no 
significant difference between striatal cultures from wildtype and knockout mice. The 
synthesis of PGE2 from wildtype and knockout microglial cultures in the presence of 
vehicle or ZM241385 were not significantly different. There was no significant 
stimulation in response to incubation with CGS21680 in any of the microglia cultures 
from either wildtype and knockout mice. The A2A antagonist ZM241385 failed to 
significantly antagonize CGS21680 in cortical and striatal microglia (Fig 28. ). 
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Figure 27. The effect of paracetamol and caffeine on LPS-stimulated 
PGE2 synthesis in (A) cortical and (B) striatal microglia from 
wildtype and A2A knockout mice. 
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The mean synthesis of prostaglandin E2 (pg/Ng of protein ± S. E. M) in response to 24 
hr incubation with paracetamol (1-100 µM) and caffeine (30 µM) alone and in 
combination. A) Cortical microglia cultured from wildtype (n=4-6) and adenosine 
A,,,, knockout (n= 4-8) mice (1-3 day old). B) Striatal microglia from wildtype (n=6- 
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-+++++++ 
1 10 100 - 10 100 
-- 30 30 30 
9) and adenosine A2A knockout (n= 8-11) mice (1-3 day old). Paracetamol and 
caffeine alone or in combination did not significantly inhibit LPS-stimulated synthesis 
of POE2 when compared individually (P>0.05, ANOVA). An overall significant 
difference (ANOVA, P<0.05) was found between the two genotypes, however the 
post hoc test failed to find any individual significant differences. 
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Figure 28. PGE2 synthesis in response to CGS 21680 in the absence 
and presence of ZM241385 from cortical and striatal microglia from 
wildtype and A2A knockout mice. 
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The mean synthesis of prostaglandin E2 (pg/pg of protein ± S. E. M) in response to 
CGS 21680 (1-1000 nM) and CGS 21680 (1-1000 nM) + ZM 241385 (30 nM) in A) 
cortical microglia from wildtype CD1 mice (n=7) B) striatal microglia from wildtype 
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CD1 mice (n=5) C) cortical microblia from A2A knockout mice (n=4) and D) striatal 
microglia from A2A knockout mice (n=4). CGS 21680 did not significantly stimulate 
PGE2 synthesis and ZM 241385 did not significantly antagonise CGS 21680 (P >0.05, 
ANOVA). 
The drug concentrations used had no effect on the morphological appearance or 
viability of the cultures. The morphological appearance of the cultures indicates that 
the cells were microglia with little/no astrocyte contamination (Fig 29). There was no 
difference between wildtype and knockout cultures. 
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Fig 29. Images of cells under phase contrast microscopy 
Example of photos taken of cortical (A and B) and striatal cultures (C and D) from 
wildtype (A and C) and knockout mice (B and D). 
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5.4. Discussion 
Microglia can be considered as resident brain macrophages, diffusely present in the 
brain to protect it from infection, toxins, ischemia and other types of insults (Levi et 
al., 1998). LPS induces a dose-dependent expression of COX 2 in neonatal microglial 
cultures, which was consistently accompanied by PGE2 (Levi et al., 1998). Therefore, 
this cell type appears to be a good model to study the effects of drugs on endotoxin- 
induced PGE2 synthesis. Microglia are primarily cultured from the neonatal cortex to 
investigate the effects of drugs on endotoxin-induced responses (Balboa et al., 2001; 
Fiebich et al., 1996; Fiebich et al., 2000; Greco et al., 2003; Guastadisegni et al., 
1997; Minghetti et al., 1997; Moss & Bates, 2001). However, striatal cultures were 
also used in the present study due to the predominant expression of the A2A receptor 
in this structure and the absense of the A2A receptors in the cortex (see Feoktistov & 
Biaggioni, 1997). 
Paracetamol was used at a maximum concentration of 100 pM due to the use of 
higher doses affecting cell viability in microglia cultures (Greco et al., 2003). 
Paracetamol (1-100 pM) appeared to inhibit LPS-stimulated PGE2 synthesis to a 
maximum of 80 % in wildtype murine cortical microglia, which was in agreement 
with Fiebich et al (2000) and Greco et al (2003) who also observed a maximum 
inhibition of ca. 80 % in rat cortical microglia. In the wildtype and knockout cortical 
murine cultures in the presence of caffeine (30 µM) alone and in combination with 
paracetamol (10-100 pM) a similar trend was observed to that of rat cortical microglia 
cultures (Fiebich et al., 2000). Caffeine (30 µM) alone appeared to suppress the LPS- 
stimulated PGE2 synthesis by ca. 50 % and in combination with paracetamol (100 
µM) almost abolished this stimulated synthesis. 
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However although there was a significant effect of treatment (ANOVA) none of these 
effects reached statistical significance when compared individually in the post hoc 
test. Striatal cultures also showed a similar pattern of inhibition in the presence of 
paracetamol alone and in combination with caffeine, but again these effects did not 
reach statistical significance when compared individually in the post hoc test. Both 
striatal and cortical microglia cultures from knockout mice appeared to be less 
sensitive to the paracetamol and caffeine induced-inhibition of PGE2 synthesis, an 
overall significant difference was seen between the genotypes in both cultures, 
although the post hoc test did not identify any significant difference. There appears 
to be a distinct trend in this data and previously reported data, and the high variability 
in these experiments may have masked significant differences. In addition the 
majority of research on microglia cultures (see above), are harvested from the rat 
cortex, therefore due to the difference in receptor expression between the rat and the 
mouse, this would imply that the mouse is not the best model for these investigations. 
The A2A receptor agonists and antagonist also failed to produce a response in the 
murine striatal and cortical cultures, suggesting that this particular subtype is not 
present in murine microglia (Fig 28). The lack of the A2A receptor in the wildtype 
and knockout cortical cultures also suggests that if caffeine inhibits PGE2 synthesis it 
would not be through the antagonism of the A2A receptor in murine cultures. 
Paracetamol may be inhibiting PGE2 synthesis, but prostaglandins are not the only 
substances that are released from activated microglia. LPS has been shown to cause 
an endogenous production of PGE2 capable of stimulating NOS activity, and a 
subsequent increase in NO production, in murine macrophage cell lines (Milano et al., 
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1995). In rat neonatal microglial cultures COX 2 and iNOS have been shown to be 
rapidly co-induced by LPS (Minghetti et al., 1997). In rat spinal cord synaptosomes 
PGE2 (1 nM) has also been shown to stimulate the release of endogenous glutamate 
(Nishihara et al., 1995). At higher concentrations PGE2 (0.1 -10 µM) has been 
shown to stimulate NO release from the dorsal and ventral regions of the rat spinal 
cord, release that was found to be Cat+-dependent and blocked by L-NAME and MK- 
801, which would indicate the activation of the NMDA receptor (Sakai et al., 1998). 
This receptor has also been suggested to be indirectly involved in paracetamol 
antinociception in vivo (Bjorkman, 1994). 
In conclusion, paracetamol and caffeine alone and in combination appear to inhibit 
LPS stimulated-PGE2 synthesis in the mouse microglia to some extent although due to 
the large variability this inhibition is not statically significant and therefore this data 
does not prove that paracetamol and/or caffeine inhibits the production of PGE2 in the 
mouse. This inhibition also appears to be more effective in the wildtype than in the 
knockout cultures, although once again due to the variability in the data this cannot be 
substantiated as there is no statistical evidence. There is no evidence that caffeine 
antagonises the A2A receptor to produce inhibition of PGE2 production, therefore this 
data does not support the work of Fiebich et al (2000), though this could reflect a 
species difference in receptor expression. 
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Chapter 6 
General discussion 
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The aim of this study was to shed some light onto the mechanism of the 
antinociceptive effect'of paracetamol and to evaluate the possible adjuvant activity of 
caffeine and the mechanism by which it achieves this. 
Paracetamol did not modulate NBTI or nociceptin binding, thus paracetamol does not 
produce its effects through either the NBTI-sensitive adenosine transport system or 
the NOP receptor. Paracetamol bound ubiquitously throughout the brain and spinal 
cord, suggesting that paracetamol does not interact with any particular 
neurotransmitter system, as neurotransmitter receptors are in general more discretely 
localised in the CNS. The binding could be to an enzyme system as enzymes unlike 
neurotransmitters are more ubiquitously expressed. However, there was a significant 
difference between binding in segments of the spinal cord, suggesting that 
paracetamol binds to specific parts of the spinal cord, indicative of a spinal site of 
action. 
The A2A knockout mice displayed hypoalgesia and in addition the administration of 
the A2A antagonist, SCH58261 alone to wildtype mice also displayed hypoalgesia, and 
thus this data supports the existence of pronociceptive A2A receptors in pain 
pathways. The lack of additive effect observed when paracetamol was administered 
to either A2A knockout mice or in combination with SCH58261 suggests an A2A 
receptor involvement in the mechanism of action of paracetamol. In addition the A2B 
receptor antagonist, PSB 1115 potentiated and attenuated paracetamol antinociception 
in the hotplate and tail immersion tests respectively. These opposing effects suggest a 
role for the A2B receptor that is dependent on the pain pathways activated, but this 
should be investigated further as PSB1115 believed to not cross the blood brain 
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barrier. The involvement of the adenosine receptors in paracetamol-induced 
antinociception must be indirect, as it has been previously demonstrated that 
paracetamol fails to bind directly to the adenosine receptors (Pelissier et al., 1996). 
Caffeine alone did not affect nociception in the hotplate test, and was pronociceptive 
in the tail immersion test, and in addition caffeine failed to potentiate the 
antinociceptive effect of paracetamol and even abolished its effect. In these models 
therefore no antinociceptive effect of caffeine was detected. The pronociceptive 
effect of caffeine is likely to be due to the antagonism of the Ai receptor, as 
stimulation of the Al receptors is known to result in an antinociceptive effect (Poon & 
Sawynok, 1998). 
Paracetamol did not inhibit the basal or glutamate/glycine stimulated release of NO in 
cerebellum slices from 10-day-old mouse pups or the basal NO release in the spinal 
cord slices from 10-day-old mouse pups. However paracetamol and caffeine alone 
each attenuated the glutamate/glycine-stimulated release of NO in the spinal cord 
slices from 10-day-old mouse pups and when the two drugs were used in combination 
the glutamate/glycine-stimulated NO release was abolished. These results support 
previous in vivo research by Bjorkman (1994; 1995) suggesting that paracetamol 
inhibits spinal NOS. However these results were only observed in 10-day-old mouse 
pups, and it is unclear whether these effects translate to adult animals, as the levels of 
NO release in adult slices were too low to measure using this method. 
Paracetamol and caffeine alone and in combination also appeared to suppress LPS- 
stimulated PGE2 release in striatal and cortical murine microglia, but the results did 
not achieve statistical sib ificance. In addition the microglia from A2A knockout 
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mice were significantly less sensitive to the drugs when compared overall. This 
reduced sensitivity was not due to the lack of A2A receptors, as microglia from 
wildtype also appeared to lack the A2A receptor, when pharmacological 
characterisation was employed. Therefore the reduced sensitivity in microglia from 
knockout mice may have been a compensatory mechanism created due to the lack of 
the A2A gene but not due to the receptor product of the gene. 
In summary both paracetamol and caffeine alone and in combination suppressed the 
stimulated release of PGE, and NO, and the PGE2 and NOS inhibition could be linked 
as they have been suggested to modulate each other (see section 1.2.3.2). It has been 
demonstrated that in the rat spinal cord PGE2 stimulates glutamate release which in 
turn stimulates NO release (Sakai et al., 1998). Therefore inhibition of PGE2 
synthesis by paracetamol could result in an inhibition of NOS as a downstream effect 
(Fig 30). Paracetamol antinociception may also involve an indirect effect on the A2 
receptors, as demonstrated in vivo. This indirect action could also involve glutamate, 
as glutamate has been shown to release adenosine at least in the rat hind paw 
(Aumeerally et al., 2004). Therefore by reducing glutamate release, there is a 
reduction in the release of adenosine and its subsequent effects. There may also be 
feedback effects of adenosine on glutamate release, as in the brain the antagonism of 
the A2A receptor and the stimulation of the Al receptor have both been shown to 
inhibit glutamate release by a presynaptic mechanism (Bhardwaj et al., 1995; Quarta 
et al., 2004). 
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Fig 30. Possible mechanisms of action of paracetamol and caffeine. Paracetamol 
reduces PGE2 synthesis, which subsequently reduces glutamate release, and therefore 
there is a reduction in NO synthesis. A reduction in glutamate release also reduces 
the release of adenosine, which would therefore diminish the activation of the A2A 
receptors and the subsequent activation of pronociceptive pathways. In addition any 
activation of the A, receptors may regulate the nociceptive responses and inhibit the 
release of glutamate. Adenosine can activate either of the subtypes dependent on the 
tissue involved and the concentration of adenosine. 
Future work 
To investigate further the role of the A2B receptor in the antinociceptive effects of 
paracetamol and caffeine, A2B receptor knockout mice or a selective antagonist that 
can cross the blood brain barrier would be useful. However A2B receptor knockout 
mice and selective antagonists are not available yet. Caffeine was not found to be 
antinociceptive in the pain models used in this thesis; therefore the use of different 
pain models may exhibit antinociceptive effects of caffeine. This pronociceptive 
effect is not due to the species chosen because others have reported pronociceptive 
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effects of caffeine in the paw pressure test in rats (Siegers, 1973; Tomic et al., 2004). 
Pronociceptive effects of caffeine have been seen in both mice and rats, although 
human studies have only reported antinociception or lack of effect, this may indicate 
that the effects of caffeine are different in rodents and humans. Alternatively the 
varying results seen in rodents may simply be due to the differences in experimental 
procedures as caffeine can antagonise both Al and A2A receptors, the effect may vary 
dependent on which subtype is dominant in each model. 
In this study the presence of A2A receptors in the mouse microglia could not be 
detected, as there was no response to the A2A agonist, CGS 21680. However there 
may be a low level of expression of A2A receptors, that pharmacological studies were 
not sensitive enough to identify, but could be detected by direct examination of 
expression using PCR or immunocytochemistry of the receptor protein. In microglia 
from rats, A2A receptor stimulation was effective in increasing PGE2 synthesis, thus 
there may be a species difference. It may be of value to study the ability of the A2A 
receptor to affect PGE2 synthesis on a human microglial cell line such as HMO6 
(Nagai et al., 2001). 
To identify the link between PGE2, glutamate and NO, spinal cord slices from I 0-day- 
old pups could be used to assess whether PGE2 stimulates NO release and whether 
paracetamol and caffeine alone and in combination inhibit this proposed pathway. In 
addition to establish the role of NO in paracetamol antinociception in adult mice in 
vivo microdialysis in the spinal cord could also be undertaken. It has been suggested 
that paracetamol inhibition of NOS involves the NMDA receptor (Bjorkman, 1994), 
therefore stimulating NO release with NMDA instead of glutamate, would clarify if 
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the inhibition of NOS by paracetamol and caffeine involves the NO-NMDA pathway 
in either of these two methods. It would also be of value to identify the specific NOS 
isoform involved. This could be evaluated by using selective nNOS inhibitors such as 
L-N. -Nitroarginine-2,4-L-diaminobutyric amide Di (trifluoroacetate) and N-[(4S)-4- 
amino-5-[(2-aminoethyl) amino]pentyl]-N'-nitroguanidine Tris (trifluoroacetate) (Hah 
et al., 2001; Huang et al., 2000) alone and in combination with paracetamol and 
caffeine or alternatively repeating the spinal cord slices experiments using slices from 
nNOS knockout mice. 
Overall, the results presented here have suggested further directions of research 
focusing on the spinal cord and a pathway that may involve prostaglandin synthesis, 
glutamate, NO and adenosine. 
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